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I Lentiviruses and their hosts 
Human immunodeficiency virus type1 (HIV-1), human immunodeficiency 
virus type 2 (HIV-2), and simian immunodeficiency virus (SIV) have been 
identified as hither unknown primate members of the Lentivirinae subfamily 
of the family Retroviridae in 1983, 1986 and 1985 respectively, HIV-1 and 
HIV-2 were identified as the causative agents of the newly emerging 
acquired immunodeficiency syndrome (AIDS) of humans (1-3) and SIV was 
shown to cause AIDS in certain primate species, HIV-1 is clearly an 
emerging virus, which is expected to have infected between 30 and 40 
million people by the year 2000, Although lentiviruses of different animal 
species share many biological features, the natural course of the disease 
they cause in their respective host species varies considerably, Table 1 
summarises the currently known lentiviruses and their pathogenic 
characteristics in different host species, Elucidation of the differences in the 
pathogenesis of infection with different lentiviruses as well as the 
underlying mechanisms, may be expected to lead to a better understanding 
of the course of the natural infection with any of these viruses and will 
provide new tools for the development of intervention strategies, Most 
notably, the understanding of the marked differences between the natural 
diseases caused by the respective primate lentiviruses HIV-1, HIV-2 and 
SIV, may lead to the identification of new therapeutic and preventive 
measures for AIDS in humans, which in the light of the current pandemic 
spreading of this disease are more needed than ever. 
I, 1 Non-primate lenliviruses 
Non-primate lentiviruses cause persistent lifelong infections, which usually 
remain subclinical in their natural host, although some infected animals 
develop slowly progressive inflammatory lesions within target organs like 
central nervous system, lymphoid tissues, lungs and joints (4), After a long 
incubation period, which may range from many months to years, the onset 
of disease symptoms is usually insidious, All lentiviruses infect monocytes 
and macrophages, but other cells like lymphocytes may also be infected 
(5), The majority of infected cells harbour the virus in a latent, often 
defective form as proviral DNA. Active viral replication is usually restricted 
to less than one per hundred or thousand cells (6), It has been suggested 
that latently infected cells, such as the blood monocyte, may transport the 
virus to the various target organs, concealing the virus from immunologic 
surveillance (6), Once in the tissue, these cells may transfer the virus to 
other target cells, Approximately four to eight weeks after infection, 
neutralising antibodies directed to the envelope glycoproteins as well as 
antibodies to the major core protein of the virus usually develop (7,8), 
Despite the in vitro effectiveness of antibodies in neutralising virus 
infectivity, studies in several primate and non-primate lentivirus systems 
have shown that their in vivo protective effect is limited (7), 
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Host Virus Disease Onset of Primary target 
chronic organs 
disease 
Sheep VISNA Wasting, insidious Brain, lung 
MAEDI paralysis, Uoints, 
virus pneumonitis mammary 
glands 
Goats CAEV Arthritis, insidious Brain 
leukoencephalitis (lung, joints, 
mammary 
glands 
Horses EIAV Anaemia insidious ? 
Cattle BIV None ? 
Cats FIV AIDS, wasting, insidious Lymphoid 
encephalitis organs, brains 
Various African SIV None Chronic 
monkey species carrier 
Macaques (Exp. SIV AIDS insidious Lymphoid 
infections) HIV-1 organs, brains 
HIV-2 
Chimpanzees SIVepz None Chronic Lymphoid 
HIV-1 Exp. carrier organs, brains 
humans HIV-1 AIDS insidious Lymphoid 
HIV-2 organs, brains 
Table 1. Lentivirus-assoeiated disease characteristics and their hosts 
The lentiviruses of the ungulate species, MaediNisna virus, caprine 
arthritis encephalitis virus (CAEV), equine infectious anaemia virus (EIAV) 
and bovine immune deficiency virus (BIV), have the macrophage as their 
primary target cell, and do not cause primarily immunodeficiency. Maedil-
Visna and CAEV cause a slowly progressive, usually fatal disease in small 
ruminants, involving the brain, lungs, joints and mammary glands (4,9). 
EIAV causes a slow disease in horses, which is characterised by a slowly 
progressive anaemia (10). BIV has so far not been associated with a 
disease in cattle (11). In contrast to the ungulate lentiviruses, FIV, which 
occurs in several feline species as a group of closely related viruses, has 
the same spectrum of primary target cells as the primate lentiviruses 
including lymphocytes, monocytes, macrophages and follicular dendritic 
cells (FDC). Interestingly, FIV also causes an immunodeficiency syndrome 
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in cats, which is usually referred to as feline AIDS. This disease has many 
pathogenic features in common with AIDS in primates (12) 
1.2 Primate lentiviruses 
1.2. 1 Classification 
Human lentiviruses are divided into two types, HIV-1 and HIV-2. HIV-1 was 
first isolated from a patient with generalised lymphadenopathy in 1983 by 
Luc Montagnier and co-workers at the Pasteur Institute in Paris (1), and his 
findings were confirmed by Robert Gallo (National Institute of Health, USA) 
in 1984 (13). HIV-2 was first isolated in 1986, from a mildly immuno-
compromised patient in West Africa (2). Primate lentiviruses other than 
HIV-1 and HIV-2 have been found in a wide range of nonhuman-primates 
(14), and are known as simian immunodeficiency viruses (SIV) with a 
subscript to denote their species of origin. Phylogenetic trees have been 
constructed from the complete lentivirus genome alignment. The tree dis-
played in Figure 1 was constructed using PHYLIP DNADIST. 
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SIVcpzAnt Figure 1. Phylogenetic relation-
ship among representative 
* HIV-1/0 primate lentiviruses. For HIV-1, 
* HIV-1/0 the three groups (M,N, and 0) 
are shown, as well as two of the 
SIVcf'ZGab ten described subtypes of HIV-1 
* HIV-1/A group M. For HIV-2, three of the 
* HIV-1/B six known subtypes are re-
presented. The SIV have a 
subscript denoting the species 
from which they were isolated: 
SIVMND 
* SIVWCM 
SIVAQMver These are chimpanzee (CPZ), 
mandrill (MND), white-crowned 
mangabey (WCM), African green * SIVsAS 
SIVAGMver monkey (AGM), baboon (BAB), 
SIVAoMgri patas monkey (PAM), Sykes' 
monkey (SYK), sooty mangabey 
SIVAQ"ton (SM), and macaque (MAC). 
SIV AG"sob There are four species of African 
*SIVPA" 
SIVevK 
SIVa" 
* HIV-2 
green monkeys, i.e., vervet, 
grivet, tantalus, and sabaeus 
monkeys; viruses from each 
exhibit similar levels of diversity 
to that shown for the two 
examples of SIV AGMver. 
Probable positions of cross-
species transmission are 
indicated by E. Adapted with permission from P.M Sharp, E. Bailes, F Gao, Hirsch 
V and B.H. Hahn. Origins and evolutions of AIDS viruses: estimating the time 
scale. To appear in: Biochem Soc Trans, feb 2000 
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Some of the genomes are known to represent recombinants or mosaics 
between two or more different lineages, so this tree should not necessarily 
be assumed to reflect the true phylogenetic history of these viruses. There 
is good genetic, phylogenetic and biological evidence to suggest that the 
lineage containing HIV-2 was ancestral in sooty mangabeys (Cerocebus 
torquatus atys) (14-17). Recently, evidence was published that a chimpan-
zee subspecies (P.t. troglodytes) is the primary reservoir for HIV-1. HIV-1 
groups M, Nand 0 are the result of at least three independent introductions 
of SIVcpz into the human population (18). 
Within the major lineages, it is possible to identify further phylogenetic 
ramifications. The prototypic isolates form a cluster of many sybtypes (18). 
As in HIV-1, the grouping of HIV-2 isolates fall into different subtypes, 
subtype A-E. There is no obvious correlation of geographical origin within 
or among each of the various subtypes. The most common HIV-2 strain, 
subtype A, contains viruses originating from diverse locations across West 
Africa, including Senegal (ST, MVP), the Cape Verde Islands (ROD), Mali 
(BEN), Ghana (GH1), Gambia (ISY, D194), and Guinea Bissau (NIH2, 
CAM2) (19, 20). Subtype B includes viruses from Ghana (D205, GH2) (21) 
and Cote d'ivoire (UC1) (22). Representatives of subtype C (2238) and D 
(F078) were identified in Liberians (23) and subtype E in Sierra Leone (24). 
For this group of HIV-2 viruses, SIV-infected sooty mangabeys are believed 
to be the source of human infection (14,17,22,23). The natural habitat of 
SIV-infected Sooty mangabeys coincides with the geographical pattern of 
HIV-2 endemicity in West Africa (17,23). Approximately 30% of sooty 
mangabeys in the wild are infected with SIVsm• Mangabeys are often hunted 
for food and kept as pets. Scratches, bites and exposure to monkey blood 
while preparing food are possible causes of interspecies transmission to 
humans (17). Furthermore, simian-simian cross-species transmission has 
occurred between naturally infected sooty mangabeys and various 
macaque species in captivity (14,15,25,26). SIVsm is not pathogenic in its 
natural host, but it is pathogenic in certain macaque species (25-27) and in 
humans. It is of interest that there are presently only single representatives 
of subtype C-E (F0784, 2238 and PAl, and so far all have failed to 
replicate at demonstrable levels in tissue culture (23,24). The individuals, in 
whom these three viruses were identified, were all healthy and came from 
areas where HIV-2 associated AIDS has not been reported. This suggests 
that subtypes C-E differ from members of subtype A and B in their patho-
genic potential. This could be the result of differences in replication charac-
teristics, transmissibility, tissue tropism, quasispecies complexity, propor-
tion of defective viruses, or combinations of these. 
1.2.2 Virus properties and replication 
Mature virions produced by cells infected with HIV-1, HIV-2 and various 
strains of SIV are similar in morphology and composition. The virions are 
approximately 110 nm in diameter. The viral envelope is a lipid bilayer that 
buds from the cellular plasma membrane and contains the protruding viral 
Env glycoproteins. The core viral particle is composed of virion core 
11 
proteins MA (p17), CA (p24) and NC (p9), and contains the viral RNA and 
enzymes (Fig 2). Like in all retroviruses, the RNA genome of HIV-1, HIV-2 
and SIV contains the three structural protein encoding regions, gag, pol, 
and env (Fig 2). The core protein capsid (CA), nucleocapsid (NC), and 
matrix (MA) are encoded by gag, and are generated by proteolytic cleavage 
of the gag precursor protein. The pol region encodes the viral enzymes 
necessary for replication, such as reverse transcriptase (RT), integrase (IN) 
and protease (PR). The env-encoded glycoprotein contains a surface (SU) 
and a transmembrane (TM) domain. 
15'LTR I 
I 
Pi? 
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Figure 2, Virion structure. A schematic representation of an HIV-i parlicle. MA = 
Malrix; CA = Core capsid; NC = Nucleocapsid; Prol = protease; RT = Reverse 
transcriplase; Inl = Integrase; SU = surface subunil; TM = transmembrane subunit 
Beside the structural genes, additional genes encode accessory pro-
teins. The regulatory genes tat and rev encode small, non-virion proteins, 
which induce transactivation of viral transcription (tat) and regulate nuclear 
export of unspliced RNA. Vpu and nef are involved in down regulation of the 
HIV-1 receptor CD4 and HLA class 1 molecules. Vif is involved in virion 
assembly and vpr facilitates nuclear transport. The accessory genes of the 
HIV-1 genome are designated nef, vif, vpu and vpx, whereas HIV-2 and 
SIV encode nef, vif, vpx andlor vpr. 
After entering the cell, retroviral RNA is reverse transcribed into proviral 
DNA by viral reverse transcriptase (RT). After reverse transcription proviral 
DNA is integrated into the genome of the host cell, joining the host cell 
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DNA. The proviral DNA now functions as a mammalian gene and can repli-
cate synchronously with host chromosomal genes. Viral precursor proteins 
are produced in the endoplasmatic reticulum of the host cell. These struc-
tural proteins assemble around viral genomic RNA at the plasma mem-
brane. The Env glycoproteins and the structure formed by the precursors, 
with two copies of viral RNA, bud through the plasma membrane. The final 
step consists of proteolytic cleavage of Gag precursor molecules, which 
occurs as the particle buds free from the cell, incorporating the Env protein 
and a portion of the plasma membrane into its outer envelope. 
HIV-1 
I 5'LTR I gag I vif ..... rev ..... ~ pol I .. . tat ... nef 
HIV-2 vpr vpu 
I vif ~ pol I nef gag 
vpx vpr 
Figure 3. Genomic organisation of the two human lentiviruses HIV-1 and HIV-2 
1.2.3 cell receptor usage 
It has been known since 1984 that the CD4 molecule is the primary 
receptor for the primate lentiviruses (HIV-1, HIV-2 and SIV) (28-31). The 
CD4 receptor, which belongs to the immunoglobulin (Ig) superfamily, is 
expressed on T -helper lymphocytes and less densely on macrophages, 
dendritic cells, and microglial cells (32-37). The highly glycosylated outer 
surface glycoprotein of HIV-1 (gp120), specifically binds to the CD4 
molecule. However, the CD4 receptor itself is not sufficient for entry of 
HIV-1 into cells. When the cloned gene for human CD4 is expressed on the 
surface of rodent cell lines, or on certain human cell lines (astrocytes), 
HIV-1 binds to CD4, but fails to undergo the process of fusion and entry. All 
strains of HIV-1, HIV-2 and SIV bind to CD4, but need for their entrance 
into human target cells additional cell surface cofactors (38). The identity of 
some of these factors was discovered late in 1995 and throughout 1996. 
The CC-chemokines RANTES, MIP-1a and MIP-1~, secreted by CD8+ T 
cells, inhibited cell fusion or virus entry in vitro of macrophage-tropic strains 
of HIV-1, indicating the involvement of a chemokine co-receptor (39,40). 
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From studies on the infectious behaviour of HIV-1, markedly distinct 
cytotropisms in vitro for different CD4+ human cells at different stages in the 
course of disease were revealed (41-43). Env fusion specificity is a major 
determinant of HIV-1 cytotropism. HIV-1 isolates have been categorised 
into two groups, based on their ability to infect distinct target cell 
popUlations: macrophage-tropic or T -tropic viruses. A number of chemokine 
receptors have shown to cooperate with the CD4 receptor to facilitate virus 
entry through interaction with gp 120 (44-46). It was discovered that a 
seven-transmembrane protein, 'fusin' or CXCR4, when co-expressed with 
CD4, allowed infection of non-human cells by T-cell line tropic HIV-1 
variants (46). CXCR4 chemokine receptors are expressed in continuous T-
cell lines and most human tissues, with high expression levels in the lung 
and the heart, and moderate levels in the brain. They are also present on 
resting T cells, B cells, and surprisingly on monocytes/macrophages. 
Subsequently a second chemokine receptor, CCR5, was reported (47-
48). This receptor was required for entry of macrophage-tropic isolates of 
HIV-1. The co-receptor CCR5 is expressed on monocytes, macrophages, 
activated and memory T cell subsets, and microglial cells. Primary T cells 
express significant levels of both CCR5 and CXCR4, accounting for their 
susceptibility to both T-cell line and macrophage-tropic viruses. 
Investigators then identified additional chemokine receptors, such as 
CCR-2b, CCR-3 (49,50), Bonzo and BOB (51,52). The clinical relevance of 
the co-receptors is not yet fully understood. It has been stated that co-
receptor usage of HIV-1 clones correlate with the viral phenotype: 
macrophage-tropic, non-syncytium-inducing (NSI) isolates exhibit CCR-5-
restricted entry, whereas T cell line tropic, SI isolates can also use CXCR-4 
(53). Longitudinal studies have shown a shift towards usage of CXCR-4 as 
coreceptor for HIV-1 during disease progression, suggesting that the 
broadening of co receptor usage contributes to the cytopathic potential of 
HIV-1 strains in vivo (43,54,55). However, CXCR-4 is expressed on macro-
phages, but is not used as a receptor by so-called X-4 tropic viruses in 
these cells. More importantly, it was demonstrated that a genetic variation 
in the CCR-5 receptor might offer protection from sexually and parentally 
transmitted HIV-1. In Caucasians, approximately 1% is homozygous for a 
defect on the CCR5 gene, and about 15% are believed to be heterozygous 
(56,57). This homozygous deletion is not associated with any known clinical 
disease, but it proved to be strongly protective against HIV-1 infection, 
despite expression of other co-receptors (CCR-2b, 3, BOB, Bonzo). The 
very closely related HIV-2 appears to be able to use CXCR4 (58,59). 
Studies comparing the requirements for HIV-1 and HIV-2 entry may 
contribute to the understanding of the pathogenicity of these human 
lentiviruses. 
1.2.4 HIV pathogenicity in small animal models 
Studies on lentivirus infections of animals and humans illustrate thai there 
is a close association between virus characteristics and disease progre-
ssion (53). The characteristics used to classify HIV strains in vitro include 
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replication rate, ability to induce the formation of multinucleated cell (syncy-
tium inducing (SI) capacity), coreceptor requirement and the ability to infect 
different target cells (54,55). SI strains in general have a high replication 
rate, infect targets via a- and 13 chemokine receptors, may infect immorta-
lised T cell lines and, albeit inefficiently, macrophages. HIV-1 NSI strains 
have a low replication rate, require expression of 13 chemokine receptors, 
do not infect T cell lines and replicate efficiently in macrophages (53). 
Animal model systems have proved to be useful to evaluate host-cell 
interactions that define the ability to infect and cause disease in the host. 
They might also provide a means of assessing the varying roles of humoral 
and cellular immunity and the pathogenic course as well as the participation 
of host or viral genetic factors in disease induction. Furthermore, accele-
rated animal model systems may provide more rapid disease models in 
which to evaluate antiviral drugs or vaccines. Studies on the interaction 
between HIV-1 and the host have been hampered by the lack of a suitable 
animal in which both vireamia and disease can be studied. Both HIV-1 and 
HIV-2 have been inoculated into several primate species in attempts to 
mimic the disease course with these virus infections in humans. Chimpan-
zees, rhesus monkeys, macaques, pig-tail macaques, mangabeys and 
baboons have been infected with HIV-1 or HIV-2, and varying results have 
been noted, and an AIDS-like syndrome has been induced in some of the 
animals (60-62). These models remain restricted to studies on development 
of viraemia. This led to the development of a number of experimental 
mouse systems, using the concept of immunodeficient mice, which permit 
survival and growth of transplanted human mononuclear cells or 
hematopoeitic tissues (63). 
Chimeric murine HIV models 
HIV-1 does not infect normal mice. CB 17 mice with a genetically defined 
severe combined immunodeficiency syndrome (SCID) accept human foetal 
tissue transplants (SCID-hu mice) or peripheral blood mononuclear cells 
(PBL) from humans (hu-PBL-SCID mice) (63). Human tissues and cells in 
these chimeric mice create a human type haematological environment to 
support HIV-1 replication (64). Because HIV-1 has been shown to replicate 
predominantly in activated macrophages and T lymphocytes in lymphoid 
organs, an alternative chimeric human-to-mouse model was developed. 
Human PBMC were grafted intraperitoneally into gamma-irradiated CBAlN 
mice. This will result in an acute xenogenic graft versus host disease (xeno-
GvHD) providing an environment in which human cells of both the mono-
cytic and the lymphocytic cell lineage's become highly activated (65). This 
allows high levels of HIV-1 replication (66,67). Depletion of human CD4+ T 
cells from the graft results in a complete abrogation of the acute xeno-
GvHD reaction. Furthermore, the close interaction between lymphoid cells 
and antigen presenting cells, which is a hallmark of the development of 
acute xeno-GvHD, also seems to be essential in the pathogenesis of HIV-1 
infection (65). The high replication rate in close association with antigen 
presenting cells exhibits more similarities with HIV-1 infected lymphoid 
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tissues than in vitro HIV-1 infected PBMC cultures. After intraperitoneal 
infection with different strains of HIV-1, with NSI or SI phenotypes, in situ 
hybridisation studies observed the presence of HIV-1 in macrophages and 
CD4+ T cells in the peritoneal tissue and the lymphoid organs. The number 
of HIV-1 RNA' cells and the phenotype of the infected cells depend, at least 
in part, on the cytotropism of the virus strain. Therefore, these small animal 
systems are important for the development and testing of antiviral drugs 
and vaccines (68), as well as studies concerning post-exposure prophylaxis 
and possibly the prevention of maternal-foetal transmission. 
1.2.5 Pathogenesis of HIV-1 versus HIV-2 infection 
HIV-1 infection 
The immune pathogenesis of HIV infection is complex. Four mechanisms 
that contribute to the progression of HIV disease have been identified: (1) 
lack of elimination of HIV after primary infection (69,70); (2) persistent virus 
replication in lymphoid organs throughout the course of infection (71,72); 
(3) chronic stimulation of the immune system, which may cause inappro-
priate immune activation and progressive exhaustion of the immune system 
(73); (4) destruction of lymphoid tissue (74). 
Primary HIV infection. The SIV models of acute infection have been 
experimental systems to determine the initial localisation and spread of the 
virus. Sequential lymph node biopsies showed that virus may be detected 
in lymph nodes as soon as one week after primary infection (75-77). In this 
stage the virus is exclusively cell-associated. During this early period 
intense virus spreading occurs, and is disseminated via blood and lymphoid 
tissues throughout the body. After 2 to 3 weeks the number of infected 
virus-expressing cells declines rapidly, probably as a result of the emer-
gence of virus-specific immune responses. In addition, virus particles are 
trapped in the follicular dendritic network of the germinal centres with 
antibody and complement. These events coincide with a decrease in 
plasma viraemia (76). Cross sectional studies in humans indicate that the 
kinetics observed in the SIV model are comparable to those obtained in 
humans (78,79). Although the immune system is capable of down regula-
ting virus replication dramatically, HIV-1 is probably never completely elimi-
nated, and progression to a chronic phase of infection occurs in most 
cases. The level of down regulation of viraemia varies, and may depend on 
viral characteristics and/or quantitative as well as qualitative differences in 
HIV-1 specific immune responses, and/or host factors like ~ 32CCR5. 
The incidence of typical symptoms following primary HIV-1 infection or 
'HIV-mononucleosis', is not accurately known, and is believed to be 30-
60%. Symptoms vary from those of a non-specific viral infection (fever, 
sweats, myalgia, headaches, sore throat, erythematous rash, lymphadeno-
pathy), to more defined symptoms or syndromes, like Guillain-Barre 
Syndrome or meningitis (80,81). Usually these manifestations of acute 
infection symptoms resolve within 2 to 3 weeks. 
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Figure 4. The level at which plasma HIV RNA stabilises after primary infection 
predicted subsequent progression to AIDS in a group of men in the multicenter 
AIDS Cohort study. (modified from Mellors et al. Science 1996, 272: 1167-1170) 
Downregulation of viraemia and resolution of symptoms mark transition 
from the acute to the chronic phase of HIV-1 infection. However, the 
presence of cells containing HIV-1 DNA and the levels of HIV-1 RNN 
mononuclear cells, indicates that virus replication is continuous (82-84). In 
1995 it was calculated that daily about 10 '0 virions are produced and 
cleared from circulation each day (66,67). More than 99% of virus is 
produced by newly infected CD4' T lymphocytes in the lymphoid tissue 
(71,72), In 1996 it was demonstrated that there is a relation between 
plasma viral load and clinical outcome (85). The risk of developing AIDS 
and death was directly correlated to the plasma viral load, which proved to 
be a beUer surrogate marker of HIV-1 disease progression than CD4' T cell 
counts (fig 4). The median time to develop AIDS after HIV-1 infection is 
estimated to be 10-12 years. When plasma HIV-1 viraemia is not detected 
(in less than 0.5% of infected individuals), the risk to develop AIDS within 
10 years is less than 5% (long-term non-progressors). 
HIV-2 infection 
Once serological testing for HIV-2 became available, anecdotal reports 
arose of a long clinical latency period for this infection (86-88). The longest, 
best-studied HIV-2 cohort has been the cohort of commercial sex workers 
in Senegal (89). In this cohort (n=136), the incidence rate of AIDS was 0.95 
per 100 person-years of observation among HIV-2 infected women, and 5.6 
in HIV-1 infected women. Kaplan Meyer analysis comparing HIV-2 and 
HIV-1 seroincident women showed a 60% rate of AIDS-free survival after 5 
years of infection with HIV-1. In contrast, none of the HIV-2 seroincident 
women developed AIDS, and therefore exhibited a 100% probability of 
AIDS free survival after 5 years. Cases with an incubation period of 14 and 
even 27 years have been described. (86-88). These observations 
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corroborate the findings about the relatively slow decline in immunological 
function observed in HIV-2 infection. CD4' T cell counts and CD4/CD8 
ratios decline less dramatically in HIV-2 infected individuals than in HIV-1 
infected individuals (89). The rate of developing an abnormal CD4 cell 
count from the time of infection onward was 1 % per year for HIV-2 infected 
individuals versus 10% per year for the HIV-1 infected women. 
The clinical symptoms of HIV-2 induced disease are similar to those of 
HIV-1 (91). Studies in Gambia and Guinea-Bissau reported a high mortality 
among symptomatic HIV-2 patients (92-94). However, studies in Gambia 
(95) and Paris (96) showed a longer survival for HIV-2 patients after AIDS 
diagnosis. This is also reflected in autopsy results from AIDS cases 
associated with HIV-2 infection. In an autopsy study of 294 HIV-infected 
patients in Ivory Coast, tuberculosis, bacteriaemia and cerebral toxoplas-
mosis were responsible for a significant proportion of all HIV-related deaths 
(97). In contrast to HIV-1 related deaths, in HIV-2 positive cadavers three 
conditions associated with extreme immunodeficiency were observed: 
severe multiorgan cytomegalovirus infection, multinucleated giant cell 
encephalitis and intra- or extrahepatic cholangitis, conditions suggesting a 
prolonged survival with HIV-2 in the terminal stage of infection. Evidence 
for a lower viral load in HIV-2 infected individuals has been reported from 
virus isolation and proviral PCR studies (98,99). In individuals with the 
same genetic and social background, this may be due to essentially 
different characteristics of both viruses, or a different interaction with the 
immune response of the host. 
1.2.5 Epidemiology and transmission of HIV-2 infection 
Urban centres in West African countries (fig 5) have the highest HIV-2 
antibody seroprevalence (100,101). The highest rate of HIV-2 infection in 
the general population has been found in Guinea-Bissau, where seropreva-
lence was 8.9% among urban and 7.7% among rural residents (102). In 
Guinea Bissau, Senegal, Gambia and the Cape Verdian Islands the inci-
dence of HIV-2 infection exceeds that of HIV-1. In Guinea-Bissau (103), 
Ivory Coast (104) and Senegal (105) HIV-2 prevalence has been stable or 
declining, while in the same populations HIV-1 prevalence has increased. 
The decline of dual sero-reactivity among female commercial sex workers 
over the years is striking, from 38% in 1992 to 13% in 1997 (data collected 
by project RETRO-CI, Abidjan, Cote d'ivoire). Many places outside West 
Africa with HIV-2 cases have historical links with Portugal (Brazil, Angola, 
Mozambique, and India). In North America and Europe infection with HIV-2 
is sporadic. 
Until recently there was little evidence that HIV-2 was becoming 
established as a locally growing epidemic anywhere beyond West Africa. 
However, HIV-2 spread has now been documented within India, primarily 
via heterosexual intercourse, without apparent direct contact with West 
Africans (106). Although the global spread may not be as fast as that of 
HIV-1 infection, HIV-2 has spread beyond the boundaries of the original 
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African source of the epidemic. Transmission of HIV-1, HIV-2 and SIV has 
been documented to occur by the same modes: sexually, perina tally and by 
blood or blood-contaminated products or devices (107-110). However, 
transmission rates of HIV-2 are significantly lower. 
Algeria 
Figure 5 Map of West Africa 
Sexual transmission of HIV-2 was studied prospectively among 1452 
registered female sex workers in Dakar, Senegal, followed from 1985-1993 
(105). The annual incidence of HIV-1 increased 12-fold over the 8-year 
study period. In contrast, the annual incidence of HIV-2 remained stable 
over these years, as did the seroprevalence. This occurred in the setting of 
a higher seroprevalence in the population during the entire study period for 
HIV-2 (11.2%) than for HIV-1 (6.2%). The annual incidence rate for hetero-
sexually acquired HIV-1 infection in this study in Senegal is similar to that 
seen in cohorts of homosexual men in the United States (111), although 
much lower than that reported from a study of female sex workers in 
Nairobi, Kenya (112). Mathematical modelling of seroincidence data 
suggests a five- to ninefold decreased infectivity of HIV-2 per sexual act, 
compared with HIV-1. 
The rate of vertical transmission of HIV-1 in the industrialised countries 
has been reported from 13-32%, and from 25 to 48% in developing coun-
tries (113). The best predictor for the risk of perinatal transmission of HIV-1 
is plasma HIV-1 RNA levels (114). Although investigation of HIV-2 perinatal 
transmission is limited, studies indicate that transmission may occur, but is 
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much less frequent than observed in HIV-1 (115-118). Table 2 shows the 
results of some prospective studies addressing this issue (119-125). The 
rate of HIV-1 transmission was in most studies 10- to 20-fold higher than 
that of HIV-2. Cross sectional surveys in different West African countries 
have shown paediatric HIV-2 infection to be extremely uncommon (126-
129). No information is available on breast milk transmission of HIV-2, but 
epidemiological data obtained from infants and their HIV-2 seropositive 
mothers suggest it to be rare. 
HIV-2 HIV-1 
Country N % transmitted n % transmitted Reference 
Guinea Bissau 53 0 NA NA 119 
France 41 0 260 21 121 
Ivory Coast 93 1.2 138 25 120 
Senegal 29 3.4 29 34 122 
Gambia 170 4.0 64 21 123 
Burkina Faso 15 25 91 19 124 
Portugal 37 5.4 NA NA 125 
Table 2 Perinatal transmission rates of HIV-1 and HIV-2. NA = not addressed 
" Antiretroviral therapy (ART) 
It has become clear that plasma and tissue HIV-1 loads are substantial and 
that high-level viral replication occurs at all stages of infection (66,67,72). 
Developing effective and sustained antiviral effects, which allow reconsti-
tution of the depleted immune system or prevent depletion, remains the 
major challenge for HIV therapy. 
Within the HIV-1 and HIV-2 replication cycles are several potential 
targets for antiviral attack. Conversion of single-stranded RNA genome to 
double stranded DNA involves DNA polymerisation and ribonuclease H 
(RnaseH) enzymatic activities of HIV-1 RT. During this process once every 
10.000 times a spontaneous mutation develops, and consequently many 
heterogenetic strains evolve. The DNA polymerisation part of this process 
is the target of nucleoside and non-nucleoside reverse transcriptase inhibi-
tors. The sensitivity of primary isolates of HIV-2 to zidovudine (AZT), 
didanosine (ddl) and lamivudine (3TC) was similar to, or slightly less, than 
that of primary HIV-1 isolates (130-132). In contrast, the other group of 
agents inhibiting reverse transcriptase, the non-nucleosides, such as 
nevirapine, has repeatedly shown very minimal to no inhibition in vitro of 
HIV-2 replication (133,134). Another target for antiviral therapy is the HIV-
protease. The HIV-protease is essential for processing the Gag-Pol precur-
sor proteins in an irreversible manner. In the presence of HIV-protease 
inhibitors immature virus particles are produced, which are non-infectious. 
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Preliminary data have shown that protease inhibitors do have in vitro 
activity against HIV-2, though with less potency than for HIV-1 (135). 
In 1998, it became accepted that ART, once started, should aim at full 
suppression of viral replication. Rapid advances in the management of HIV 
infection has been achieved by ART, which includes a combination of 
reverse transcriptase inhibitors and a protease inhibitor, the current stand-
ard of care (137). Although ART has only been generally used in industria-
lised countries during the past few years, it has dramatically reduced 
morbidity and mortality rates (137). Two factors critical for long-term patient 
outcome - initial viral response and the durability of that response - have 
been shown to depend on the potency of the regimen and the therapy 
compliance of the patients. Studies on convenient regimens, focusing on 
only once or twice daily dosing schedules, without dietary restrictions, and 
with minimal side effects are essential. Encouragingly, powerful ART 
reduces the viral load not only in the plasma compartment, but also in the 
lymphoid tissues (138). Both the number of virus producing cells and the 
number of viral particles on the surface of the follicular dendritic cells 
decline proportional to the decrease in plasma HIV-1 RNA. However, total 
eradication of infectious HIV from a patient has so far not been achieved. 
Recently it was suggested that a special sanctuary site for HIV-1 persists in 
the form of latently infected mononuclear cells (139). These cells would 
contain integrated proviral DNA, which is not expressed. Replication 
inhibitors are not applicable here. It has been suggested that additional 
immunomodulatory therapy (e.g. general immune activation by cytokines or 
vaccination) is required to clear this compartment. 
The efficacy of ART is presently being monitored by high sensitive 
methods, such as the quantitative (ultrasensitive) HIV-1 RT-PCR. Clinically 
used goals of successful ART are a decline of HIV-1 RNA to less than 500 
copies/ml or less than 20 copies/ml using the ultrasensitive assay. Due to 
difficulties in establishing a valid technique for measuring plasma HIV-2 
RNA loads, the only surrogate parameter available to evaluate ART in 
HIV-2 infection is the peripheral CD4+ T cell count, which unfortunately has 
proven to be inadequate. Alertness on loss of effectiveness of ART over 
time is relevant, since it was quickly learned that reduced effectiveness of 
ART may result from the cumulative acquisition of multiple mutations, 
leading to viral escape. Multiple mutations are required for high level 
resistance to zidovudine and protease inhibitors, while a single mutation is 
sufficient for high-level resistance to lamivudine and non-nucleoside 
reverse transcriptase inhibitors. Studies have demonstrated that different 
combinations of mutations have distinct effects on HIV-1 susceptibility to 
antiviral drugs (Table 3). As the number of mutations in HIV-1 RT increases 
to three or four, there can be a 100-fold reduction in susceptibility to 
zidovudine (140). 
Data on HIV-2 susceptibility to antiretroviral drugs are limited. HIV-2 RT 
has about 60% sequence identity with HIV-1 RT, and catalytic properties 
that are quite similar (141). The observation that the folding of the "fingers 
and the palm" of the more distant related RT of murine leukaemia virus is 
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the same as HIV-1 RT supports the idea that the structure of HIV-1 RT and 
HIV-2 RT are sufficiently similar to assume that amino acids in equivalent 
positions in the respective sequences will have similar roles in the two 
enzymes. 
Mutations introduced ZDV IC50, ~M Fold resistance 
AZT 
None 0.01* 1x** 
M41L 0.04 4x 
T215Y 0.16 16x 
M41L, T215Y 0.60 60x 
D67N, K70R, T215Y 0.31 31x 
M41L, D67N,K70R, T215Y 1.79 179x 
D67N,K70R, T215Y, K219Q 1.21 121x 
D67N, K70R, T215F, K219Q 11.4 114x 
ddl 
K65R 10 
L74V 5-10x 
M184V 2-5x 
3TC 
M184V/I 100x 
Multidrug resistance 
Q151M 0.1 1 Ox AZT; 5x ddl/ddC 
A62V,v751,F77L,F116Y,Q151 M 1.9 190x AZT; 50x ddl; 
20x ddC; >10x d4T 
Table 3. Susceptibility to AZT, ddl, ddC and 3TC of HIV-1 variants with defined 
mutations in RT. * 50% inhibitory concentration (IC50), *' fold decrease in IC50 
1/1 AIM OF THIS STUDY 
During the late fifties a population of experienced West African sailors 
started to settle in Rotterdam. Today approximately 15.000 West Africans 
and their relatives live in Rotterdam. They are of Afro-Portuguese ethnic 
origin, with a lively contact with and frequent travel to their relatives and 
friends in their country of origin. Both HIV-1 and HIV-2 are prevalent in this, 
mostly heterosexual, population. The studies presented in this thesis were 
initiated to increase our understanding of the different clinical courses of 
HIV-1 and HIV-2 induced disease among this population of West African 
descent. 
In chapter 2 disease progression rates among HIV-2 infected individuals 
in relation to virus characteristics are assessed and compared with the 
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disease progression rates among HIV-1 infected individuals in the same 
population. In chapter 3 we study molecular pathological aspects of HIV-
infection by assessing the amount and distribution of productively infected 
cells in lymphoid tissues by HIV-2 RNA in situ hybridisation and immuno-
histochemistry. In chapter 4 we assess the source of HIV-1 production 
during end-stage disease. In chapter 5 we evaluate the capacity of a panel 
of human cells stably transfected with chemokine receptor genes to support 
infection with HIV-2 primary isolates from patients at different stages of 
disease, and compare the results with data from studies on HIV-1 co-
receptor usage. Chapter 6 describes our efforts to study the in vivo 
pathogenic potential of HIV-2 isolates and biological clones in a chimeric 
human to mouse model for in vivo HIV infection. We studied the direct 
(killing of infected cells) and indirect (inhibition/modulation of antigen 
presenting cells) cytopathic effect of HIV-2 strains on the development of 
acute xeno-GvHD symptoms, CD4/CD8 ration and the ability of the graft to 
repopulate mouse tissues. In chapter 7, 8 and 9 we describe several 
aspects related to the management of HIV-2 infection. In chapter 7 we 
studied genotypic and phenotypic patterns of resistance of HIV-2 virus 
strains to nucleoside reverse transcriptase inhibitors (NRTls) from patients 
before and after antiretroviral therapy with NRTls. In chapter 8 we describe 
the development of a quantitative assay to measure plasma HIV-2 RNA, 
and in chapter 9 we show the response to ART in dually HIV-1/HIV-2 
infected patients. Finally, a summarising discussion is presented in chapter 
10, which also includes the response observed to triple therapy in patients 
with infection with HIV-2 monoinfection. 
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Objective: Assessment of disease progression rate amongst twelve HIV-2 
infected West European residents (nine of West African descent), as 
compared to disease progression rate among HIV-1 infected individuals of 
the same population, and characteristics of the HIV-2 strains involved. 
Methods: HIV-2 infected individuals were identified by commercially 
available serological assays, their clinical status and CD4+ cell counts were 
monitored, and HIV-2 was isolated from their peripheral blood mononuclear 
cells. T cell line tropism and syncytium inducing capacities of the isolated 
viruses were determined and their phylogenetic relationships were 
analysed by comparing PCR amplified nucleotide sequences of reverse 
transcriptase (RT) gene segments. 
Results: Eight of the twelve HIV-2 infected individuals presented with pro-
gressive disease and one of them progressed from CDC group Ai to A3 
within 36 months after seroconversion. The ratio of asymptomatic versus 
symptomatic individuals, among residents of the Rotterdam region of West 
African descent, was 2:7 for HIV-2 and 8:9 for HIV-1 infected individuals. 
From six of the nine individuals with progressive disease HIV-2 was 
isolated. The time required for virus isolation correlated inversely with the 
individuals CD4+ cell counts. Five of the HIV-2 isolates replicated in 
immortalised T cell lines, and two isolates from patients with AIDS induced 
syncytia. Five HIV-2 isolates from Cape Verdian Isles born patients 
grouped together within subtype A. The HIV-2 isolate from a patient of 
Ghanese origin belonged to subtype B. In the RT genes from HIV-2 isolates 
of two zidovudine treated patients mutations were identified, one of which 
has also been shown to be involved in zidovudine resistance in HIV-1. 
Conclusion: Disease progression in HIV-2 infection may be as rapid as in 
HIV-1. HIV-2 isolation and viral phenotype were related to disease status, 
and mutations identical to those observed in HIV-1 zidovudine resistance 
were observed in patients treated with zidovudine. 
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INTRODUCTION 
Since the discovery of HIV-2 as the second cause of acquired immune 
deficiency syndrome (AIDS) in West Africa in 1985 [1,2], the virus has been 
shown to have virtually spread world-wide [3J. However, sexual and peri-
natal transmission of HIV-2 is much less efficient than that of HIV-1, proba-
bly as a result of low viral burdens during the relatively long asymptomatic 
period [4-10J. This is probably the reason why, despite its wide distribution, 
the numbers of HIV-2 infected individuals have remained relatively low [3J. 
During the long asymptomatic period, it is usually difficult to isolate HIV-2, 
but like in HIV-1 infection, HIV-2 can be isolated from virtually all HIV-2 
seropositive patients with AIDS [8-10J. Most of these viruses show early 
and high reverse transcriptase (RT) activity and exhibit a syncytium 
inducing (SI) phenotype in peripheral blood mononuclear cell (PBMC) 
cultures [8]. It has been suggested that cytopathic HIV-2 strains were only 
found within subtype A and that attempts to isolate viruses belonging to 
HIV-2 subtypes C, D and E and to a lesser extent subtype B, usually 
remained unsuccessful [11J. 
Here we describe data on the pathogenesis and characteristics of 
viruses isolated from eleven HIV-2 infected individuals living in the 
Rotterdam area, which all except two belonged to West African immigrant 
communities. In addition, the same data are presented for one HIV-2 
infected individual born and living in France. By comparing the number of 
seropositive individuals with and without progressive disease amongst 
HIV-1 and HIV-2 infected individuals of West African origin in the 
Rotterdam area, it was suggestive of similar pathogenicity of the pre-
dominantly involved HIV-2 subtype A and HIV-1 in the same community. 
MATERIALS AND METHODS 
Study population 
From August 1989 onward, clinical and immunological parameters and 
from August 1994 onward virological parameters were monitored of eleven 
HIV-2 seropositive individuals and one individual with a dual HIV-1 and 
HIV-2 infection, who regularly visited clinics in Rotterdam or Paris. All 
individuals gave informed consent and the study was approved by the 
medical ethical committee of the Rotterdam hospital. 
Age, sex, country of birth and probable mode of transmission in these 
individuals is shown in Table 1. Nine out of 12 individuals originated from 
West Africa, individual RH2-4 was a Dutch born male spouse of individual 
RH2-5, a Cape Verdian female. RH2-11 was a Dutch born female former 
regular sexual partner of a Cape Verdian male (serostatus unknown). 
Patient PH2-1 was a French born homosexual man living in Paris, with a 
documented HIV-2-seroconversion in 1992. 
Two patients had been treated with zidovudine for two years (RH2-2) 
and six months (RH2-5) respectively at the moment of virus isolation. 
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All patient sera tested negative for HIV-1, HTLV-I, HBsAg, except for 
individual RH2-8, who was infected with both HIV-1 and HIV-2. 
Subject Age Sex Countr Probable Disease CD4 Serology 
yof mode of state count d HIV-1 HIV-2 
birthC transmission (CDC state) 
RH2-11 54 Fb NL Heterosexual C3 10 + 
RH2-9 35 F CV Heterosexual C3 10 + 
RH2-10 35 M CVI Heterosexual C3 10 + 
RH2-2 36 M CVI Heterosexual C3 10 + 
RH2-6 34 F Ghana Heterosexual C3 10 + 
RH2-5 40 F CVI Heterosexual A3 110 + 
RH2-7 39 M CVI Heterosexual A3 130 + 
PH2-1 50 M France Homosexual A1 570 + 
RH2-1 38 M CVI Heterosexual Cl 600 + 
RH2-3 36 F CVI Heterosexual Ai 800 + + 
RH2-8 35 F Ghana Heterosexual Ai 1000 + 
RH2-4a 54 M NL Heterosexual Ai 1200 + 
RHH 51 M CVI Heterosexual C3 10 + 
RHl-2 36 F CVI Heterosexual C3 10 + 
RHl-3 28 M IVC Heterosexual C3 10 + 
RHl-4 35 F Ghana Heterosexual C3 10 + 
RHl-5 31 M Sen Heterosexual C3 50 + 
RHl-6 36 M CVI Heterosexual C3 60 + 
RHl-7 27 M Ghana Heterosexual C3 80 + 
RHl-8 27 M CVI Heterosexual C3 90 + 
RH1-9 35 M CVI Heterosexual A3 170 + 
RH1-l0 29 M CVI Heterosexual A2 220 + 
RH1-ll 32 F Ghana Heterosexual B2 290 + 
RHl-12 37 F CVI Heterosexual A2 350 + 
RH1-13 29 F CVI Heterosexual A2 400 + 
RH1-14 45 M CVI Heterosexual A1 510 + 
RH1-15 36 F CVI Heterosexual A1 580 + 
RHl-16 37 F CVI Heterosexual A1 750 + 
RH1-17 31 M Ghana Heterosexual A1 860 + 
Table 1. Demographic and Clinical Characteristics of the Study Participants at 
Entry. ahusband of RH2-5. cCVI Cape Verde Islands, NL the Netherlands, IVC, 
Ivory Coast, Sen Senegal. bM, male; F, female. d106 cellsll 
Serology and virus isolation 
Sera were tested for antibodies to HIV-1 and HIV-2 (ELFA, bioMerieux, 
Lyon, France) and by type specific Western Blot (WB) (HIV-Blot 2.2, 
Diagnostic Biotechnology, and New LA V Blot 2, Sanofi Diagnostics 
f='asteur). Peripllerarblood mononuclear cells (PBMC) were isolated by 
Ficoll density centrifugation as described previously [12]. All PBMC 
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samples were cocultured with three days phytohemagglutinatin prestimu-
lated donor seronegative lymphocytes (PHA-PBMC) according to standard 
protocols [12]. All cultures were maintained for up to 6 weeks and 
monitored for the presence of HIV-p24 antigen (V5 ELISA, Organon 
Teknika, Oss, The Netherlands) in the supernatant at weekly intervals. T 
cell lines (MT2, SupT1, H9) and monocyte derived macrophages were 
infected with culture supernatants of the HIV-2 positive PBMC cultures 
which were twice weekly analysed for the presence of p24 antigen in 
supernatants and for syncytium formation twice weekly [13J. HIV-1 IIiB 
kindly provided by the MRC AIDS directed programme [14] and HIV-1 
strains ACH 172.BA-L (NSI) provided by Dr. H. Schuitemaker from the 
Central Laboratory for Blood Transfusion Service in Amsterdam [15] were 
used for reference purposes. 
Polymerase chain reaction (PCR) detection of RT sequences and 
phylogenetic analysis 
High molecular-weight DNA was extracted from MT2 cells that had been 
co-cultured with PBMC from patients RH2-2, RH2-2, RH2-6, and RH2-7 or 
directly from PBMC of patients RH2-1 and PH2-1, using cell lite beads [16]. 
Amplification was performed as described previously [11J. Briefly, RT 
sequences were amplified in a nested PCR with primers RTC/RT2 and 
RT3/RT4 for 1.5 minutes at 94°C, 1 minute at 40°C, 2 minutes at 74°C for 
30 cycles with 10 minutes extension at the end. The amplified fragments 
were cloned in pTA cloning vector (Invitrogen, San Diego CAl according to 
the manufacturers protocol. Clones were sequenced with the Taq Dye 
Deoxy Terminator sequencing kit on the 373A sequencing system of 
Applied Biosystems (Foster City, CAl, All clones were sequenced on both 
strands using custom made primers, except for a small (200 bp) part of 
RH2-2, to which none of the reverse primers hybridised. 
The phylogenetic relationships of the viruses were determined from their 
RT nucleotide sequences using the UPGMA method in the software of 
Geneworks (intelligenetics, Mountain View, CAl. Alignment of the protein 
sequences was performed with the Geneworks software. 
RESULTS 
Clinical status and serology 
The clinical status of the 12 HIV-2 seropositive individuals at entry in the 
study is shown in Table 1. According to the revised classification system of 
the Centres of Disease Control [17] five patients (RH2-2, RH2-6, RH2-9, 
RH2-10, RH2-11) were classified in category C3, one (RH2-1) in category 
C1, two (RH2-5 and RH2-7) in category A3 and three (RH2-3, RH2-4, RH2-
8) in category A 1. RH2-2 had a history of tuberculosis, recurrent oral 
candiasis and cytomegalovirus (CMV) induced retinitis. RH2-6 suffered 
from extreme wasting. RH2-9 had intracerebral malignant lymphoma, RH2-
10 was diagnosed with disseminated Mycobacterium avium-intracellulare, 
and RH2-11 had a history of Pneumocystis Carinii and CMV-retinitis. All 
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five of them suffered from end stage AIDS at the time of entry in the study. 
RH2-1 suffered from Kaposi's sarcoma since 1989, which was localised on 
the lower extremities. The other six patients were asymptomatic at entry. 
For eight of the individuals no information was available about the time 
of seroconversion. From three patients (RH2-9, RH2-10 and RH2-11) 
PBMC were not available. One individual, PH2-1, could be studied for 36 
months onward from the time of seroconversion, during which period his 
CD4+ cell counts decreased from about 600 to 160 cellsimm3 (Fig. 1). No 
overt clinical signs developed in this patient during the observation period. 
Western blot analysis of his serum samples collected during the first 16 
weeks after seroconversion showed that antibodies against all major HIV-2 
proteins developed (Fig. 1). 
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Figure 1. 
Sequential Western 
blot profiles of 
HIV-2 specific 
serum antibodies in 
patient PH2-1 
during seroconver-
sion in October 
1992, and his CD4+ 
cell count of during 
the 36 months 
period after sero-
conversion. 
Comparison of clinical and immunological status of HIV-1 infected indivi-
duals in the same West African origin in the Rotterdam hospital during the 
same study period showed that nine out of 17 HIV-1 infected individuals 
suffered from progressed HIV-related disease at the time of first presen-
tation in the clinic (table 1). The mean age of the HIV-1 infected population 
was 32 years, and the probable mode of transmission was heterosexual 
contact. 
Virus isolation 
HIV-2 was isolated in PHA-PBMC from the PBMC of six of the eight 
individuals with CD4+ cell counts ranging from about 600 to 10 cellsimm3 
(Table 2). The time of first HIV-p24 antigen detection in culture super-
natants, which ranged from seven to 42 days after inoculation, proved to 
correlate inversely with the patients CD4+ cell counts at the time of 
sampling (r = 0.95, ci = 0.99). The rapidly replicating HIV-2 isolates from 
patients RH2-2 and RH2-6, who suffered from end-stage AIDS, induced 
syncytia in the PHA-PBMC, whereas the other four HIV-2 isolates failed to 
do so. The four HIV-2 isolates from the patients with the lowest CD4+ cell 
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counts (130-10 cell/mm3) were shown to replicate in MT2 cells. The two 
isolates from the end-stage AIDS patients RH2-2 and RH2-6 induced 
syncytia and p24 antigen production after seven days (Table 2). Isolates 
from RH2-6, RH2-7 and PH2-1, who all had CD4' counts < 200 cells/mm3 , 
replicated in Sup T1 cells as shown by the presence of detectable p24 
antigen in the supernatants within 14 days. The HIV-2 isolates from 
patients RH2-6 and PH2-1 also induced syncytia in these cells (Table 2). 
No replication could be demonstrated with any of the HIV-2 isolates in H9 
cells. 
Day of first p24 antigen detection upon infection of 
PHA-PBMC MT-2 cells sup T1 cells H9 cells 
Individual 
RH2-11 NA" NA NA NA 
RH2-9 NA NA NA NA 
RH2-10 NA NA NA NA 
RH2-2 7 (Sit 4 (SI) 
RH2-6 7 (SI) 4 (SI) 7 (SI) 
RH2-5 14 (NSI) 7 (NSI) 
RH2-7 21 (NSI) 7 (NSI) 7 (NSI) 
PH2-1/ba 21 (NSI) 14 (SI) 
RH2-1 42 (NSI) 
PH2-1/aa C NTd NT NT 
RH2-3 NT NT NT 
RH2-8 NT NT NT 
RH2-4 NT NT NT 
virus 
HIV-1 IIiB 4 (SI) 4 (SI) 4 (SI) 4 (SI) 
HIV-1 ACH 172.BAL 6 (NSI) NT NT 
Table 2. HIV-2 Isolation and In Vitro Characteristics. aPH2-1/a, seven months after 
seroconversion, CD4' cell count 570/mm3; PH2-1/b, 36 months after 
seroconversion, CD4' cell count 200/mm 3• b(SI), syncytium inducing; (NSI), non-
syncytium inducing. c_, no p24 antigen demonstrated within six weeks of 
incubation. dNT, not tested. eNA, no materials available 
peR amplification of RT genes sequences 
To further characterise the HIV-2 isolates, RT gene segments were 
amplified and sequenced. The open reading frames from all the clones that 
were fully sequenced (n= 11) were intact with the active YMDD site present 
and no stop codons observed. Fig. 2 shows an alignment of the deduced 
amino acid sequences of one clone for each of the six HIV-2 isolates. 
Limited ... amino acid diversity wa:> .obs.ervecj in the individuals originating 
from the Cape Verdian Isles (91-94% identity). Phylogenetic analysis 
indicated that all these isolates grouped together (Fig. 3) and comparison 
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with published sequences included them into subtype A [11,18]. The 
French patient, who had probably been infected by an African immigrant in 
France of unknown origin, also grouped within subtype A (89-92% identity 
with the subtypes A from the Rotterdam area). The HIV-2 isolate from 
patient RH2-6, who is of Ghanese origin, proved to be more distantly 
related (84-86% identity with the subtype A isolates) and grouped within 
subtype B [11]. which was confirmed by Bootstrap analysis. 
Mutations related to zidovudine resistance 
RT fragments corresponding to the region that is implicated in zidovudine 
resistance in HIV-1 [19] were amplified for the two HIV-2 isolates from 
patients who had been treated with zidovudine for two years (RH2-2) and 
six months (RH2-5) respectively. In HIV-2 isolate RH2-2 mutation K28 -> 
R28 and in isolate RH2-5 K177-->M177 were identified. The former change 
has also been implicated in HIV-1 zidovudine resistance while the latter 
may be specific for HIV-2 isolates 
DISCUSSION 
In this paper we have presented clinical and virological data from twelve 
HIV-2 infected individuals living in West Europe. Nine of them were of West 
African origin and three were born in Western Europe. All except one (PH2-
1) had probably been infected through heterosexual contacts. Seven of the 
West African patients presented with an AIDS indicator disease or a CD4-
cell count <200/mm3• Therefore, the number of HIV-2 infected patients of 
West African origin with progressed HIV-related symptoms upon presen-
tation to the Rotterdam hospital was seven out of nine (Table 3). This ratio 
seems relatively high, when compared to data of HIV-2 infected patients 
presented by others [4,5]. It may be speculated that the relatively high 
number of symptomatic individuals in this group was caused by a 
reluctance to seek medical attention in the absence of clinical symptoms. 
This would imply that only the tip of an iceberg of HIV-2 infected individuals 
amongst the West African immigrant population of the Rotterdam area 
would have been included in this study. However, during the same obser-
vation period only nine of the 17 HIV-1 infected individuals from the same 
immigrant population presented with progressed HIV-related disease 
(Table 1). The median age of the HIV-2 and HIV-1 infected population was 
37 and 32 years respectively. 
Although no data were available on place and duration of both HIV-1 
and HIV-2 infection, several observations prompted us to speculate that 
HIV-1 and HIV-2 infections in our population had a similar rate of disease 
progression. First the ratios of asymptomatic versus symptomatic 
individuals were not in favour of a more rapid disease progression in HIV-1 
infected individuals within this group with the same social background, the 
same median time of residence in Europe and the same mean time of 
follow-up (32 months). Second, the rapid decline in CD4+ cell counts 
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observed in the French individual (PH2-1) over a 36 months observation 
period which clearly showed that HIV-2 infection may run a rapidly 
progressive course. This is not in agreement with the relatively slow 
disease progression reported by others for HIV-2 infected individuals [4,5J. 
SO far we could not identify any predisposing factors, like co-infection with 
other blood borne viruses or a seleelive immigration pattern amongst these 
individuals (data not shown). 
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Figure 2. Alignment of RT protein fragment sequences from six HIV-2 viral 
isolates. The nucleotide sequences were determined from peR amplification 
products, translated and aligned; ROD (HIV-2 subtype A) and 7312A (HIV-2 
subtype B) were used for reference purposes. The arrows (Y) indicate mutations 
corresponding with zidovudine resistance in HIV-1. 
The results of virus isolation studies in PHA-PBMC and T cell lines, 
indicating more successful virus isolation from individuals with progressed 
disease and low CD4+ cell counts, are in agreement with the data presen-
ted by others [8,20-22J. The correlation between a SI virus phenotype in 
PHA-PBMC and in MT2 cells, with more progressed disease and/or lower 
CD4+ cell counts, is similar to observations in HIV-1 infected individuals 
[20-22J. It indicates that like in HIV-1 infection this marker may be of 
prognostic value. No exact information about geographical origin of the 
HIV-2 infection of the individuals in our study could be obtained. 
Nt3verthele§s, in the phylogene\icanalysis of theRTgenesegmentsail the 
viruses from individuals of Cape Verdian origin clustered within subtype A. 
HIV-2 ROD, which also originated from an individual of Cape Verdian origin 
41 
[23], also clusters within this subtype. This phylogenetic analysis also 
indicated that the HIV-2 isolate from the individual born in Ghana (RH2-6), 
clustered within subtype B. This is the first subtype B strain reported to 
have a 81 phenotype. Preliminary sequencing data of the envelope genes 
of RH2-4, RH2-5 and PH2-1 indicate that RH2-4, who was born in The 
Netherlands, was infected by his wife RH2-5 of Cape Verdian origin. 
Furthermore, phylogenetic analysis of the envelope genes confirmed that 
RH2-4 and PH2-1 clustered within subgroup A, as was also demonstrated 
by RT gene analysis (R. Gruters, not published). Whether the RT mutations 
observed in the HIV-2 genes that are involved in HIV-1 zidovudine 
resistance result in increased resistance to zidovudine remains to be 
elucidated. To our knowledge this is the first description of mutations in 
HIV-2 possibly related to zidovudine treatment. 
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Figure 3. Phylogenetic tree of HIV-2 isolates estimated from their nucleotide 
sequences of RT fragments (UPGMA); ROD (HIV-2 subtype A), 7312A (HIV-2 
subtype B) and HXB (HIV-1) were used for reference purposes. 
Further evaluation of the development of clinical signs in the HIV-2 
infected individuals of this study population, together with changes in 
genotypic and phenotypic characteristics of their viruses, may show to what 
extent more or less variable viral characteristics contribute to, or correlate 
with, the pathogenesis of HIV-2 induced disease. 
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Summary 
Lymphoid tissue specimens collected from 10 HIV-2 infected individuals at 
different stages of the infection, were analysed by immunohistochemistry 
and in situ HIV-2 RNA hybridisation. Like in asymptomatic HIV-1 infected 
individuals, productively infected cells in the lymphoid tissue of asympto-
matic HIV-2 infected individuals, were predominantly found in areas with 
low numbers of CDS+ cells. In lymphoid tissue from asymptomatic HIV-2 
infected individuals, we found higher numbers of CDS+ cells in the follicles 
and five fold lower numbers of productively HIV infected cells, as compared 
to asymptomatic HIV-1 infection. Furthermore, plasma levels of viral RNA 
proved to be at least hundred times lower at this stage. In contrast, in HIV-2 
infected patients who had developed AIDS, plasma virus levels were only 
five times lower than in HIV-1 infected patients with AIDS. Productively 
infected CD4 + T cells were predominantly found around foci of inflamma-
tion. Collectively, the data presented indicate that a low level of virus 
production in lymphoid organs may explain the relatively long asymptomatic 
stage in HIV-2 infection. 
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Introduction 
The lentiviruses human immunodeficiency virus type 1 and type 2 (HIV-1 
and HIV-2), are the etiological agents of acquired immunodeficiency 
syndrome (AIDS) (1,2). HIV-1 is pandemic and although the number of 
reported HIV-2 related AIDS cases increases worldwide, high HIV-2 sero-
prevalence is still largely confined to West Africa (7-11). The in vitro charac-
teristics, like viral tropism for a- or ~-chemokine receptor positive CD4+ 
cells, induction of cytopathic changes (3-5), as well as the in vivo patho-
genesis they induce are similar. The most poignant differences between 
HIV-1 and HIV-2 infections are a generally slower disease progression (6) 
and significantly lower transmission rates observed in the latter (8-10). 
These observations parallel immunological changes observed in the 
respective infections both infections: CD4+ T cell counts and CD4/CD8 
ratios generally decline less dramatically in HIV-2 infected individuals (6). 
The mechanism underlying these differences between HIV-1 and HIV-2 
are not known. Virus isolation and proviral PCR studies have indicated that 
the overall viral burden in HIV-2 infected individuals is lower than that in 
HIV-1 infected individuals (14,15). Furthermore a recent study showed that 
plasma HIV-2 viral RNA levels in HIV-2 infected individuals with more than 
14% CD4 cells are significantly lower than in HIV-1 infected individuals at 
the same stage of the disease. In AIDS patients with less than 14% CD4 
cells, the plasma levels of HIV-1 RNA and HIV-2 RNA were comparable. 
The limited information presently available on the pathogenesis of HIV-2 
as compared to HIV-1 infection, prompted us to study the tissue architec-
ture as well as the nature and localisation of HIV-2 infected cells in lymph-
oid tissues collected from HIV-2 seropositive individuals at different stages 
of the infection. Similar studies have in the past significantly improved the 
knowledge on the pathogenesis of HIV-1 infection. It is well established that 
the lymphoid organs represent a major reservoir for HIV-1 (24,25). The viral 
burden in the lymph nodes proved to be magnitudes higher than in the 
peripheral blood (19). As a consequence of permanent infection, lymphoid 
tissue shows several architectural changes ranging from follicular hyper-
plasia to lymphocyte depleted nodes. 
No published data are available on changes of lymphoid tissue in HIV-2 
infection. Our study was done to assess HIV-2 replication in lymphoid 
tissues obtained at different stages of the infection. The data were compa-
red with plasma HIV-2 RNA levels determined with a recently developed 
assay, and with lymphoid tissue and plasma samples obtained from both 
HIV seronegative and HIV-1 seropositive individuals using the same 
techniques. 
Materials and methods 
Patients and materials 
Surgical lymphoid tissue biopsy specimens were collected with informed 
consent from 10 HIV-2 infected West African individuals (nine from the 
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Cape Verde Islands, one from Guinea Bissau) residing in Rotterdam, for 
diagnostic purposes. From seven patients who exhibited some lymph node 
enlargement, a cervical lymph node biopsy was taken and from three 
patients with tonsil hypertrophy a tonsil biopsy was taken. Two patients on 
anti-retroviral therapy (RH2-17 and RH2-5) failed to show clinical improve-
ment upon therapy as judged from a continuing decline in CD4+ T cell 
counts (RH2-17) or a new AIDS defining event (RH2-5): a disseminated 
Mycobacterium tuberculosis (MTB) was diagnosed using lymph node 
biopsy material. Clinical data of these 10 HIV-2 infected individuals are 
presented in table 1. HIV-2 infected individuals were divided into two 
groups on basis of a CD4 count either below (group 1) or above (group 2) 
200 celis/pI. 
Patient gender age 
RH2-12 F* 
RH2-4 M 
RH2-3 F 
RH2-13 F 
RH2-14 F 
RH2-15 M 
RH2-16 
RH2-17 
RH2-5 
RH2-51 
RH2-5r 
RH2-18 
F 
M 
F 
M 
36 
47 
38 
31 
39 
29 
59 
59 
42 
42 
35 
CDC CD4+ Tonsil/lymph 
stage cells/,Ll node 
990 Tonsil 
740 Tonsil 
660 Tonsil 
580 Lymph node 
570 Lymph node 
310 Lymph node 
antiviral 
therapy 
No 
No 
No 
No 
No 
No 
A1 
A1 
A1 
A1 
A1 
A2 
A2 
A2 
C3 
C3 
270 
230 
Lymph node No 
A3 
Lymph node AZT/3TC/SQV 
150 Lymph node 
120 Left tonsil 
Right tonsil 
110 Lymph node 
AZT/3TC 
AZT/3TC 
No 
Table 1. Clinical Characteristics HIV-2 Seropositive Patients. F is female and M is 
male 
For comparison lymph node specimens obtained previously from HIV-1 
infected patients were selected. Six lymphoid tissue specimens had been 
collected from HIV-1 infected patients with little or no lymph node 
enlargement and CD4+ cell counts >500/pl (16). Four HIV-1 infected lymph-
oid tissue biopsies had been obtained from HIV-1 infected patients with 
AIDS (17). Biopsy specimens from 10 HIV-negative individuals were 
sl;l.l.e.ct.e.d from our previously published studies (16). All HIV,2 seropositive 
individuals, regularly attending the clinic in Rotterdam, were selected for 
quantitative HIV-2 RNA determinations. Forty-eight HIV-1 and 17 HIV-2 
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infected individuals, not on highly active antiretroviral treatment (HAART), 
were sampled and divided in two groups based on CD4 cell counts below 
or above 2001;11, as was done for the molecular pathological examinations. 
Light microscopy 
Histological procedures were followed as previously described (16). In 
short, part of the tissue was fixed overnight with 4% neutral buffered 
formalin and subsequently embedded in paraffin or directly embedded in 
Tissue Freezing Medium (Leica Instruments, Nussloch, Germany), snap 
frozen in liquid nitrogen and stored at -70GC. Dewaxed 51lm paraffin 
sections were cut and stained with hematoxylin and eosin, Giemsa, Gomori 
silver impregnation, Ziehl-Neelsen and Grocott's staining. 
Immunohistochemistry 
Dewaxed paraffin sections were boiled in a domestic pressure cooker for 
3 min. and chilled down to room temperature. Cryostat 5 11m sections were 
fixed with 2% paraformaldehyde for 10 min. Paraffin or frozen sections 
were incubated with the primary antibodies ( CD4, Novocastra, Newcastle 
upon Tyne, UK, 1:40; CD8, Dako 1:10; CD23, Dako 1:100; CD45 RO, Dako 
1: 100; CD68, Dako 1:10, KiM4p, generously gifted by M. Parwaresch, 
University of Kiel, Germany). Binding of antibodies was visualised by the 
alkaline phosphatase anti-alkaline phosphatase technique using New 
Fuchsin as chromogen. The sections were then either counter-stained with 
hematoxylin and mounted, or dehydrated and subjected to in situ 
hybridisation to detect HIV RNA. 
In situ hybridisation 
35S-labeled, single stranded, anti-sense HIV-1 and HIV-2 RNA probes 
(Lofstrand Labs., Gaithersburg, MD,USA) were used. The HIV-2 probe was 
constructed and kindly provided by C.H. Fox (Molecular Histology Lab, 
Gaitersburg, MD). The in situ hybridisation was done as previously 
described (16,18). In short, frozen sections were fixed in 4% 
paraformaldehyde for 20 min. Paraffin sections were either treated with 
Proteinase K (0.01 mg/ml) for 8 min. at room temperature or boiled in a 
pressure cooker in citrate buffer (pH 6) for five minutes and run in duplicate. 
The sections were incubated with prehybridisation mixture (50% 
formaldehyde, 0.5 M NaCI, 10 mM Tris-HCI, pH 7.4, 1 mM EDTA, 0.02% 
Ficoll-polyvinylpyrrolidone-BSA and 7 mg of tRNA/ml) for 2 hours at 37'C 
and then covered with hybridisation mixture (prehybridisation mixture 
supplemented with 10% dextran sulfate and 2x106 dpm of probe/ml) 
overnight at 45'C. The sections were washed with three changes, each in 
50% formamide: 50% 2 x standard saline citrate (SSC), 2 x SSC-0.1 % 
Triton, and finally 0.1 x SSC. Sections were digested with RNase 
(Boehringer Mannheim, GmbH, Mannheim, Germany) at 37'C for 40 
minutes. After an additional washing step the slides were dipped into photo 
emulsion (NTB2; Kodak, Rochester, NY) exposed for 3-7 days and 
developed, counter-stained with hemalaun and mounted. As a negative 
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control, sections were hybridised with a 35S labelled sense probe. The 
sections were examined with a microscope equipped with epiluminescent 
illumination (Axiophot; Carl Zeiss Inc., Jena, Germany). Cells were conside-
red positive for viral gene expression if the grain count was more than six 
times the background. 
Figure 1. HIV-2 In Situ Hybridisation and Immunohistochemistry on Lymphoid 
Tissue. A lymph node biopsy of patient RH2-13 showing irregular follicular hyper-
plasia with irregular shaped follicles (A). The structure of FOC (arrows), visualised 
with red staining (C023), is reasonably intact and HIV-2 ISH overlay is visualised 
with green epiluminescence (8). A tonsil biopsy of RH2-5 showing HIV-2 producing 
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cells, visualised by silver grains, in the lymphoid epithelium CD8' cells are stained 
red (C) 
Semiquantitative Image Analysis of C04+, COB+ or HIV-RNA + cells 
Using a 20 x objective, regions of germinal centres (GC) and T cell 
dependent areas (T zones) were marked on the monitor. Total CD4+ and 
CD8+ cells were counted in these areas. Ten fields of GC and T zones were 
counted on each slide. The percentages of cell subsets were calculated in 
the designated areas. For the quantification of the number of HIV-RNN 
cells per mm2, the microscope was equipped with an image analyser (Carl 
Zeiss Inc., Jena, Germany). The numbers of HIV-RNA+ cells located in the 
GC and extra follicular tissue were counted in the whole cutting level of the 
tissue specimen. The surface areas occupied by the GC and extra follicular 
tissue was determined. 
Quantitative viral RNA assays 
For the quantification of HIV-1 viral RNA levels in plasma, the Cobas 
Amplicor assay (Roche Diagnostics, Almere, The Netherlands) was used. A 
recently described in-house developed assay was used to quantify the 
plasma HIV-2 RNA levels (Schutten et al submitted). In short, viral RNA 
was isolated from EDTA plasma using a slightly modified High Pure Viral 
RNA Isolation kit (Roche Molecular Diagnostics, Mannheim, Germany). 
cDNA was made with AMV-RT using the 3'primers HIV-2TMrpr1 5'-
CCACACGCTGCCTTTGGTA-3' and HIV-2TMrpr2 5'-TCTGCATGGCTGC-
TTGATG-3'. The cDNA was detected with the Taqman real time detection 
PCR method using two different primer/probe sets. Set one encompassed 
a region between the 5' L TR and the Gag/Pol open-reading frame 
(nucleotides 380 to 441 of the HIV-2 NIHZ isolate). Set 2 encompassed a 
region in the gag gene (nucleotides 1078 to 1144 of the HIV-2 NIHZ 
isolate). As standard for the quantification, an electron microscopy counted 
virus stock from the HIV-2 NIHZ isolate was used (ABI, catalogue number 
10-128-000, Maryland, USA). 
Results 
Tissue architecture 
Follicular hyperplasia with irregularly shaped follicles (Fig. 1A) were 
observed in 4 lymphoid tissue samples obtained from HIV-2 infected 
individuals with peripheral CD4+ T cell counts >200Irtl. The GC showed a 
starry sky pattern. The mantle zone was also attenuated in these 
specimens. In all nodes proliferation of high endothelial venules was 
observed. The T dependent zone contained elevated numbers of activated 
lymphocytes. The biopsy taken from patient RH2-5, HIV-2 positive, CD4+ T 
cell count <200/111, showed multiple granulomas with or without caseation 
<lod.epitheloid ... cell l<lyers (Fig2). Multiou.cle .. <lted cells of L<logh<los(ype 
were observed. The tonsil (right) biopsy taken from this patient after six 
months of specific MTB treatment showed an increased number of 
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granulocytes in a part of the squamous epithelium (not shown). This 
increase was not observed in the left tonsil. On basis of the histological 
examination, we were unable to identify the causative agent of this focal 
inflammation. The lymphoid tissue obtained from a cervical lymph node 
from patient RH2-18 showed evidence of a monocytic B cell reaction in the 
subcapsular and intermediate sinuses. Multiple giant cells were present in 
these areas (Fig. 3A). In sections taken at other levels of the same lymph 
node no aberrant histological observations were made (Fig. 3B). 
RH2-3 
RH2-12 
Peripheral blood Lymphoid tissue 
C04 C08 C041 C04 count C08 count C04/C08 
count count C08 -G-C--E-L-T--G-C-E-L-T--G-C--E-L-T-
660* 530 1.24 
990 1270 0.78 
89 318 81 183 1.00 1.74 
70 298 89 200 0.76 1.15 
';; RH2-13 580 960 0.60 90 314 71 174 1.27 1.80 
39 153 1.20 1.00 
30 167 0.80 0.87 
:J 
2 RH2-16 270 1480 0.18 47 159 
(9 
RH2-17 230 1150 0.23 37 177 
Mean 545 1078 0.60 66 253 
RH2-5 150 490 0.31 20 177 
N RH2-51 120 470 0.25 33 201 
Q 5 RH2-5r 120 470 0.25 40 237 
~ 
(9 RH2-18 110 2480 0.04 NO NO 
62 175 1.00 1.23 
27 234 0.74 0.75 
41 229 0.80 0.87 
52 207 0.70 1.15 
73 142 NO NO 
Mean 125 977 0.21 37 205 48 203 0.75 0.92 
HIV-1 649 NO 0.57 NG NG NG NG 1.7 1.4 
NO NO NO NG NG NG NG 20 3.7 
Table 2. Immuno Histopathological Characteristics. * CD4 and COB counts are 
given in cells per ~tl and mm' in peripheral blood and lymphoid tissue respectively. 
Mean numbers per group are given in bold face 
Immuno-histopathology and distribution of HIV-2 RNA positive cells in 
lymphoid tissue biopsies from individuals with peripheral CD4 cell counts 
>20011Ji (group 1) 
In several individuals with low peripheral blood C04' T cell counts conside-
rable numbers of tissue C04' T cells. were. observed (table 2). To further 
address this issue, we used a previously described semi-quantitative 
method to count the numbers of C04' and C08' T cells in GC and in T 
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zones (17) (Table 2). For comparison previously obtained data from sero-
negative and HIV-1 infected subjects, generated with the same method 
(16), were used. It could be calculated that the number of CD4+ T cells in 
peripheral blood of HIV-2 seropositive individuals as compared to HIV-
negative individuals was 46% lower whereas the CD4+ T cell counts in the 
GC and T cell zone of lymphoid tissues from HIV-2 infected individuals 
were about 13% and 20% lower than in HIV negative individuals. The mean 
tissue CD4/CD8 ratios in the GC of tissue biopsies obtained from HIV-1 
and HIV-2 infected individuals were 1.7 and 1.0 respectively. The lower 
CD4/CD8 ratio in the GC area of the HIV-2 seropositive individuals was 
largely due to higher numbers of CD8' cells (data not shown). The mean 
CD4/CD8 ratio in the peripheral blood and lymphoid tissue T zones did not 
differ substantially between the two groups (0.6 both and 1.2 versus 1.4 
respectively). 
Figure 2. HIV-2 in situ hybridisation and immunohistochemistry of a lymph node of 
patient RH2-5, co infected with Mycobacterium tuberculosis. Within the lymph node 
granulomas are observed with large caseous necrotic centres (GNG) surrounded 
by an epitheloid cell layer and many macrophages (A). In the perinecrotic zone 
(PNZ) a large number of HIV-2 producing cells were observed (silver grains, 
indicated by arrows). Immunolabeling showed an abundance of CD6S' macro-
phages (red staining, A and inset II), but virus producing cells proved to be 
Cb4+Cb45RO' Tcelis(redsfaining, inset I) 
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Both in the HIV-1 and the HIV-2 infected individuals, HIV-RNN cells 
were mainly confined to GC in lymph nodes and tonsils and to the lymph 
epithelium of the tonsils (Fig.1 B, table 3). In both areas low numbers of 
CD8+ T cells were found (Table 2). We subsequently determined the 
phenotypes of the virus producing cells by double labelling for HIV-2 RNA 
with in situ hybridisation and immunohistochemical staining for CD4, 
CD45RO, CD68 or lysozyme. All productively HIV-2 infected cells proved to 
be CD45RO+CD68'lysozyme', identifying them as CD4+ T cells. When 
compared with lymphoid tissues from HIV-1 infected individuals, there 
seemed to be a relatively low number of trapped HIV-2 RNA overlying the 
FDC network (Fig 1 C). For HIV-1, it has been shown that the number of 
productively infected cells is directly related to both the amount of trapped 
virus onto the FDC processes and to plasma viral load (20). We therefore 
counted numbers of virus producing cells in GC and the T zones (table 2). 
The mean number of HIV RNN cells per mm2 in the total surface area is 
approximately five times lower for the tissues obtained from asymptomatic 
HIV-2 infected patients (0.29) than the number found in tissues from 
asymptomatic HIV-1 infected patients (1.34) (table 3). 
Immuno-histopathology and distribution of HIV-2 RNA positive cells in 
lymphoid tissue biopsies from individuals with peripheral CD4 cell counts 
<2001pl (group 2) 
In the biopsies from individual RH2-5, high numbers of HIV-2 RNN cells 
were observed around the granulomas in the lymph node (Fig 2) and in the 
area in the right tonsil where the increase of granulocytes had been 
observed (data not shown). The number of HIV-2 RNN cells was markedly 
higher than in areas without aberrant histological signs (Table 3). The 
lymph node biopsy of individual RH2-18 showed many HIV-2 RNN cells in 
sections 2 and 3, where also the monocytic B cell reaction and Langhans 
type giant cells were observed (table 3, Fig 3A). Section 1 showed fewer 
HIV-2 RNN cells (table 3, Figure 3B). Most HIV-2 RNN cells, in both tonsil 
and lymph node biopsies from individual RH2-5, were CD45RO+CD68' 
lysozyme' cells, identifying them as CD4+ T cells (Figure 2 inset). In 
sections 2 and 3 from the lymph node specimen of individual RH2-18 
multiple HIV-2 RNA+CD68+ multinucleated cells were observed at the sites 
of the monocytic B cell reaction (data not shown). In the other parts of the 
lymph node all productively HIV-2 infected cells were CD45RO+CD68' 
lysozyme'. 
Quantitative HIV-1 and HIV-2 plasma viral RNA loads 
Thirty-three HIV-1 and 9 HIV-2 infected individuals with a CD4 cell count 
below 200/pl and 15 HIV-1 and 8 HIV-2 infected individuals with a CD4 cell 
count above 2001;11 were selected. The results of quantitative HIV-1 and 
HIV-2 viral load determinations are shown in figure 4. The difference 
between the mean quantitative plasma viral loads of HIV-1andHIV-2 
infected patients with CD4 count less than 200l;tI was significant (Student T 
test, p=0.014). In six out of eight samples from HIV-2 seropositive indivi-
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duals with more than 200 CD4 cells per rtl plasma viral RNA levels proved 
to be below the detection limit « 500 copies/ml), whereas only one of the 
HIV-1 samples was below the detection limit of 500 copies/ml. Mean HIV-2 
RNA plasma viral loads were at least 2 10glO lower than in HIV-1 infected 
individuals in this stage of the infection (Figure 4). 
CD4 count 
HIV RNA' cells/mm2 
GC ELT TOTAL 
RH2-12 990' 0.28 0 0.03 
199/87 914 0.04 0 0.01 
RH2-3 660 0.87 0.15 0.3 
~ 
"- RH2-13 580 0.13 0 0.05 
::J 
0 RH2-15 310 1.66 0.90 1.03 '-(') 
RH2-16 270 1.19 0.08 0.45 
RH2-17 230 2.38 0 0.2 
Mean 565 0.95 0.16 0.29 
RH2-5 150 5' 7* 38** 
RH2-51 120 1.8 Ind 1.14 
N RH2-5r 1.77 Ind 2.4 
"- RH2-18#1 110 0.36 0.62 0.55 ::J 0 
'- RH2-18#2 6.7 7.61 7.28 (') 
RH2-18#3 7.52 2.31 2.93 
mean 127 3,63 2,83 2,86 
209/96 580 1.62 0.7 1.12 
149/96 570 1.66 0.97 1.28 
1008/88 500 1.06 0.32 0.53 
~ 
>- 126/96 500 1.93 1.27 1.62 
I 799/95 400 0.73 0.32 0.49 
629/97 380 5.18 1.68 3.01 
mean 488 2.03 0.88 1.34 
Table 3. • Peripheral blood CD4' T cell per (11. Ind = indeterminate, * = All HIV-
RNA' cells/total surface area, not processed in the mean ** = the mean total 
number of HIV-RNA' cells in three granulomas 
Discussion 
In the present study we have shown that the plasma and tissue viral loads 
in HIV-2 infected individuals is significantly lower than that in HIV-1 infected 
individuals at the same stage of infection. Productively infected cells in both 
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HIV-1 and HIV-2 infected individuals were mainly located in areas with low 
numbers of CDB+ T cells. Higher numbers of CDB+ T cells were found in the 
GC of the HIV-2 infected individuals than in the GC of HIV-1 infected 
individuals. Relative to the healthy uninfected control individuals studied, 
both HIV-1 and HIV-2 infected individuals had higher numbers of CD4+ cells 
in their lymphoid tissue as compared to the peripheral blood. 
Figure 3. HIV-2 in situ hybrid is at ion of a lymph node of patient RH2-18. HIV-2 
particles are visualised with green epiluminescent light. Arrows indicate infected 
cells. 
In HIV-1 infection the number of productively infected cells in lymphoid 
tissues, as determined by HIV-1 RNA in situ hybridisation, directly corre-
lates with plasma viral load (19). In the HIV-2 infected individuals with a 
CD4 count above 200htl, the numbers of productively infected cells proved 
to be approximately five times lower than in HIV-1 infected individuals at 
the same stage of the infection. From these data it may be concluded that 
the mean plasma viral load in the HIV-2 positive individuals also should be 
about five times lower than in HIV-1 seropositive individuals. However, the 
mean plasma HIV-2 RNA load, obtained with the recently developed quan-
titative HIV-2 RT-PCR, proved to be at least 100 times lower. Two obser-
vations suggest that a slower replication rate is responsible for the lower 
plasma viral load in the HIV-2 infected individuals. The in situ hybridisation 
staining, which is directly correlated with the number of virus particles, in 
general proved to be less intensive for HIV-2 infected cells than for HIV-1 
infected cells (ref.17 and fig 1C, 2, 38,). We furthermore recently obtained 
a pre-seroconversion sample from an HIV-2 infected individual which 
proved to contain approximately 104 HIV-2 RNA copies per ml. This is 
significantly lower as compared to pre-seroconversion samples from HIV-1 
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infected individuals suggesting a lower production rate of HIV-2 than of 
HIV-1. This may subsequently result in a low post-seroconversion-nadir 
and a relatively low stable set point of plasma HIV-2 RNA. In HIV-1 infec-
tion the level of plasma HIV-1 RNA is correlated with survival (21). Analo-
gous to HIV-1 infection, the low levels of plasma HIV-2 RNA during and 
after primary infection may explain the prolonged asymptomatic phase of 
HIV-2 infection as compared to HIV-1. Both the number of productively 
infected cells and the plasma HIV RNA levels of the HIV-2 infected patients 
with CD4+ cells <200hd proved to be approximately five times lower than 
those found in HIV-1 infected individuals with CD4 counts below 200hd and 
equal to those found in HIV-1 infected individuals with CD4 counts >200hd. 
These data implicate that in contrast to what was generally assumed 
disease progression in the end stage of the HIV-2 induced pathogenesis is 
slower as compared to that of HIV-1. These data therefore corroborate 
findings of Lucas ef al (28), who showed that opportunistic infections that 
are in general only found in HIV-1 infected individuals who are immuno-
suppressed for a long period of time, are found more often in HIV-2 
infection than in HIV-1 infection. This already suggested a prolonged 
survival of HIV-2 infected individuals in the end stage of the disease. 
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Figure 4, Plasma Vira.l. RNA Load .in HIV-1 and HIV:2 Seropositivelndiyiduals. 
Plasma HIV RNA levels in individuals with CD4 counts below (left panel) and 
above (right panel) 200/f11. The mean CD4 cell counts are given. Mean plasma viral 
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loads ( ) are given and the Student T test P value for the comparison of the 
plasma HIV-1 and HIV-2 RNA values for the patients <200 CD4/p!. • Calculation of 
mean plasma viral load is not possible due to non accurate values <500 copies/m!. 
It has been shown that during the acute phase of HIV-1 infection, the 
appearance of HIV-1 specific CDS+ T lymphocytes coincides with a drop in 
plasma HIV-1 RNA (22). Furthermore, antiviral pressure exerted by HIV-1 
specific T lymphocytes during this stage, may lead to rapid selection of 
escape variants (23). It is therefore generally accepted that HIV-1 specific 
CDS+ T cells are a major antiviral component of the HIV specific immune 
response. This is supported by our observation that the numbers of 
productively infected cells are significantly lower in areas where relatively 
high numbers of CDS+ cells are present. In HIV-seronegative individuals 
CDS+ T cells are rarely found in the GC, but they can be found in the GC of 
lymphoid tissues from HIV-infected individuals. It has therefore been 
suggested that HIV-1 specific CDS+ T cells migrate into the GC since high 
amounts of virus can be found in these areas (24). Here we have shown 
that the CD4/CDS ratio in the GC of HIV-2 infected individuals is markedly 
lower than in HIV-1 infected tissue, due to a higher number of CDS+ T cells 
in the GC of HIV-2 infected individuals. In the T zones and the peripheral 
blood no significant differences between the two groups were found. It may 
therefore be speculated that CDS+ T cells in HIV-2 infected individuals are 
more efficient in controlling virus replication than in HIV-1 infected 
individuals. 
In HIV-1 infection it has been shown that viral loads increase during 
opportunistic infections at end stage disease (25,26). Successful specific 
treatment for the infectious agent usually results in a return of plasma viral 
loads to baseline levels. Also in the HIV-2 infected biopsies, one of them 
co-infected with MTB, increased numbers of productively infected cells 
were found at the sites of focal inflammation. In HIV-1 infection it has 
recently been postulated that there is a switch towards macrophages as the 
major source of virus production during such inflammatory reactions 
involving high numbers of activated macrophages (27). In the MTB infected 
lymph node of patient RH2-5, in which high numbers of activated 
macrophages were found, and in the tonsil of the same patient, which 
showed increased numbers of granulocytes, productively HIV-2 infected 
cells all proved to be CD4+ T cells. These data are in agreement with our 
recent findings in HIV-1 infected individuals, co-infected with MTB or 
Mycobacterium avium complex, in which CD4+ T cells remained the major 
source of HIV-1 production (17). Studies on the lymph node of patient 
RH2-1S, obtained at the time when the histology showed a monocytic B cell 
reaction, did reveal production of HIV-2 by CD6S+ multinucleated giant cells 
of monocytic origin in some areas, whereas in other areas CD4+ T cells 
proved to be the main source. 
Collectively, the data indicate that the slower disease progression and 
the lower transmission rate in HIV-2 infection can be explained by a slower 
replication rate of HIV-2 as compared to HIV-1. 
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SUMMARY 
Objective: To assess the source of HIV-1 production in lymphoid tissue 
biopsies from HIV-infected patients, with no prior anti-retroviral protease 
inhibitor treatment, with a CD4' cell count >150/f.l1 (group I) or <50/f.l1 (group 
II), co-infected with Mycobacterium tuberculosis or Mycobacterium avium 
complex. 
Design and methods: Lymphoid tissue biopsies from 11 HIV-1 infected 
patients, taken for diagnostic purposes, were studied by HIV-1 RNA in situ 
hybridisation and immunohistochemistry 
Results: Patients of group I showed well organised granulomas, in contrast 
to patients of group II, in which granuloma formation was absent. HIV-1 
RNA' cells in group I patients were mainly found around the granulomas, 
whereas in group II HIV-1-producing cells were confined to areas with 
remaining intact lymphoid tissue. Despite the abundant presence of 
macrophages, the productively infected HIV-1-positive cells in both groups 
were almost exclusively CD4' T cells. 
Conclusion: In contrast to previously published data, CD4 T cells appear 
to remain the major source of HIV-1 production in end-stage disease 
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Introduction 
Molecular histopathological studies of lymphoid and non-lymphoid tissues 
of HIV-1 infected individuals have contributed considerably to our know-
ledge of the mechanisms involved in HIV-1-induced disease. Soon after 
infection, when HIV-1-specific humoral and cellular immune responses can 
be demonstrated, virus production is confined largely to CD4 T cells located 
within lymphoid tissues such as lymph nodes, mucosa associated lymphoid 
tissue (MALT) and spleen (1-4). During the entire asymptomatic stage of 
the disease, CD4 T cells are the major source of HIV-1, whereas produc-
tively infected cells expressing macrophage or dendritic cell markers are 
observed rarely in lymphoid tissues. Productively infected macrophages 
and dendritic cells have been observed in nasopharyngeal lymphoid 
tissues, cervix and brain (5-10); however, these cells are generally believed 
to contribute minimally to the high levels of virus produced throughout the 
course of the infection. During the asymptomatic and early symptomatic 
stages (CD4>200/~d), follicular hyperplasia with irregularly shaped follicles 
is often observed (11,12). Large numbers of virus particles within immune 
complexes are then captured onto the processes of follicular dendritic cells 
(1,2). 
In the intermediate stages of the infection, the numbers of productively 
infected CD4' T cells within lymphoid tissue increase (1,2). Ultimately how-
ever CD4' T cells almost disappear and the architecture of lymphoid tissue, 
especially with regard to the germinal centres and the follicular dendritic 
cells network, is disrupted and the ability to trap virus is lost. Also at this 
stage of the disease, virus production is relatively high (13). The increase of 
cell-free plasma HIV-RNA and the virtual absence of CD4' T cells, which 
are thought to be the major source of virus production, is up till now an 
unresolved paradox. Recently it has been suggested by Orenstein et ai, 
that a possible explanation may be the switch from CD4' T cells to another 
cell type as the major source of virus during end-stage disease (14). An 
alternative explanation could be that due to the increased replication rate of 
HIV-1 at end-stage disease, as well as a higher percentage of infected 
cells, a small reservoir of CD4' T lymphocytes is sufficient to produce the 
observed increased levels of cell-free virus in plasma (15). 
To address this issue we studied lymphoid tissue biopsies from 11 HIV-1 
infected patients co-infected with Mycobacterium tuberculosis (MTB) or 
Mycobacterium avium- complex (MAC), by HIV-1 RNA in situ hybridisation 
and immunohistochemistry. Patients co-infected with MTB or MAC were 
selected because of their lymphoid tissue generally contains large numbers 
of macrophages. The hypothesis of Orenstein et ai, that at end-stage 
disease the bulk of HIV-1 production shifts from CD4' T cells to macro-
phages, may be tested by studying these patients. 
Material and methods 
Patient materials. 
Lymph node specimens taken from eleven HIV-1-seropositive patients 
for diagnostic purposes, were selected for this study. The selection criteria 
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were: HIV-1 laboratory diagnosis; MTS or MAC laboratory diagnosis; peri-
pheral blood CD4+ T cells <500/1l1 or AIDS-defining disease; no prior anti-
retroviral therapy with protease inhibitors. The peripheral blood CD4 cell 
counts and co-infections are listed in Table 1. 
Immunohistochemistry 
Tissues were fixed overnight with 4% buffered formalin (pH 7) and 
subsequently embedded in paraffin. The tissues were cut for routine 
histology (Giemsa, Ziehl-Neelsen, haematoxylin & eosin and Gomori's 
silver impregnation). For immunohistochemistry, dewaxed 51lm paraffin 
sections were placed in a domestic pressure cooker containing 0.01 M 
sodium citrate solution (pH 6), boiled for 2 min, and chilled to room 
temperature (16). Primary antibodies towards CD4 (Novocastra, Newcastle 
upon Tyne, UK), CD68 (KP1), lysozyme and CD45RO (UCHL-1) 
(Dakopatts, Copenhagen, Denmark) were used as described previously 
(17). The sections were subsequently either counter-stained with haema-
toxylin & eosin and mounted, or they were dehydrated and subjected to HIV 
RNA in situ hybrid",is.;;.;a",t::.;:io;.;.n;;..' ______________ _ 
Patient CD4+ T Co-infection 
celis/ill 
1 427 MTS 
2 440 MTS 
3 300 MTS 
4 200 MTS 
5 170 MTS 
6 <50 MTS 
7 <50 MTS 
8 <50 MAC 
9 <50 MAC 
Undefined 10 ND MTS 
11 ND MTS 
Table 1. Clinical characteristics of 11 HIV-1 seropositive patients. aGroup I, pat-
ients with CD4 cell count 50-500/ftl; Group II, patient with CD4 cell count <50 /fll. 
ND, not done 
In situ hybridisation 
A r35S1-labelled, single stranded, anti-sense HIV-1 RNA probe (Lofstrand 
Labs., Gaithersburg, Maryland, USA), which contains 1.4-2.7 kb fragments 
collectively representing approximately 90% of the HIV-1 genome, was 
used as previously described (3). In short, paraffin sections wer.e ... e.itheJ 
treated with proteinase K (0.01 mg/ml) for 8 min. at room temperature or 
heat denatured in citrate buffer (pH 6). The sections were incubated with 
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prehybridisation mixture (50% formamide, 0.5 M NaCI, 10 mM Tris-HCI (pH 
7.4), 1 mM EDTA, 0.02% Ficoll-polyvinylpyrrolidone-BSA and 7 mg of 
tRNA/ml) for 2 hours at 37"C and then covered with hybridisation mixture 
(prehybridisation mixture supplemented with 10% dextran sulfate and 2x106 
d.p.m. of probe/ml) overnight at 45°C. The sections were washed, RNAse 
treated (Boehringer Mannheim GmbH, Mannheim, Germany) for 40 min. at 
37°C and rewashed and then dipped into emulsion (NTB2; Kodak, 
Rochester, New York, USA). After exposure for 3-7 days the slides were 
developed, counter-stained with haemalaun and mounted as previously 
described. As negative controls, sections were hybridised with a radio-
labelled sense probe. The sections were examined with a microscope 
equipped with epiluminescent illumination (Axiophot, Carl Zeiss Inc., Jena, 
Germany). Cells were considered positive for viral gene expression if the 
amount of grains counted was more than six times the number in the 
background. 
Results 
Lymph nodes from patients with 150-500/pl peripheral CD4 T cells, 
hereafter referred to as group I patients, contained multiple well-organised 
granulomas occupying 50-90% of the cutting surface. In parts of the tissue 
that were not involved in the granuloma formation, the nodal architecture 
with T cell dependent zone and several small inactive germinal centres was 
preserved. The granulomas were composed of epitheloid cells, multi-
nucleated cells of the Langhans'- type and CD4+ as well as CD8+ T lymph-
ocytes. The central part of the granulomas often showed caseation (data 
not shown). In contrast, in lymph nodes from patients with peripheral CD4+ 
T cell counts <50hll, hereafter referred to as group II patients, well-
organised granulomas were absent. The nodal architecture was obscured 
by heavy confluent infiltrate consisting of macrophages, intermingled with 
reactive plasma cells. The macrophages contained many acid-fast bacilli. 
The number of CD4+ T lymphocytes was decreased; they were present only 
in the remnants of lymphoid tissue seen as small islets at the periphery of 
the lymph nodes or between the bands of macrophages (Fig. 1 a). 
In the lymphoid tissues from the group I patients, the number of HIV-1 
RNA-positive cells was unevenly distributed. Significant numbers of cells 
with a heavy in situ hybridisation overlay were observed mainly around the 
granulomas and occasionally within the granulomas (Fig. 1b). The numbers 
of HIV RNA-positive cells within the parts of the nodes where granulomas 
were observed, were approximately 10 fold higher than those in lymphoid 
tissue areas that did not contain granulomas (data not shown). In lymphoid 
tissues from end stage disease patients (group II), the numbers of HIV-1 
RNA-positive cells were not significantly increased as compared to 
lymphoid tissue areas where no infiltrate of macrophages was observed. 
HIV-1 producing cells were confined to areas with remaining lymphoid 
tissue (Fig. 1 a). 
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Fig.1 HIV-1 in situ hybridisalion on lymph nodes co·infected with Mycobacteria. (a) 
One MAC·infected lymph node from an HIV-1 infected palient NO.8. The HIV-1 
RNA signal (arrow) is present only in areas with some intact lymphoid architecture 
(original magnification 40x). (b) A M. Tuberculosis infected lymph node (patient 
No.1) with considerable numbers of CD4' T cells (red), and a significantly higher 
number of HIV-1 RNA-posilive cells (arrows). The insert (I) shows double staining 
of HIV-1 RNA and CD45RO positive cells (original magnification 400x). (e) Abun-
dant numbers of macrophages (red) did not correspond with HIV-1 RNA' cells 
(arrows). (d) Occasionally an HIV-RNA'CD68'lysosym' cell was observed (arrow). 
The phenotype of the productively HIV-1-infected cells was subse-
quently determined by double labelling of HIV RNA by in situ hybridisation 
and··immunohistochemical staining· forCD4,CD45RO,CD68orlysozyme. 
Despite the abundant presence of macrophages and Langhans'- type giant 
cells, the HIV RNA' cells in the lymphoid tissues from patients of group I 
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proved to be almost exclusively CD45RO+CD68'lysozyme- (Fig. 1 b, insert I, 
d), identifying them as CD4 T cells, The HIV-1 RNA-positive cells in lym-
phoid tissues from end stage disease patients (group II) also proved to be 
CD4+ T cells, Occasionally an HIV-1 RNA+CD45+CD68+lyzosym+ cell was 
observed (Fig 1d), excluding the possibility that productively HIV-1-infected 
macro phages were not identified due to down-regulation of CD68 and 
lysozyme expression by HIV-1 infection. Furthermore, the in situ 
hybridisation grain counts of HIV-1 RNA-positive CD4 T cells were 
generally much heavier than those on HIV-1 RNA-positive macrophages, 
suggesting a lower level of virus production in the latter cells (Fig. 1c,d). 
Discussion 
We have shown that in contrast to previously published data, CD4 T cells 
remained the major source of HIV-1 production at end stage infection. The 
histological appearance and cellular composition of granulomas in lymphoid 
tissue from group I patients did not differ from those seen in immuno-
competent patients (18). Granuloma formation is characteristic in the cell 
mediated immune response to MTB, and it is well established that CD4+ T 
cells playa pivotal role in host defence against intracellular microorganisms 
(18). Around the granulomas massive HIV-1 production was mainly 
confined to CD4+ T cells. This finding is in agreement with the observed 
increase of the non-cell associated plasma viral load during opportunistic 
infections (19,20) and in studies on lymphoid tissue from HIV-1 infected 
patients co-infected with opportunistic organisms(14). Treatment of oppor-
tunistic or bacterial infections in HIV-1-infected patients resulted again in a 
decrease of plasma viral load levels to the levels observed before the onset 
of the opportunistic infection (19-21). The abundant presence of macro-
phages in lymphoid tissue from both groups did not apparently contribute to 
the viral load. Not only was the number of HIV-1 RNA+ infected macro-
phages low, but also the level of in vivo virus production by macrophages, 
assessed by in situ hybridisation grain counting, was lower than in CD4+ T 
cells. In addition, in in situ double labelling analyses of biopsies collected 
from 50 lymphatic tissues of more than 50 individuals at different stages of 
HIV-1 infection, productively infected macrophages have been observed 
only scarcely (unpublished observations). Considering the observation that 
at end-stage disease, in approximately 50% of patients so-called X4/-
syncytium inducing/rapid-high HIV-1 strains arise, which have shown to be 
less macrophage-tropic as compared to HIV-1 strains isolated from 
asymptomatic individuals (22,23), we postulate that at end stage disease 
CD4 T cells, rather than macrophages, remain the major source of HIV-1 
production. Whether these clearly conflicting observations with previously 
published data (14) may attribute to differences in patient selection or 
laboratory techniques remains to be determined. The paradox of increasing 
viral loads with progressively declining circulating CD4+ T cells therefore 
remains. We and others (24-26) have; however, recently shown that in 
patients with low peripheral CD4+ T cells the decrease of tissue CD4+ T cell 
count is slower. It may be assumed that patients with CD4+ T cell counts < 
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50/111, still have sufficient numbers of CD4+ T cells to allow the production of 
the high viral loads generally observed in such patients. Recent studies in 
AIDS patients have shown a sharp increase of the peripheral blood CD4+ T 
cell count after starting highly active antiretroviral therapy (26,27), probably 
reflecting redistribution of CD4 + T cells from epitheloid organs such as the 
lung or the gut. Taking into account the increased percentage of produc-
tively infected cells and the increased virus replication rate of HIV-1 strains 
isolated, it seems likely that also at the end stage of the disease sufficient 
CD4 + T cells are present in the individual to explain the high viral load 
observed. 
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CHAPTER 5 
Coreceptor usage of human immunodeficiency virus type 2 primary 
isolates and biological clones is broad and does not correlate with 
their syncytium inducing capacities. 
Journal of Virology 1998; 72:6260-63 
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Summary 
Entry of human immunodeficiency virus type-1 (HIV-1) into target cells is 
mediated by binding of the surface envelope glycoprotein to the CD4 
molecule. Interaction of the resulting CD4/glycoprotein complex with Q- or 
j3-chemokine receptors, depending on the biological phenotype of the virus, 
will then initiate the fusion process. Here, we show that primary HIV-2 
isolates and biological clones, in contrast to those of HIV-1, may use a 
broad range of coreceptors, including CCR-1, CCR-3, CCR-5 and CXCR-4. 
The syncytium-inducing capacity of these viruses did not correlate with their 
ability to infect via CXCR-4 or any other coreceptor. One cell-free passage 
of the intermediate isolates in mitogen-stimulated, CD8+ cell-depleted, 
peripheral blood mononuclear cells (PBMC) resulted in the outgrowth of 
variants using CCR-5 only, whereas the coreceptor usage of late and early 
isolates did not change. Since HIV-2 is less pathogenic in vivo than HIV-1, 
these data suggested that HIV pathogenicity in vivo is not directly related to 
the spectrum of coreceptors used in in vitro systems. 
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HIV entry is mediated by the binding of its surface glycoprotein to the 
cellular CD4 molecule, which acts as the primary receptor (8,18), and the 
subsequent interaction of the resulting CD4/envelope glycoprotein complex 
with another specific cellular co-factor (26,28). Several members of the 
seven transmembrane G-protein-coupled receptor family have recently 
been shown to be possible coreceptors for HIV-1 or HIV-2 (10,13,15, 
22,25). Two members of this family, the chemokine receptors CCR-5 and 
CXCR-4 (also termed LESTR or Fusin), are the main coreceptors for 
macrophage and T cell-line tropic HIV-1 variants, respectively (1,2,4,7,9, 
12,24). A small subset of dual-tropic HIV-1 strains is also able to use other 
members of this family as coreceptors, such as chemokine receptors 
CCR-2b or CCR-3 (4,11,14) or the orphan receptors Bonzo (also termed 
STRL33) and BOB (10,17). Moreover, longitudinal studies have shown a 
shift towards the usage of CXCR-4 as coreceptor for HIV-1 during disease 
progression, suggesting that broadening of coreceptor usage contributes to 
the cytopathic potential of HIV-1 strains in vivo (6). Compared to HIV-1, 
HIV-2 is less transmissible, less cytopathic in vivo, and induces generally a 
slower progression towards AIDS (19). However, we recently showed that 
rapid progression can be observed in some HIV-2 infected individuals (27). 
Similar to HIV-1, an inverse correlation was observed between the replica-
tion rate of viruses in vitro and the CD4+ T cell count of the patient from 
which they originated (27). Depending on the time required to detect virus 
after cocultivation of patient PBMC with phytohemagglutinin (PHA)-stimu-
lated PBMC and the CD4 count of the patient, we could distinguish 
between early (>500 CD4fJ.t1), intermediate (100<CD4/1l1<500) and late 
«100 CD4/1l1) isolates. Studies comparing the requirements for HIV-1 
versus HIV-2 entry may contribute to our understanding of the pathoge-
nesis caused by these human lentiviruses. 
Here, we have evaluated the capacity of a panel of human cells stably 
transfected with chemokine receptor genes to support infection with HIV-2 
primary isolates from patients at different stages of the disease (27) (table 
1). Five of the isolates studied (PH2-1, RH2-1, RH2-2, RH2-5 and RH2-7) 
belong to the HIV-2 subtype A, whereas one isolate, RH2-6, belongs to the 
subtype B (27). The mega-glioblastoma astrocytic cell line U87MG, stably 
transfected with the human CD4 gene and expression plasm ids encoding 
various coreceptors (15), was infected with each of these isolates. Cells 
expressing both CD4 and chemokine receptors were selected regularly with 
250flg/ml Geneticin (Gibco-BRL) and 1 flg/ml puromycin (Calbiochem), 
respectively, and CD4 expression of all these cell lines was confirmed by 
FACS analysis (data not shown). 
Two to 4.104 adherent cells were incubated for 7 to 15 hours at 3JOC in 
24-wells plates with a viral inoculum of 250ft! containing 2000 cpm of RT 
activity. Cells were then washed once with DMEM 10%FCS and cultured in 
1.5ml DMEM/10%FCS. Virus replication was monitored at days 10 or 11 
post-infection by quantification of RT activity in 150IJi of culture super-
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natant. The abilities of HIV-2 primary isolates to infec! U87MG/C04 cells 
expressing different coreceptors are shown in figure 1. 
Patient Clinical status C04 Biological Phenotype Subtyped (CDC criteria) count/pi clones 
RH2-1 C1 600 NAa NSI A 
PH2-1 A3 200 NSI A 
C1 NSI 
C12 NSI 
E6 NSI 
H8 NSI 
05 Sib 
H12 SIC 
RH2-7 A3 130 NSI A 
A5 NSI 
C9 NSI 
C12 NSI 
D7 NSI 
G12 NSI 
RH2-5 A3 110 NSI A 
A10 NSI 
E4 NSI 
E11 NSI 
F7 NSI 
G7 NSI 
RH2-2 C3 10 NA SIc A 
RH2-6 C3 10 NA SIc B 
Table 1: Description of HIV-2 primary isolates or biological clones and patients 
. clinical status. aN.A. Not available, b SI phenotype on PBMC, cSI phenotype on 
PBMC and MT-2 cells, d on basis of nucleotide sequences of reverse-transcriptase 
fragments (27) 
The early isolate (RH2-1) only used CCR-5 as its coreceptor (figure 1A). 
Intermediate, NSI isolates (table 1) PH2-1, RH2-5 and RH2-7, and late, SI 
isolate RH2-2, all belonging to HIV-2 subtype A, appeared to use a broad 
range of coreceptors: in addition to CCR-5, CCR-1 and CCR-3were 
efficiently used (Figure 1A). These isolates were also all able to use 
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CXCR-4, and some entered U87MG/CD4 cells via CCR-2b at different 
levels of efficiency. This proved not to be dependent on their SI/NSI 
phenotype (figure 1 A). No significant differences in coreceptor usage were 
observed between intermediate and late subtype A isolates (figure 1 A and 
table 1). The late, subtype B, SI isolate RH2-6 (table 1), however only 
infected U87MG/CD4 cells expressing the CXCR-4 receptor. In contrast 
with a previous study (25), these isolates were unable to infect U87 MG/ 
CD4 cells not transfected with any co receptor. Therefore, the broad range 
of coreceptor usage of HIV-2 primary isolates could not be attributed to 
their ability to infect U87MG/CD4 cells via an unidentified coreceptor 
constitutively expressed by these cells. 
Virus isolates were passaged with cell-free infection for one week in 
CD8-depleted, PHA-stimulated PBMC. Progeny viruses were then assayed 
for their coreceptor usage. Replication of thus passaged NSI isolates was 
only detectable in CCR-5 expressing cells, whereas the range of 
coreceptors used by SI isolates did not seem to be influenced by this 
passage (figure 1 B). However, four to seven days prolonged cultivation 
after the standard eleven days of NSI isolates in U87MG/CD4 cells showed 
also a low level of virus production in CCR-1 or CCR-3 expressing cells 
(data not shown). This indicated that CCR-1 and CCR-3 using variants 
were still present in the isolates after a one week passage in CD8-depleted 
PHA-PBMC. Thus, a short-term passage in CD8-depleted, PHA-stimulated 
PBMC increased preferentially the frequency of CCR-5-restricted variants 
present in the NSI isolates. 
The selective expansion of a viral subpopulation in CD8-depleted PHA-
PBMC suggested that the HIV-2 isolates tested consisted of a pool of 
variants with different coreceptor requirements. In order to determine the 
actual coreceptor usage of such HIV-2 variants, we isolated 16 biological 
clones from patients PH2-1, RH2-5 and RH2-7 (table 1). In short, PBMC 
from these donors were plated in 96-well round bottom plates (Coulter) at 
2x105, 2x104 and 2x103 per plate with 4x106 PHA-stimulated PBMC from 
seronegative individuals per plate. Each well was further treated individually 
and new medium and cells were added once a week, according to standard 
protocols (27). All wells were monitored after two to three weeks for the 
presence of p24 antigen (V5 ELISA, Organon Technika). P24 positive wells 
of 96-wells plates in which less than five positive wells were detected, were 
considered as clonal. These were further co-cultivated with PHA-stimulated 
PBMC. Before the assessment of their coreceptor usage, these clones 
were passaged for one week on CD8-depleted, PHA-stimulated PBMC. Of 
the 16 biological clones isolated, two (PH2-1 #05 and PH2-1 #H12) 
exhibited a SI phenotype on MT-2 cells and/or PHA-PBMC, whereas the 
other 14 were NSI variants (table 1). The two SI biological clones were 
obtained from the same individual who progressed rapidly towards AIDS 
(within 3 years), suggesting that the fusogenic potential of the envelope 
gfycoproleincompfex contributed 10 disease progression in this patient. 
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Figure 1: Coreceptor Usage of HIV-2 Primary Isolates. Infections were performed 
with primary isolates cultured for two weeks in PHA-PBMC (A) and then passaged 
for one week in COB-depleted, PHA-PBMC (B). Each value represents the mean 
. and standard deviation of 3 independent experiments and is expressed in cpm/-
150J.l1 supernatant. The cut-off value has been set at 2 times the mean of all the 
background values, N.T.: Not tested. 
All the clones were tested for their coreceptor usage by infection of 
U87MG/CD4 cells and appeared to be able to use CCR-5 at very high 
efficiency (figure 2). All but one (PH2-1 #C1) were also able to use at least 
one other chemokine receptor as a coreceptor. CCR-1, CCR-3 and 
CXCR-4 were used by13, 150r 13 clones of the 16 clones; respectively. In 
contrast, CCR-2b was only used by 3 clones isolated from the same 
so 
patient: RH2-7 #C9, #07 and #G12 (figure 2B). However, the HIV-2 
biological clones exhibited a higher efficiency of infection via CCR-5 than 
via the other coreceptors. This was shown by consistent higher RT values 
in CCR-5 expressing cells, and detection of virus production two to four 
days earlier in CCR-5 expressing cells (data not shown). Finally, no 
consistent differences in co receptor usage were observed between the SI 
clones PH2-1 #05 and #H12 and the 14 NSI clones. 
It has been stated previously that coreceptor usage of HIV-1 clones was 
correlated with the viral phenotype: macrophage-tropic, NSI HIV-1 variants 
exhibit a CCR-5-restricted entry, whereas SI, T-cell line-tropic isolates can 
also use CXCR-4 (3,16,24). The importance of CCR-5-mediated entry has 
moreover been clearly demonstrated in vivo by the resistance to HIV-1 
infection of individuals who have a homozygous deletion in CCR-5 (20,21, 
23). Our experiments showed that all but one (RH2-6) HIV-2 biological 
clones and primary isolates, of SI or NSI phenotype, can use CCR-5. 
Therefore, as described for HIV-1, CCR-5 seems the main coreceptor for 
primary HIV-2 strains. However, our results do not show a difference 
between HIV-2 SI and NSI clones with respect to their usage of either 
CXCR-4, or of any other coreceptor. Thus, in contrast to what has been 
shown for HIV-1 (3,7,16), there seems to be no correlation between any 
specific coreceptor usage and HIV-2 syncytium-inducing capacity. 
A limited set of HIV-1 strains can use other chemokine receptors than 
CCR-5, such as CCR-2b and CCR-3, as their coreceptor (4,11,14). In 
contrast to HIV-1, almost all HIV-2 biological clones and primary isolates 
used in this study exhibited the usage of a broad range of coreceptors, 
including CCR-1, CCR-3 and/or CXCR-4 in addition to CCR-5. CCR-1 
usage by HIV-1 isolates in vitro has never been documented, and is also 
consistently absent in our system [C.Guillon, manuscript in preparation]. 
Moreover, 14 out of the 16 clones tested, including the two SI clones, were 
able to use at least three of these chemokine receptors for entry into 
US7MG/CD4 cells. Therefore, and in contrast with previous reports (25), 
broad coreceptor usage seems characteristic of intermediate and late 
primary H IV -2 variants. 
Mitogen-stimulated CDS+ T cells have been shown to produce the 
natural ligands of CCR-5, RANTES, MIP-1cx and MIP-1P, which may 
therefore compete with the HIV envelope glycoprotein for binding to CCR-5 
(5,12). The broad coreceptor usage of the unpassaged HIV-2 isolates may 
therefore have been the result of a negative pressure exerted by CDS+ T 
cells on CCR-5 restricted variants. The preferential selection of CCR-5 
restricted viruses within one week of cultivation in CDS-depleted PHA-
stimulated PBMC implies however that CCR-5-mediated entry is the main 
mechanism of infection of CD4+ cells in vitro by HIV-2 NSI isolates, and that 
other coreceptor usage may occur when efficiency of CCR-5 mediated 
entry has decreased. 
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Figure 2: Co receptor Usage of HIV-2 Biological Clones. Infections were pertormed 
with biological clones from A) patient RH2-5, B) patient RH2-7, and C) patient 
PH2-1. Each value represents the mean and standard deviation of at least 3 
independent experiments and is expressed in cpm/150r" supernatant. 
It has been hypothesised that broadening of H IV -1 coreceptor usage 
contributes to the in vivo cytopathogenicity of HIV by increasing the amount 
of potential target cells (6). Despite the broad coreceptor usage of HIV-2 
isolates, in vitro, ,disease progressioninHIV-;z ,infectedindiyiduglsis ,signifi-
cantly slower than for HIV-1 patient's (19). Moreover, using HIV in situ 
hybridisation and in situ histochemistry of lymphoid tissues from early and 
82 
intermediate stage disease patients, we have recently obtained evidence 
that the number of productively infected cells is significantly lower in HIV-2 
infection than in HIV-1 infected individuals [ME van der Ende, submitted]. 
This suggests that the broad coreceptor usage observed in vitro does not 
add to the in vivo cytopathogenicity of HIV-2, in contrast to syncytium 
inducing capacity or viral load. Therefore, additional longitudinal studies are 
required to further elucidate the relevance of coreceptor usage in disease 
progression after HIV-2 infection. 
U87MG/CD4 transfected cells were kindly provided by Dr. D. Littman. This 
work was supported by Dutch AIDS Fundation grant n01022 and European 
Community Biomed grant PL96-2115. 
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SUMMARY 
We have studied the pathogenic properties of four primary HIV-2 isolates 
and two primary HIV-2 biological clones in an in vivo human to mouse 
chimeric model. The cell associated viral load and the ability to reduce the 
severity of the induced graft versus host disease symptoms, the CD4/CD8 
ratio and the level of repopulation of the mouse tissues by the graft, were 
determined, All HIV-2 strains irrespective of their in vitro biological pheno-
type replicated to high titres and significantly reduced the graft versus host 
disease symptoms and the CD4/CD8 ratios, Reduction of graft repopulation 
induced by the respective HIV-2 strains showed that the in vitro replication 
rate, syncytium inducing capacity and ability to infect human macrophages 
did influence the in vivo pathogenic potential whereas broadening of 
coreceptor usage did not. 
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INTRODUCTION 
HIV-1 and HIV-2 are the causative agents of the acquired 
immunodeficiency syndrome (AIDS)(Barre-Sinoussi et al., 1983; Clavel et 
al., 1986;Levy et al., 1986). The most prominent feature of the 
pathogenesis of AIDS is the quantitative and qualitative deterioration of the 
CD4+ T cell subset. Although CD4+ T cells are already affected soon after 
infection, it may take one to more than fifteen years before immune failure 
leads to overt clinical symptoms (Gruters et al., 1990;Gruters et al., 1991). 
Both virological and host-delimited factors have been shown to determine 
the length of the asymptomatic period (Cheng-Mayer et al., 1988;Dean et 
al., 1996;Fenyo et al., 1988; van Baalen et al., 1997). Epidemiological 
studies have shown that, although progression to AIDS may in specific 
cases be relatively fast, disease progression in HIV-2 infected individuals is 
in general much slower than disease progression in HIV-1 infected 
individuals (Marlink et al., 1994; van der Ende et al., 1996; Whittle et a/., 
1994). Virological factors that underly this difference between HIV-1 and 
HIV-2 induced disease progression, are presently not known. Studies in in 
vitro and in vivo systems, specifying viral characteristics which determine 
the pathogenicity of HIV strains, may aid in the understanding of HIV 
induced pathogenesis. 
The characteristics used to classify HIV strains in vitro include replication 
rate, ability to induce the formation of multinucleated cells (syncytium 
inducing (SI) capacity), coreceptor requirement and ability to infect different 
target cells (T cell lines versus macrophages)(Asjo et al., 1986;Berger et 
al., 1998;Cheng-Mayer et al., 1988;Schuitemaker et al., 1992b; Tersmelte et 
a/., 1989). For HIV-1 it has been shown that these in vitro characteristics 
exhibit a high degree of correlation. E.g. SI strains in general have a high 
replication rate, infect target cells via u,- and f3-chemokine receptors, may 
infect immortalised T cell lines and only inefficiently infect macrophages. 
NSI strains on the other hand, have a low replication rate, require 
expression of f3-chemokine receptors, do not infect T cell lines and replicate 
efficiently in macrophages (Berger et al., 1998;Schuitemaker et al., 1991). It 
should however be noted that individual virus strains may also display 
intermediate biological phenotypes (Groenink et al., 1991;Sabri et al., 
1996; Schuitemaker et al., 1992a). Several differences in in vitro charac-
teristics of HIV-1 and HIV-2 have become apparent. The replication rate as 
defined by the time required to measure virus after initiation of standard 
virus culture from donor peripheral blood mononuclear cells, is generally 
lower for HIV-2 than for HIV-1 (Alberl et al., 1990;van der Ende et a/., 
1996). Furthermore, we and others have recently shown that clear differen-
ces exist in coreceptor requirements (Guillon et al., 1998;McKnight et a/., 
1998). The linkage between HIV-1 SI phenotype and CXCR-4 coreceptor 
usage, was not observed for HIV-2. Furthermore, HIV-2 strains in general 
proved to have a broader coreceptor usage than HIV-1. Taken together, 
these observations suggest that in vitro usage of the CXCR-4 coreceptor 
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and broadening of the coreceptor usage by HIV do not add to enhanced in 
vivo pathogenicity. 
To further address this issue we studied the in vivo pathogenic potential 
of HIV-2 isolates and biological clones in a chimeric human to mouse 
model for in vivo HIV infection (the xeno-GvHD mouse model)(Huppes et 
al., 1992;Huppes et al., 1993;Schulten ef al., 1996). In this model high 
numbers of human peripheral blood mononuclear cells (PBMC) are grafted 
into the peritoneal cavity of immune deficient mice. In these mice an acute 
graft versus host reaction develops within seven to 14 days. The human 
lymphocyte population that repopulates the mouse tissues is characterised 
by high CD4/CD8 ratios (Schulten et al., 1996). Depletion of human CD4+ T 
cells from the graft results in a complete abrogation of the acute xeno-
GvHD reaction. Depletion of antigen presenting cells (APC, macrophages) 
from the human graft results in lower CD4/CD8 ratios and a concomitant 
delay of the xeno-GvHD symptoms (Huppes et al., 1993). We therefore set 
out to study in this model the direct (killing of infected CD4+ T cells) and 
indirect (inhibition/modulation of antigen presentation) pathogenic effect of 
different HIV-2 strains and isolates on the development of acute xeno-
GvHD symptoms, CD4/CD8 ratio and the ability of the graft to repopulate 
mouse tissues. 
HIV-2 replication Biological coreceptor Macrophage 
Strain ratea phenotypeb usage' -tropism 
RH2-1 42 Early NSI R5 + 
RH2-2 <7 late SI R1,R3,R5,X4 
RH2-6 <7 late SI X4 + 
PH2-1 14 Intermediate R1,R3,R5,X4 + E6 NSI 
PH2-1 14 Intermediate R5 + D5 SI 
Table 1. Characteristics of the HIV-2 Strains a first day of a positive si~nal in p24 
antigen ELISA after start of virus isolation (van der Ende et al. 1996). Biological 
phenotype according to ME van der Ende et al. (van der Ende et al. 1996). c 
coreceptor usage according to Guillon et al. (Guillon et al. 1998, Berger et a/. 1998) 
MATERIALS AND METHODS 
Virus strains and xeno-GvHD mice 
Xeno-GvHD mice were prepared as previously described (Huppes et al., 
1992;Huppes et al., 1993;Schulten et al., 1996). In short, 3-4 weeks old 
XID mice (CBAlHNOlaHsd, Harlan Netherlands BV. Zeist) were give total 
body irradiation (9 gray) with sytigetieibhbhelTiarrbWsupport(5X105 
cells/mouse intra veneously.). Subsequently, ficoll gradient isolated human 
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PBMC from HIV seronegative individuals (blood type A, rhesus +) were 
given at 2x107 per gram mouse bodyweight intra peritoneally (Lp.). These 
xeno-GvHD mice were challenged Lp. with HIV-2 within one hour after they 
had been grafted with human PBMC. Mice grafted with human PBMC from 
one and the same HIV seronegative blood donor were equally distributed 
over the respective groups of mice receiving different HIV-2 strains. Each 
group consisted of five mice. The primary HIV-2 strains used in this study 
had been isolated in mitogen stimulated PBMC only and the in vitro 
characteristics have previously been described (Guillon et al., 1998;van der 
Ende et al., 1996). Relevant virus characteristics are given in Table 1. The 
doses of challenge virus were equilibrated on basis of the counts per 
minute measured in a RT assay (van Baalen et al., 1998) and equalled 
approximately 30 mouse infectious doses 50% per mouse. 
Parameters of acute xeno-GvHD reaction and HIV-2 infection 
Directly after the onset of acute xeno-GvHD symptoms (furry coat, 
breathing problems and wasting), mice were sacrificed and lymphocytes 
were isolated from the peritoneal cavity. Human to mouse chimerism was 
confirmed and the CD4/CD8 ratio of the human graft was calculated, using 
FACSscan analysis with human CD3 and CD8 conjugates (Becton 
Dickinson, Leiden, The Netherlands) according to the instructions of the 
manufacturer. The viral loads of the lymphocytes isolated from the 
peritoneal cavities were determined in an infectious centre assay 
(ICT)( Schulten et al., 1996). In short, human lymphocytes isolated from the 
peritoneal cavity were counted and titrated in duplo from 2x105 to 2 cells 
per well onward using five fold dilution steps in 96 round bottomed plates. 
PBMC that were pre-stimulated with mitogen for three days, were added as 
feeder cells (5X104 per well). The cells were cultured for seven days in 
RPM I 1640 (BioWhittaker, Verviers, Belgium) supplemented with 10% 
foetal calf serum (BioWhittaker), penicillin (100U/ml), streptomycin 
(10[lg/ml) and 50 IU recombinant human IL-2/ml (Eurocetus, Amsterdam, 
The Netherlands), after which virus was detected by RT assay. The 
minimal number of cells isolated from the peritoneal cavity required to 
detect virus was taken as a measure for the cell associated viral load. 
HIV-2 in situ hybridisation and immunohistochemistry 
Xeno-GvHD mouse tissues including spleen, lung, bowel, hart, liver and 
bone were prepared from mice, which had been grafted with PBMC 
isolated from the same individual. Tissues from two mice infected with the 
same HIV-2 isolate/strain were analysed. Tissues were fixed overnight with 
4% formalin and subsequently embedded in paraffin. For routine 
immunohistochemistry, dewaxed 5 [1m paraffin sections were heat 
denatured with 0.01 M buffered sodium citrate (Norion et al., 1994). The 
sections were incubated with CD45 (LCA)(Dakopatts, Copenhagen, 
8enmark)according to the manufacturers'· instructions {Tenner-Racz ela/., 
1998). Binding of antibodies was visualised by the alkaline phosphatase 
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anti alkaline phosphatase technique using New Fuchsin as red chromogen. 
We have previously shown that this conjugate does not stain mouse cells 
(Schutten et al., 1996) After immuno-staining the sections were either 
counter-stained with hematoxylin and mounted or dehydrated and 
subjected to HIV RNA in situ hybridisation. 35S-labeled, single stranded, 
anti-sense HIV-2 RNA probes (Lofstrand Labs., Gaithersburg, MD, USA), 
which contained 1.4-2.7 kb fragments, collectively representing approx-
imately 90% of the HIV-2 genome, were used as previously described 
(Embretson et al., 1993;Fox et al., 1991). In short, paraffin sections were 
either treated with Proteinase K (0.01 mg/ml) for 8 min. at room 
temperature or heat denatured. The sections were incubated with 
prehybridisation mixture (50% Formamide, 0.5 M NaCI, 10 mM Tris HCI, pH 
7.4, 1 mM EDTA, 0.02% Ficoll-polyvinylpyrrolidone-BSA and 7 mg of 
tRNA/ml) for 2 hours at 37"C and then covered with hybridisation mixture 
(prehybridisation mixture + 10% dextran sulfate and 2x106 dpm of probe/ 
ml) overnight at 45°C. The sections were washed, RNAse treated 
(Boehringer Mannheim GmbH, Mannheim, Germany) for 40 min. at 37°C 
and further developed, counter-stained with hemalaun and mounted as 
previously described. As a negative control, sections were hybridised with a 
radiolabeled sense probe. The sections were examined with a microscope 
equipped with epiluminescent elumination (Axiophot; Carl Zeiss Inc., Jena, 
Germany). Cells were considered positive for viral gene expression if the 
number of grains overlying a cell was more than six times the background. 
CD45' cellsd HIV-2' cells· 
HIV-2 strain Xeno- ICT CD4/CD8 Lung Spleen Lung Spleen GvHD ratio 
++a 
-
b 4-9c +++ N.A. 
RH2-1 + 160 0.8-1.2 ++ +++ +++ +++ 
RH2-2 + 400 0.6-1.1 ++ ++ +++ + 
RH2-6 300 0.3-0.5 
PH2-1 E6 + 2000 0.7-1.2 ++ +++ +++ +++ 
PH2-1 05 + 160 0.6-0.8 + + 
Table 2 a Severity of the xeno-GvHD symptoms ++ = severe, + = minor, +/- minor 
in some of the animals, - = no symptoms observed within the observation period 
(11 days). bNumber of infectious centres per 4x105 cells isolated from the 
~eritoneal cavity. cThe range of the CD4/CD8 ratio within each group of mice. 
Amount of CD45' cells in the organ +++ = very high, ++ = high, + = low, - = 
occasionally a positive cell, N.A. = not applicable due to xeno-GvHD induced 
necrosis of the organ. Camount of HIV-2 RNA cells +++ = very high, ++ = high, + = 
low,-=occasionally a positive cell 
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RESULTS 
Acute xeno-GvHD symptoms and CD41CDB ratio 
Grafting human PBMC from HIV seronegative individuals at 2x107/gram 
mouse bodyweight Lp. has been shown to induce an acute xeno-GvHO 
reaction within 14 days in approximately 100% of the animals (Huppes et 
al., 1992;Schulten et a/., 1996)(Table 2). In general the development of 
acute xeno-GvHO symptoms is fast and little variation is observed between 
animals grafted with PBMC from donors with the same ABOlrhesus factor. 
The acute xeno-GvHO symptoms that were observed in the groups of 
HIV-2 infected xeno-GvHO mice were in general less severe as compared 
to the control mice (Table 2). No significant differences were observed 
between the different groups of HIV-2 infected mice, either with respect to 
the absolute numbers of human lymphocytes isolated from the peritoneal 
cavity (data not shown), or with respect to the number of infected centres in 
the ICT (Table 2). Quite unexpectedly no significant differences in 
symptoms or C04/C08 ratio were observed between xeno-GvHO mice 
infected with the early HIV-2 RH2-1 (R5) isolate or late isolate HIV-2 RH2-2 
(R1,R3,R5,X4). Acute xeno-GvHO symptoms were not observed in the 
mice infected with the late subtype B isolate HIV-2 RH2-6 (X4) and 
C04/C08 ratios from these mice were lower as compared to mice in the 
other groups (Table 2). Although the differences between mice infected 
with the SI and NSI biological clone from PH2-1 were minor, the xeno-
GvHO mice infected with the SI biological clone PH2-1 05 (R5) did show 
less severe xeno-GvHO symptoms as compared to the mice infected with 
the NSI biological clone PH2-1 E6 (R1 ,R3,R5,X4) (Table 2). 
Immunohistochemistry of tissues from xeno-GvHD mice 
In order to study the ability of the human PBMC graft to repopulate the 
mouse tissues after infection with HIV-2, tissues from the xeno-GvHO mice 
(spleen, lung, hart, bone, bowel) were prepared and analysed for the 
amount of human cells present by immunohistochemical staining for human 
C045. Variation in the distribution of the human lymphocytes was low 
between mice grafted with the same donor PBMC (data not shown). High 
numbers of human cells, especially in highly vascularised tissues like the 
lung, were observed in xeno-GvHO mice which were uninfected (Table 2). 
Only small remnants of necrotised spleen could be obtained from these 
mice, in which the mouse tissue was almost completely replaced by human 
cells (Figure 1A). Within the tissues only C045+C068' cells (T cells) were 
found and C045+C068+ cells (macrophages) were exclusively found 
adhered to and migrating into tissues isolated from the peritoneal cavity 
(Schulten et a/., 1996). In all HIV-2 infected xeno-GvHO mice relatively high 
numbers of human T cells and macrophages could be observed in the 
tissues isolated from the peritoneal cavity. Similar to the uninfected mice, 
macrophageswere exclusively .. found .. migratinginto .8nd .. adherec1.\R the. 
tissues isolated from the peritoneal cavity (data not shown). The number of 
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human cells in the lungs of the xeno-GvHD mice infected with HIV-2 RH2-1 
(R5), RH2-2 (R1,R3,R5,X4) and PH2-1 E6 (R1,R3,R5,X4), was significantly 
lower as compared to the number of human cells in the lung of the control 
mice (Table 2). The structure of the spleen obtained from these mice was 
relatively intact and contained many CD45+ cells, mainly within the peri-
arteriolar lymphocyte sheets (Figure. 1 B,C and E, Table 2). Hardly any 
CD45+ cells were found in the lung and spleen of mice infected with HIV-2 
RH2-6 (X4) (Figure. 1 D, Table 2). Similarly the lung of HIV-2 PH2-1 D5 
(R5) infected mice was almost completely devoid of human cells and low 
amounts of human cells were observed in the spleen (Figure. 1 F, Table 2). 
Figure 1.Comparison of the amount of human lymphoid cells and productively 
HIV-2 infected cells in xeno-GvHD mice as determined by CD45 staining (red 
alkaline phosphatase staining) and HIV-2 RNA in situ hybridisation (black grains). 
A. uninfected control, B. HIV-2 RH2-1 (R5), C. HIV-2 RH2-2 (R1 ,R3,R5,X4), D. 
HIV-2 RH2-6 (X4), E. HIV-2 PH2-1 E6 (R1,R3,R5,X4), F. HIV-2 PH2-1 D5 (R5) 
H/v-2 infection of xeno-GvHD mice 
The ability of theHIV~2isolatesand -biological- ciones to productively infect 
cells expressing the macrophage marker CD68 was determined by double 
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labelling (HIV-2 RNA in situ hybridisation with CD68 immunohistochemistry) 
(Table 1). Productively infected macrophages were observed in all HIV-2 
infected xeno-GvHD mice except for mice infected with the late isolate 
RH2-2 (R1,R3,R5,X4)(Table 1). Also the relative number of productively 
infected cells was determined in the tissues with high numbers of human 
lymphocytes (spleen and lung) (Table 2). HIV-2 RNA in situ hybridisation 
signal above background was absent in the negative control mice. High 
amounts of HIV-2 RNN cells were observed in the peritoneal cavity of all 
mice infected with the different HIV-2 isolates and biological clones (data 
not shown). High numbers of productively infected cells could be observed 
in lung and spleen of xeno-GvHD mice infected with HIV-2 RH2-1 
(R5)(Figure 1 C). Despite the fact that no significant differences in the 
amounts of CD45+ cells were observed between xeno-GvHD mice infected 
with HIV-2 RH2-1 (R5)(Figure 1 C) or HIV-2 RH2-2 (R1 ,R3,R5,X4) (Figure 
1 D), a significant lower number of productively infected cells was found in 
the tissues of xeno-GvHD mice infected with HIV-2 RH2-2 (R1,R3,R5,X4 
)(Table 2). Similar to HIV-2 RH2-1 (R5) infected xeno-GvHD mice, many 
productively infected cells were found in the tissues of xeno-GvHD mice 
infected with HIV-2 PH2-1 E6 (R1,R3,R5,X4) (Figure. 1E, Table 2). 
Although the number of cells and therefore also the number of productively 
infected cells in the peripheral tissues of xeno-GvHD mice infected with 
HIV-2 PH2-1 D5 (R5) (Figure 1 F) were significantly lower as compared to 
HIV-2 RH2-1 (R5), RH2-2 (R1,R3,R5,X4)and PH2-1 E6 (R1,R3,R5,X4), still 
a relatively high percentage of the cells observed in the peripheral tissues 
of these mice were productively infected (Table 2). 
DISCUSSION 
In the present paper we have shown that the SI capacity, replication rate 
and the ability to infect macrophages influenced the pathogenic properties 
of HIV-2 strains in the xeno-GvHD mouse model for HIV infection. 
Moreover a SI macrophage-tropic HIV-2 biological clone that only uses 
CCR-5 as coreceptor proved to be more pathogenic than a highly 
homologues NSI macrophage-tropic biological clone with a potentially 
broader coreceptor usage (CCR-1, CCR-3, CCR-5 and CXCR-4). These 
data show that broadening of the potential cellular host range does not 
increase the pathogenic potential of HIV. 
Both direct and indirect mechanisms have been suggested to contribute 
to the pronounced CD4+ T cell depletion observed in HIV infected 
individuals (for review see Zinkernagel & Hengartner (Zinkernage/ et a/., 
1994). The direct mechanisms include acute single cell lysis of infected 
cells (Samson et a/., 1996) and depletion of uninfected CD4+ cells by fusion 
with infected cells (syncytium formation)(Tersmette et a/., 1993). It has also 
been shown that cells of the monocyte/macrophage lineage do not function 
praperly,whichmayresult in disregulation af activation and/orm aturati.o.n .. of 
CD4+ T cells due ta functionally disturbed antigen presentation (Meyaard et 
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ai" 1993), This may also indirectly contribute to the decline of CD4+ T cells, 
Two observations suggest that this last phenomenon contributed to the 
HIV-2 induced CD4+ T cell depletion in our xeno-GvHD mouse model. First, 
no significant differences were observed in the CD4/CD8 ratio and the 
number of CD45+ cells in spleen and lung of mice infected with the early, 
macrophage-tropic NSI isolate RH2-1 (R5) and the late non macrophage-
tropic SI isolate RH2-2 (R1 ,R3,R5,X4), This despite the fact that the late SI 
isolate is highly cytopathic for CD4+ T cells in vitro and the early NSI isolate 
does not induce single cell lysis to a significant extent (personal 
observations), The fact that the percentage of infected cells was high in the 
RH2-1 (R5) infected mice and low in the RH2-2 (R1,R3,R5,X4) infected 
mice also suggests that these virus strains cause CD4+ T cell depletion by 
two different mechanisms, E,g, it seems likely to assume that HIV-2 RH2-2 
(R1,R3,R5,X4) infected cells are directly killed and therefore do not reach 
the peripheral tissues studied, whereas RH2-1 (R5) infected cells are 
obviously not killed directly, but rather seem to be functionally affected, 
Second, RH2-2 (R1,R3,R5,X4)and RH2-6 (X4) are both highly cytopathic 
for CD4+ T cells in vitro, The macrophage-tropic isolate RH2-6 (X4) proved 
to be far more pathogenic in vivo with respect to abrogating GvHD 
symptoms and inhibiting migration of T cells to peripheral tissues, than the 
non macrophage-tropic isolate RH2-2 (R1 ,R3,R5,X4), 
SI capacity, replication rate and coreceptor requirements have all been 
shown to positively correlate with rapid disease progression in HIV-1 
infected individuals, Because for HIV-1 these factors are generally linked, it 
has not been possible to distinguish which factors have a causal relation 
with disease progression, Since SI capacity and coreceptor usage are not 
linked for HIV-2, we could study these factors independently, The 
observation that in vitro coreceptor usage of HIV-2 strains is broader as 
compared to HIV-1 already suggested that broadening of coreceptor usage 
does not necessarily lead to increased in vivo pathogenicity, Indeed in the 
xeno-GvHD model RH2-6 (X4) proved to be far more pathogenic with 
regard to all aspects studied as compared to RH2-2 (R1, R3, R5, X4), 
suggesting that broadening of the coreceptor usage does not significantly 
add to the in vivo pathogenicity, This is further supported by the obser-
vation that the NSI biological clone PH2-1 E6 (R1, 3, 5, X4) was less well 
able to inhibit migration of T cells and may therefore be regarded more 
pathogenic as compared to it's SI counterpart PH2-1 D5 (R5) (R-5), 
We have recently shown that the number of productively infected cells in 
lymphoid tissue from HIV-2 infected individuals is significantly lower than in 
HIV-1 infected individuals, It has furthermore been shown that the number 
of productively infected cells is positively correlated with the plasma viral 
load, which is in turn correlated with disease progression, Interestingly, we 
did not observe major differences in cell associated viral loads nor in the 
pathogenicity of the HIV-2 strains as compared to previously studied HIV-1 
strains (Schuttenetal, ,1996), Itthereforeseemsthalintheabsenceofa 
substantial humoral and cellular antiviral immune response both in vitro and 
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in our human to mouse chimeric model, HIV-1 and HIV-2 may have 
comparable replicative and pathogenic potential. We therefore hypothesise 
that the lower viral loads and slower disease progression in HIV-2 infected 
humans as compared to HIV-1 infected individuals is related to a difference 
in the interaction of the virus with the HIV specific immune response. 
References 
Albert, J., Naucler, A., Bolliger, B., Broliden, P. A., Albino, P., Ouattara, S. A., 
Bjorkegren, C., Valentin, A., Biberfeld, G. and Fenyo, E. M. (1990) 
Replicative capacity of HIV-2, like HIV-1, correlates with severity of immuno-
deficiency AIDS 4, 291-295. 
Asjo, B., Albert, J., Karlsson, A., Morfeld-Manson, L., Biberfeld, G., Lidman, K. 
and Fenyo, E. M. (1986) Replicative properties of human immunodeficiency 
virus from patients with varying severity of HIV infection Lancet ii, 660-662. 
Barre-Sinoussi, F., Chermann, J. C., Rey, R., Nugeyre, M. T., Chamaret, S., 
Gruest, J., Dauget, C., Rozenbaum, W. and Montagnier, L. (1983) Isolation 
of a T-Iymphotropic retrovirus from a patient at risk for acquired immune 
deficiency syndrome. Science 220, 868-871. 
Berger, E. A., Doms, R W., Fenyo, E. M., Korber, B. T., Littman, D. R, Moore, 
J. P., Sattentau, Q. J., Schuitemaker, H., Sodroski, J. and Weiss, R A. 
(1998) A new classification for HIV-1 Nature 391,240. 
Cheng-Mayer, C., Seto, D., Tateno, M. and Levy, J. A. (1988) Biologic features 
of HIV-1 that correlate with virulence in the host Science 240,80-82. 
Clavel, F., Guetard, D., Brun-Vezinet, F., Chamaret, S., Rey, M. A., Santos-
Ferreira, M. 0., Laurent, A., Dauget, C., Katiama, C., Rouzioux, C., 
Klatzmann, D., Champalimaud, J. L. and Montagnier, L. (1986) Isolation of a 
new retrovirus from West African patients with AIDS Science 233, 343-346. 
Dean, M., Carrington, M., Winkler, C., Huttiey, G. A., Smith, M. W., Allikmets, 
R, Goedert, J. J., Buchbinder, S. P., Vittinghoff, E., Gomperts, E., Donfield, 
S., Vlahov, D., Kaslow, R., Saah, A., Rinaldo, C., Detels, R and O'Brien, S. 
J. (1996) Genetic restriction of HIV-1 infection and progression to AIDS by a 
deletion allele of the CKR5 structural gene. Hemophilia Growth and Develop-
ment Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort 
Study, San Francisco City Cohort, ALIVE Study Science 273, 1856-1862. 
Embretson, J., Zupanic, M., Ribas, J. L., Burke, A., Racz, P., Tenner-Racz, K. 
and Haase, A. T. (1993) Massive covert infection of helper T lymphocytes and 
macrophages by HIV during the incubation period of AIDS Nature 362, 359-362. 
Fenyo, E. M., Morfeld-Manson, L., Chiodi, F., Lind, B., Von Gegerfelt, A., 
Albert, J., Olausson, E. and Asjo, B. (1988) Distinct replicative and cytopathic 
characteristics of human immunodeficiency virus isolates Journal of Virology 62, 
4414-4419. 
Fox, C. H., Tenner-Racz, K., Racz, P., Firpo, A., Pizzo, P. A. and Fauci, A. S. 
(1991) Lymphoid germinal centers are reservoirs of human immunodeficiency 
virus type 1 RNA Journal of Infectious Diseases 164,1051-1057. 
Groenink, M., Fouchier, R A. M., De Goede, R E. Y., De Wolf, F., Cuypers, H. 
T. M., Gruters, R A., Huisman, H. G. and Tersmette, M. (1991) Phenotypical 
heterogeneityiAspanel of··infectious··molecularHIV-1 clonesderived .. from a. 
single individual. Journal of Virology 65, 1968-1975. 
97 
Gruters, R. A., Otto, S. A., AI, B. J. M., Verhoeven, A. J., Verweij, C. L., Van 
Lier, R. A. W. and Miedema, F. (1991) Non-mitogenic T-cell activation signals 
are sufficient for induction of HIV transcription European Journal of Immunology 
21,167-172. 
Gruters, R. A., Terpstra, F. G., De Jong, R., Van Noesel, C. J. M., Van Lier, R. 
A. W. and Miedema, F. (1990) Selective loss of T-cell functions in different 
stages of HIV infection European Journal of Immunology 20,1039-1044. 
Guillon, C., van der Ende, M. E., Boers, P. H. M., Gruters, R. A., Schutten, M. 
and Osterhaus, A. D. M. E. (1998) Coreceptor usage of human 
immunodeficiency virus type 2 primary isolates and biological clones is broad 
and does not correlate with their syncytium-inducing capacities Journal of 
Virology 72, 6260-6263. 
Huppes, W., De Geus, B., Zurcher, C. and van Bekkum, D. W. (1992) Acute 
human vs. mouse graft vs. host disease in normal and immunodeficient mice 
European Journal of Immunology 22, 197-206. 
Huppes, W., Paulonis, J., Dijk, H., Van Rooijen, N. and van Bekkum, D. W. 
(1993) The role of natural antibodies and ABO (H) blood groups in transplanta-
tion of human lymphoid cells into mice European Journal of Immunology 23,26-
32. 
Levy, J. A., Cheng-Mayer, C., Dina, D. and Luciw, P. A. (1986) Aids retrovirus 
(ARV-2) clone replicates in transfected human and animal fibroblasts Science 
232,998-1001. 
Martink, R., Kankl, P., Thior, I., Travers, K., Eisen, G., Siby, T., Traore, I., 
Hsieh, C. C., Dia, M. C. and Gueye, E. H. (1994) Reduced rate of disease de-
velopment after HIV-2 infection as compared to HIV-1 Science 265, 1587-1590. 
McKnight, A., Dittmar, M. T., Moniz-Periera, J., Ariyoshi, K., Reeves, J. D., 
Hibbitts, S., Whitby, D., Aarons, E., Proudfoot, A. E., Whittle, H. and 
Clapham, P. R. (1998) A broad range of chemokine receptors are used by 
primary isolates of human immunodeficiency virus type 2 as coreceptors with 
CD4 Journal of Virology 72, 4065-4071. 
Meyaard, L., Schuitemaker, H. and Miedema, F. (1993) T-cell dysfunction in HIV 
infection: Anergy due to defective antigen presenting cell function? Immunology 
Today 14,161-164. 
Norton, A. J., Jordan, S. and Yeomans, P. (1994) Brief, high-temperature heat 
denaturation (pressure cooking): a simple and effective method of antigen 
retrieval for routinely processed tissues Journal of Pathology 173, 371 -379. 
Sabri, F., Chiodi, F. and Fenyo, E. M. (1996) lack of correlation between V3 
amino acid sequence and syncytium-inducing capacity of some HIV type 1 
isolates. AIDS Research & Human Retroviruses 12, 855-858. 
Samson, M., Libert, F., Doranz, B. J., Rucker, J., Liesnard, C., Farber, C. M., 
Saragosti, S., Lapoumeroutie, C., Cognaux, J., Forceille, C., Muyldermans, 
G., Verhofstede, C., Burtonboy, G., Georges, M., Imai, T., Rana, S., Yi, Y., 
Smyth, RJ, Collman, R. G., Doms, R. W., Vassart, G. and Parmentier, M. 
(1996) Resistance to HIV-1 infection in caucasian individuals bearing mutant 
alleles of the CCR-5 chemokine receptor gene. Nature 382, 722-725. 
Schuitemaker, H., Koot, M., Kootstra, N. A., Dercksen, M. W., De Goede, R. E. 
Y., Van Steenwijk, R. P., Lange, J. M. A., Eeftink Schattenkerk, J. K. M., 
Miedema, F. and Tersmette, M. (1992) Biological phenotype of human 
immunodeficiency virus type 1 clones at different stagEls 6flhfect16h: 
98 
progression of disease is associated with a shift from monocytotropic to T-cell-
tropic virus populations Journal of Virology 66,1354-1360. 
Schuitemaker, H., Kootstra, N. A., De Goede, R. E. Y., De Wolf, F., Miedema, F. 
and Tersmette, M. (1991) Monocytotropic Human Immunodeficiency Virus 1 
(HIV-1) variants detectable in all stages of HIV infection lack T-cell line tropism 
and syncytium-inducing ability in primary T-cell culture Journal of Virology 65, 
356-363. 
Schuitemaker, H., Kootstra, N. A., Groenink, M., De Goede, R. E. Y., Miedema, 
F. and Tersmelte, M. (1992) Differential tropism of clinical HIV-1 isolates for 
primary monocytes and promonocytic-cell lines AIDS Research of Human 
Retrovirusses 8,1679-1682. 
Schutten, M., Tenner-Racz, K., Racz, P., van Bekkum, D. W. and Osterhaus, A. 
D.M.E. (1996) Human antibodies that neutralize primary human immuno-
deficiency virus type 1 in vitro do not provide protection in an in vivo model 
Journal of General Virology 77, 1667-1675. 
Tenner-Racz, K., Stellbrink, H. J., van Lunzen, J., Schneider, C., Jacobs, J. P., 
Raschdorff, B., Grosschupff, G., Steinman, R. M. and Racz, P. (1998) The 
unenlarged lymph nodes of HIV-1-infected, asymptomatic patients with high 
CD4 T cell counts are sites for virus replication and CD4 T cell proliferation. The 
impact of highly active antiretroviral therapy J Exp Med 187, 949-959. 
Tersmette, M., Lange, J. M. A., De Goede, R. E. Y., De Wolf, F., Eeftink 
Schattenkerk, J. K. M., Scheliekens, P. Th. A., Coutinho, R. A., Huisman, J. 
G., Goudsmit, J. and Miedema, F. (1989) Association between biological 
properties of human immunodeficiency virus variants and risk for AIDS and 
AIDS mortality Lancet i, 983-985. 
Tersmette, M. and Schuitemaker, H. (1993) Virulent HIV strains? AIDS 7,1123-5. 
van Baalen, C. A., Pontesilii, 0., Huisman, R. C., Geretti, A. M., Klein, M. R., De 
Wolf, F., Miedema, F., Gruters, R. A. and Osterhaus, A. D. M. E. (1997) 
Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T 
lymphocyte frequencies inversely correlate with rapid progression to AIDS 
Journal of General Virology 78, 1913-1918. 
van Baalen, C. A., Schutten, M., Huisman, R. C., Boers, P. H. M., Gruters, R. A. 
and Osterhaus, A. D. M. E. (1998) Kinetics of antiviral activity by human 
immunodeficiency virus type i-specific cytotoxic T lymphocytes (CTL) and rapid 
selection of CTL escape virus in vitro Journal of Virology 72,6851-6857. 
van der Ende, M. E., Schulten, M., Ly, T. D., Gruters, R. A. and Osterhaus, A. 
D. M. E.(1996) HIV-2 infection in 12 European residents: virus characteristics 
and disease progression AIDS 10,1649-1655. 
Whittle, H., Morris, J., Todd, J., Corrah, T., Sabaliy, S., Bangali, J., Ngom, PT, 
Rolfe, M. and Wilkins, A. (1994) HIV-2-infected patients survive longer than 
HIV-1-infected patients AIDS 8,1617-1620. 
Zinkernagel, R. M. and Hengartner, H. (1994) T-cell-mediated immunopathology 
versus direct cytolysis by virus: implications for HIV and AIDS. Immunology 
Today 15,262-268. 
CHAPTER 7 
Antiviral resistance of biological HIV-2 clones obtained from 
individuals on nucleoside reverse transcriptase inhibitor therapy. 
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SUMMARY 
Objective: To study the development of phenotypic and genotypic 
resistance of HIV-2 during nucleoside reverse transcriptase inhibitors 
(NRTI) treatment. 
Methods: Biological HIV-2 clones were generated from three patients 
before and after initiation of antiretroviral therapy with zidovudine (AZT) in 
patient RH2-7, AZT and didanosine (ddl) in patient PH2-1, and after 
addition of lamivudine (3TC) to AZT -monotherapy in patient RH2-5, The 
sensitivity to NRTI of the virus clones, as defined by the 50% inhibitory 
concentration (IC50), was determined in vitro. The predicted amino acid 
sequences of the reverse transcriptase proteins from these clones were 
determined, 
Results: Comparing the sensitivity of the biological HIV-2 clones obtained 
after start of therapy to those from antiviral naive patients, resistance had 
developed to AZT (patients RH2-7 and RH2-5) and 3TC (patient PH2-1 and 
RH2-5), No resistance to AZT was observed in the biological clone from 
PH2-1 obtained after start of therapy, The resistant clones from RH2-5 and 
PH2-1 but not RH2-7, contained amino acid mutations at positions where 
HIV-1 has been shown to mutate after AZT and 3TC treatment. 
Conclusions: Phenotypic resistance of HIV-2 to nucleoside analogues, 
,which developed in HIV-2 infected patients treated with NRTI, was asso-
ciated with genotypic changes. Some of the mutations at amino acid posi-
tions in the HIV-2 reverse transcriptase gene corresponded with those 
involved in HIV-1 resistance, although no conventional mutations assoc-
iated with resistance to AZT were obseNed, 
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Introduction 
Human immunodeficiency virus type 2 (HIV-2), the second causative agent 
of the acquired immunodeficiency syndrome (AIDS), belongs like HIV-1 to 
the subfamily of lentivirinae of the Retroviridae family (1). In vitro charac-
teristics of both HIV-1 and HIV-2, such as tropism for CD4+, a- or (3-chemo-
kine receptor positive cells and capacity to induce cytopathic changes as 
well as in vivo induced pathogenesis are quite similar (2-6). Despite the 
similarities, both perinatal and sexual transmission rates of HIV-2 are 
significantly lower (7-9), which has so far resulted in a more restricted 
spread of HIV-2 then HIV-1. Although the virus has spread globally, it is 
only more prevalent than HIV-1 in certain West African countries, such as 
Guinea-Bissau, the Gambia, Senegal, and the Cape Verde Islands. Via 
trade routes HIV-2 had limited spread to other parts of the world such as 
Angola, Mozambique, Gao and Western Europe (10). The natural history of 
disease development in HIV-2 infection is protracted. Epidemiological 
studies among cohorts of asymptomatic HIV-1 and HIV-2 infected 
individuals have demonstrated an AIDS incidence of 0.94 and 0.23 per 100 
person years of observation in HIV-1 and HIV-2 infected individuals 
respectively (11). These observations are in line with the immunological 
changes observed in HIV-2 infected individuals. CD4+ T cell counts and 
CD4/CD8 ratios decline slower than in HIV-1 infected individuals (11). 
Furthermore we have recently showed Significantly lower tissue and plasma 
viral loads in HIV-2 infected individuals than in HIV-1 infected individuals at 
comparable stages of disease development (submitted for publication). 
In HIV-1 infection it has been shown that both the risk of developing 
disease and the lack of efficacy of antiviral therapy are strongly associated 
with HIV-RNA plasma levels (12,13). NRTI treatment strategy from 1987 to 
1994 was initially limited to AZT monotherapy, which delays disease 
progression in asymptomatic and advanced HIV-1 disease and decreases 
plasma HIV-1 RNA by approximately 0.3 10glO copies/ml (14,15). 
Subsequent results from studies on combination NRTI therapy showed 
slower disease progression and an improved survival for antiviral naive 
HIV-1 infected patients on combination therapy versus monotherapy (16-
18). A more sustained increase in CD4+ cell counts and decrease in plasma 
HIV-1 RNA of approximately 1 log,o copies/ml were observed in individuals 
receiving duo-therapy with two NRTI. In HIV-1 infected patients it has been 
shown that the virostatic properties of AZT, as well as the clinical and 
immunological benefits, decrease during the course of monotherapy (19). 
Increasing evidence indicates that treatment failure of NRTI therapy is 
closely linked to levels of phenotypic resistance and an associated 
genotypic mutation pattern (20). Viral genotyping may therefore be an 
important tool in choosing anti-HIV therapy regimens (21-23). 
Limited data on antiretroviral treatment of HIV-2 infected individuals are 
available. Qnlysmall differences have been observed between the in vitro 
sensitivity of primary HIV:1 and HIV-2 isolates to AZT, ddland 3TC(24). 
No data are yet available on the development of genotypic or phenotypic 
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resistance of HIV-2 strains from patients on NRTI therapy. We therefore 
studied biological clones from three HIV-2 infected patients treated with 
NRTI and determined their phenotypic and genotypic resistance patterns. 
200 
-c: OJ 
RH2·5 0 
<> 100 
.... 
0 
0 
8 12 16 20 28 
G7 G7 
150 
-5100 
0 RH2·7 <> 
.... 50 0 
0 
0 0 4 8 12 16 20 24 28 
... RH2~7 A5 RH2-7 G12 
400 
§300 
0 
<> 
.... 200 PH2·1 
0 
0100 
0 
0 4 8 
months 
Figure 1. CD4' cell counts in three HIV-2 seropositive patients treated with NRTls. 
Material and methods 
Patients 
Patients in this study regularly visited our outpatient clinics in Rotterdam 
(n=2) and Paris (n= 1). Clinical, immunological and virological parameters 
were monitored from 1994 onwards. Patient RH2-7 (39-year-old hetero-
sexual male) and patient RH2-5 (a 40- year-old heterosexual female) were 
both living in Rotterdam and originated from the Cape Verdian Isles. Patient 
PH2-1 was a French born homosexual man living in Paris. All three patients 
were asymptomatic at the time of starting therapy. The relevant clinical data 
on antiretroviral treatment and CD4' cell counts after start of therapy are 
given in Fig 1. 
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Isolation of biological virus clones 
The isolation of biological H IV clones have been described previously (6). 
Briefly, participant peripheral blood mononuclear cells were cocultivated at 
three different dilutions, 2x102, 2x103, and 2x104 cells per well, with three 
days mitogen-prestimulated (PHA-L, Boehringer Mannheim, Germany), 
HIV-negative donor PBMC (4 x 104 per well) in 96-well microtiter plates 
(Costar). Every week 50jJi of culture supernatant was collected from each 
well for detection of p24 antigen (V5 ELISA, Organon, Boxtel, the 
Netherlands). At the same time, 2x102 cells from each well were transferred 
to a new well, and 4 x 104 fresh mitogen-prestimulated healthy donor 
PBMC were added to propagate the culture. Productively infected wells 
were considered to contain a clonal virus strain, when less then 5 out of 96 
wells were tested positive. The biological clones were further cultured using 
mitogen stimUlated PBMC and expanded to high titered stocks by a one-
week passage on US7/CCR-5 cells (6). For comparison a previously 
described HIV-1 molecular clone, obtained from an antiviral-naive individual 
was used (25,26). 
Antiviral drug susceptibility testing 
The sensitivity of the biological clones to the NRTI was determined in vitro, 
using a similar method previously described for HIV-1 drug testing (27). 
Virus stocks were thawed and titered by RT activity. Mitogen-stimulated 
CDB-depleted PBMC from HIV seronegative donors were inoculated in 
triplicate with 50TCID5o in the presence of 10 fold dilutions of AZT, 3TC, 
and ddl, starting at 10jJM. After one week, supernatants were tested for RT 
activity (2B). The concentration of the drug that resulted in a 50% reduction 
in RT activity, the 50% inhibitory concentration (IC5o) was calculated by the 
median effect equation (27). Virus clones were considered resistant, when 
the IC50 was >5 times higher than the IC50 of the naive clones (in patients 
RH2-7 and PH2-1) or the clone before therapy adjustment (in patient 
RH2-5). 
Polymerase chain reaction detection of RT sequences 
High molecular weight DNA was extracted with Celite beads (Janssen 
Chimika, Beersen, Belgium) from PBMC that were infected with the 
biological virus clones from the patients (29). Amplification was performed 
as previously described (30). Briefly, RT sequences were amplified in a 
polymerase chain reaction with primers 5'RD1 (5'CCCCAATCAACATTT-
TTGGCA G3') and 3'RD3 (3'CCTAGTTCTGCATTTACTTGCCC3') (kindly 
provided by Dr. C Boucher) for 2 min at 92'C, 1 min at 50'C, 2 min at 72'C 
for 35 cycles with a final extension of 10 min. at 72'C. The amplified 
fragments were cloned Into the PCR2.1 cloning vector (Invitrogen, San 
Diego, California, USA) according to the manufacturer's protocol. Clones 
were sequenced with the Taq Dye Deoxy Terminator sequencing kit on the 
373A sequencing system of AppliedBlosystems(FosterClty, California; 
USA). All clones were sequenced on both strands using custom-made 
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primers. Alignment of the protein sequences was performed with the 
Lasergene software (Dnastar, Madison, USA). A 3-D model structure of the 
HIV-2 ROD RT protein was generated on basis of the HIV-1 RT protein 
crystal structure 1 RT2 (31) using Swiss-Model 3.0 and PdB Viewer both 
kindly provided by Drs. M.C. Peitch and N. Guex (GlaxoWelicome 
Experimental Research, Geneva, Switzerland)(32,33) 
Results 
Patients 
The indication for initiation or adjustment of antiretroviral therapy in all three 
patients was a low CD4+ cell count. After 20 months of treatment with AZT, 
patient RH2-7 developed renal failure caused by HIV-nephropathy, a few 
months later he was diagnosed with disseminated Mycobacterium avium 
complex. Patient PH2-1 remained asymptomatic during treatment with 
AZT/ddl, and was switched to a protease inhibitor containing regimen 
because of a declining CD4 cell count. Patient RH2-5 was treated with AZT 
monotherapy and in addition AZT/3TC combination therapy for 14 and 18 
months respectively until she progressed to AIDS as she developed 
Mycobacterium Tuberculosis. 
Virus clones Patient AZT 3TC ddl Drug regimen 
RH2-5 G7 AZT 0.1 0.02 N.T.' 
RH2-5 A10 AZT + 3TC 0.06 0.9 N.T. 
PH2-1 E6 None 0.01 0.02 6 
PH2-1 C12 AZT + ddl 0.015 0.25 6 
RH2-7 G12 None 0.005 N.T 3 
RH2-7 A5 AZT 0.1 N.T 2 
HIV-1 ACH320.2A.1.2 None 0.003 N.T. 0.3 
Table 1. Susceptibility of HIV-2 clones to NRTI. For the HIV-2 biological clones the 
IC50 of the NRTI used in this study are given in micro molar. • N.T. = Not tested 
Virus phenotypic sensitivity to NRTI 
Biological HIV-2 clones were obtained from patients RH2-7 and PH2-1 
before treatment (RH2-7 G12 and PH2-1 E6) and after 20 and 6 months 
after initiation of antiretroviral therapy respectively (RH2-7 A5 and PH2-1 
C12). The first virus clone from patient RH2-5 (RH2-5 G7) was obtained 
after 6 months of AZT monotherapy and the second clone 12 months after 
adding 3TC to the regimen (RH2-5 A 1 O)(Figure 1). The sensitivity to AZT of 
RH2-7, G12 and PH2-1, E60btained from antiviral naive patients provedto 
be comparable to the HIV-1 molecular clone obtained from an antiviral 
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replication of all HIV-2 clones and the HIV-1 clone was high and therefore 
did not allow us to determine development of resistance to ddl. This has 
also been observed by others and may be caused by the inefficient 
conversion of ddl to the biologically active form ddA-triphosphate when 
activated peripheral blood mononuclear cells are used for phenotype 
resistance (34,35). 
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Figure 2. Alignment of the predicted amino acid sequence from HIV-2 reverse tran-
scriptase (RT) protein fragments. The arrows (v) indicate mutations corresponding 
with NRTI resistance in HIV-1 
Sensitivity of the biological HIV-2 clones obtained after start of therapy 
were compared to those obtained before therapy or, for the clones obtained 
from patient RH2-5, to clones from antiviral naive individuals. The biological 
clones from patients on AZT monotherapy (patient RH2-5 and RH2-7) were 
10 to 20 times less sensitive to inhibition by AZT. Sensitivity to AZT RH2-5 
A10 relative to RH2-5 G7 was unchanged. No resistance to AZT was 
observed for PH2-1 C12. Both clones from patients on duo NRTI therapy 
were less sensitive to inhibition with 3TC, clone PH2-1 C12 10x less 
sensitive and clone RH2-5 A 10 45x less sensitive. 
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Genotypic analysis of biological clones 
The RT genes from the biological HIV-2 clones were sequenced (Fig.2). 
From several biological clones the sequence was determined directly on 
the PCR product. In none of these, multiple polymorphism's were observed, 
supporting the clonality of these biological clones. Multiple differences in 
amino acid sequences were observed between the clones obtained before 
and after therapy. For convenience the predicted amino acid differences 
between the clones before and after therapy are given in table 2. 
HIV-1 RT and HIV-2 RT have similar catalytic properties and a 60% 
sequence identity (36). The observation that the folding of the palm of the 
more distant related RT of murine leukaemia virus is the same as HIV-1 
RT, supports the idea that HIV-1 RT and HIV-2 RT are sufficiently similar 
that amino acids in equivalent positions in the sequence will have similar 
roles in the two enzymes (36). Therefore we set out to study positions 
within the RT gene where HIV-1 mutates in case of resistance to NRTI. 
RH2-7 A5 
T14P (ACA--->CCA) 
P51 S (CCT ---> TCT) 
T84A (ACT --->GCT) 
R223K (AGA--->AAA) 
E250D (GAG--->GAT) 
R286K (AGA--->AAA) 
M287L (A TG---> TTG) 
RH2-5 A10 
K22R (AAA--->AGA) 
K35S (AAA--->AGT) 
M411 (ATG--->ATA) 
E49R (GAA--->AGA) 
V1111 (GTA--->A TA) 
Q1511 (CAG--->ATA) 
M184V (ATG--->GTG) 
G213R (GGA--->AGA) 
T237N (ACC--->AAC) 
V350L (GTA---> TT A) 
PH2-1 C12 
E 122K (GAA--->AAA) 
K125R (AAG--->AGG) 
M184V (ATG--->GTG) 
Q248R (CAG--->CGG) 
K277R (AAA--->AGA) 
R281 K (AGA--->AAA) 
E292G (GAA--->GGA) 
Y317C (TAC--->TGC) 
Table 2. Changes of amino acids on Ihe RT gene obtained from three HIV-2 clones 
from patients after therapy with NRTI. Mutations associated with HIV-1 resistance 
to NRTI are printed in bold face 
The predicted amino acid sequence of RH2-7 A5 showed no mutations 
relative to RH2-5 G12 at positions analogous to those associated with 
resistance to AZT in HIV-1 infection. According to the predicted protein 
structure one mutation, K223R, was found near the active site of RT 
(Figure 3). Mutations of RH2-7 A5 relative to RH2-7 G12 at positions 14, 
51, 84 and at positions 249, 286, 287 were at more distant sites respec-
tively in the fingers and thumb of the HIV-2 RT protein. 
Genotypic analysis of the first biological clone from patient RH2-5, 6 
months on AZT, revealed a methionine at position 151, which may explain 
the low susceptibility to AZT. As we do not have virus strains from patient 
RH2-5 before initiation of treatment, we cannot be sure whether this 
mutation· was indeed induced by AZTselection. pressure. However,in none 
of the hitherto described HIV-2 virus isolates of naive patients mutations at 
this position have been observed (37). 
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Genotypic analysis after duo therapy with NRTI was done on the clones 
obtained from PH2-1 (AZT/ddl) and RH2-5 (AZT/3TC). Both virus clones 
showed a M184V mutation. For HIV-1 this mutation is associated with a 
strong reduced sensitivity to 3TC in phenotypic assays (23). The second 
clone obtained from patient RH2-5 showed isoleucine instead of methionine 
at position 151. Furthermore, a M41L mutation appeared, which is for HIV-1 
associated with low-level resistance to AZT (20). 
Discussion 
In the present paper we have described the development of phenotypic and 
genotypic resistance to NRTI during treatment of HIV-2 patients. Mutations 
associated with resistance, although in some cases occurring at similar 
positions as in HIV-1, proved to be different with respect to topography and 
time of appearance when compared to mutations generally observed in 
HIV-1. 
In HIV-1 infection the genotypic resistance pattern for NRTI correlates 
with the level of phenotypic resistance (20). Loss of antiviral efficacy 
acquired under selection pressure of AZT mono-therapy involves a gradual 
and stepwise accrual of mutations in functional regions of the RT gene at 
positions K70R, T215Y and M41 L respectively. Despite the fact that the 
second virus clone from patient RH2-7, obtained after 20 months of AZT 
monotherapy, was 20 fold less sensitive to AZT in the phenotypic assay, 
genotypic analysis did not show any mutations associated with resistance 
to AZT. To further elucidate this discrepancy an additional biological clone, 
from the same patient and the same time point, was sequenced. Also in 
this biological clone no mutations were found at positions associated with 
HIV-1 AZT resistance (data not shown). According to the predicted HIV-2 
RT protein structure, the R223K mutation was positioned near to the active 
site, and therefore seems a likely candidate to confer AZT resistance. It can 
however not be excluded that the other mutations of RH2-7 G 12 indirectly 
conferred AZT resistance. Site-directed mutagenesis should be done to be 
able to define regions and positions that are involved in resistance to 
zidovudine HIV-2 RT. In patient RH2-5 the virus clone obtained after 6 
months of AZT monotherapy was phenotypically resistant to AZT. Geno-
typic analysis showed the appearance of methionine at position 151. The 
0151M mutation requires a change of two nucleotides within one codon. In 
HIV-1 infections this mutation develops in asymptomatic individuals after 
more than one year of combination therapy with AZT and zalcitabine (ddC) 
or ddl (38,39). Recently this mutation has been shown to induce resistance 
to multiple NRTI in HIV-1 infection, and is associated with a set of other 
mutations, including A62V, V751, F77L, F116Y (38,39). Among these five 
mutations, 0151 M is thought to be the first mutation to develop. Up till now 
the factors which predispose virus strains to develop the set of multidrug 
resistance mutations in favour of AZT resistance mutations are not known. 
It has been' suggestedihat certain nucleotide or amino acid sequences 
predispose these viruses not to acquire any AZT -related mutations (39). In 
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the virus clone RH2-5 A 10 no new mutations associated with multidrug 
NRTI resistance in HIV-1 infection were observed. According to the 
predicted protein structure, several mutations are positioned in the fingers 
of the RT protein. It is not excluded that they also contribute to resistance. 
Figure 3. The predicted protein structure of reverse transcriptase of HIV-2, accor-
ding to the Swiss-Prot database. Amino acid residues in red mark the active site; 
yellow amino acids residues are mutations of RH2-7 A5 relative to RH2-7 G7. 
In HIV-1 infection the benefit of combination therapy with two NRTI 
compared to monotherapy may be explained by constraints on coincidental 
developing resistance mutations for two NRTI (40,41). Furthermore it has 
been shown that mutations that confer resistance to one NRTI may prevent 
mutations associated with resistance to other NRTI in the regimen (42,43). 
Susceptibility of the virus PH2-1 C12 to 3TC, obtained after 6 months of 
AZT/ddl combination therapy, was significantly lower as compared to PH2-
1 E6. This decrease most probably resulted from the change of methionine 
to valine at position 184. This mutation was unexpected and early, since in 
HIV-1 infection the M184V mutation is in general observed after 3TC or 
AZT/3TC therapy and rarely after AZT/ddl combination therapy. In HIV-1 
infection, the M184V mutation may develop within 4-12 weeks after 
initiation of AZT/3TC treatment, whereas genotypic resistance to AZT is in 
general rare or absent after 24 weeks (42,43). Monotherapy with either AZT 
or ddl induces mutations associated with resistance to AZT or ddl within 48 
weeks in the majority of the patients (40). During duo therapy with AZT and 
ddl mutations associated with resistance to ddl (codon 69, 74 or 184) were 
rarely observed. The number of mutations associated with AZT resistance 
was comparable to the nomber fOUhdihlheAZT mOhbtherapygroop.1t has 
therefore been suggested that selection for AZT resistance may impose a 
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background that restricts evolution of ddl resistance. The genotypic 
resistance pattern in patient PH2-1, the M184V mutation and the absence 
of AZT resistance, seems to be more in agreement with AZT/3TC therapy 
in HIV-1 infected individuals than to AZT/ddl therapy. It may be 
hypothesised that for optimal enzymatic activity of HIV-2 RT the M184V 
mutation is preferable. 
In conclusion, genotypic mutations in the HIV-1 RT gene are predictive 
for phenotypic resistance to NRTI and clinical failure, and are relevant for 
making rational effective drug choices. In our study we have shown that this 
correlation of phenotypic and genotypic resistance is not so clear in HIV-2 
infection. Switching NRTI therapy in HIV-2 infected individuals cannot be 
decided only on genotypic analysis results. As the number of HIV-2 infected 
patients on antiretroviral treatment is increasing, further studies are 
needed. 
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SUMMARY 
We describe an assay for the quantification of HIV-2 RNA in EDTA plasma 
based on RT-PCR using the Taqman real-time PCR detection method, As 
standard an electron microscopically counted virus stock of HIV-2 strain 
NIHZ was used, The lower detection limit is 5x102 HIV-2 RNA copies per ml 
of EDTA plasma, The assay is linear within the range required (5x102-106 
HIV-2 R.NA copies/ml of EDTA plasma) with an intra assay variability of 
2,5% and an inter-assay variability ranging from 2% at 106 copies to 7,5 % 
at the lower detection limit. Three primer/probe combinations were 
developed to circumvent false negative samples due to nucleotide variation 
in the target sequence, Using these primer/probe sets we were able to 
detect HIV-2 DNA sequences from all HIV-2 seropositive individuals and 
two out of five dual HIV-1 and HIV-2 seropositive individuals visiting our 
clinic, 
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Introduction 
The human immunodeficiency virus type 1 and 2 (HIV-1 and HIV-2) are the 
causative agents of the acquired immunodeficiency syndrome (AIDS) 
(Barre-Sinoussi et al. 1983; Clavel et al. 1986). They both belong to the 
genus of the lentiviruses. In contrast to the worldwide spread of HIV-1, HIV-
2 infections are more confined to West-Africa (Marlink, 1996). A significant 
percentage of the AIDS cases in Senegal, the Gambia, and Ivory Coast are 
caused by HIV-2 infection (Ariyoshi et al. 1996; Marlink, 1996; Norrgren et 
al. 1997; Norrgren et al. 1999; Pieniazek et al. 1999; Poulsen et al. 
1997). HIV-2 infected individuals are also found in West European 
countries with former colonial and/or trade links with West-African countries 
such as the Netherlands France, Portugal and Spain (Machuca et al. 1999; 
Marlink, 1996; van der Ende et al. 1996). 
Molecular diagnostic assays currently used to quantify the number of 
HIV-1 RNA molecules in plasma and serum are highly type specific 
(Nkengasong et al. 1998; Nkengasong et al. 1999) They have proven to 
be of significant clinical relevance since it was shown that the rate of 
disease development is directly related to the plasma viral RNA level 
(Mellors et al. 1996). The current guidelines as set out by the Panel on 
Clinical Practices for Treatment of HIV Infection for starting anti-retroviral 
therapy (available at http://hivatis.org/) are therefore based on both clinical 
parameters and on a cell free plasma or serum viral load above 2x104 HIV-
1 RNA copies per ml. HIV-1 infected individuals are believed to fail on anti-
retroviral therapy regimens if their cell free viral load after 12-16 weeks of 
treatment is above the detection limit of the standard quantitative HIV-1 
plasma viral load assays. 
Of the 650 HIV infected patients attending our hospital, 20 are HIV-2 
seropositive (van der Ende et al. 1996), data not shown). They all belong 
to, or have direct links with a population of West African immigrants 
residing in the Rotterdam area. Six of them proved to be dually HIV-1/HIV-2 
seropositive by Western blot analysis according to WHO guidelines 
(Gene labs Diagnostics Ltd, Singapore). Since it has been shown that the 
antiviral activity and drug-resistance patterns of drugs against HIV-1 not 
always parallel those against HIV-2, more research in this area is required 
(Kempf et al. 1995; van der Ende et al. 2000). We therefore developed a 
quantitative molecular assay for the measurement of HIV-2 viral RNA in 
plasma, based on real time detection of HIV-2 RNA enabling us to detect 
HIV-2 RNA over a 4 log range in clinical samples. 
MATERIALS AND METHODS 
Patients and viruses. 
Peripheral blood mononuclear cells (PBMC) and EDT A plasma were 
collected from HIV seropositive individuals visiting our out-patient clinic, 
usingvacutainerCPT·andhemogard K3EDTAtubesrespectively(Beckton 
Dickinson, Franklin Lakes, USA). HIV-1 and HIV-2 seropositivity was 
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determined with the HIV BLOT 2.2 and the HIV-2 western blot version 1.2 
from Genelabs Diagnostics (Genelabs Diagnostics Ltd., Singapore) using 
WHO criteria. Patients PBMC were aliquoted and stored at -135°C until 
use. As a "gold standard" an electron microscopically counted virus stock 
from the HIV-2 NIHZ strain was used (Advanced Biotechnologies 
Incorporated, Maryland, USA). Prior to lysis with 10mM Tris, 150mM NaCI, 
1mM EDTA and 1% Triton X-100 pH7.5 the stock contained 1.84x1010 virus 
particles per ml. 
Primer/probe Position 1 Composition 
HIV-2TMfpr1 379-398 5'-MCMACCACGACGGAGTGC-3' 
~ 
Q) HIV-2TMrpr1 422-440 5'-CCACACGCTGCCTTTGGTA-3' 
(f) 
Tmprobe 1 400-419 5' -TCGGCCCGCGCITTTCTAGG-3' 
HIV-2TMfprB 379-398 5'-M TCMCCACGACGGAGAGC-3' 
co 
Q) HIV-2TMrprB 423-442 5'-CTCCTCACGCTGCCTGGT-3' 
(f) 
Tmprobe B 400-419 5' -CCGGCCTGCGCTTTT ACAGG-3' 
HIV-2TMfpr2 1083-1101 5'-GGCTGCACGCCCTATGATA-3' 
N HIV-2TMrpr2 1131-1149 5'-TCTGCATGGCTGCTTGATG-3' 
~ 
OJ 
(f) Tmprobe 2.1 1103_1129 5'-TCGCCCACACMTTMGCAT-TTGGTTG-3' 
Tmprobe 2.2 1103_1129 5'-TCGCCCACACAATTMGCAT-TTGATTA-3' 
HIV-2TM1sfpr 207-227 5'-CGCCTGGTCATTCGGTGTTCA-3' 
HIV-2TM1 srpr 542-561 5'-AGTTTCTCGCGCCCATCTCC-3' 
HIV-2TM2sfpr 881-899 5'-AGGMCTGCAGAGMM TG-3' 
HIV-2TM2srpr 1250-1273 ~:-GTGCTTGTTGTCCCTGCTATGTCA-
Table 1. Primers and Probes. 1 The nucleotide position of the oligonucleotide 
within the HIV-2 NIHZ strain is given 
Primers and probes. 
The.primersand probes were designed on basis of the HIVc2 subtype A 
consensus sequence using the Primer Express software (PE Biosystems, 
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Nieuwerkerk aan de IJssel, The Netherlands). Due to the relatively high 
variability of HIV-2, we chose to develop two primer/probe sets for subtype 
A (set1 and set 2) and one primer/probe set for subtype B (set B) (Table1). 
Set one and set B encompass a region between the 5' L TR and the 
Gag/Pol open-reading frame (nucleotides 380 to 440 of the HIV-2 NIHZ 
isolate). For set B the composition of the primers and probe were slightly 
modified to fit the HIV-2 subtype B consensus sequence. Set 2 
encompassed a region in the gag gene (nucleotides 1083 to 1149 of the 
HIV-2 NIHZ isolate). Primers were synthesised by Isogen Bioscience BV 
(Isogen Bioscience BV, Maarssen, The Netherlands) and the probes were 
labelled at the 5' end with the fluorochrome FAM and at the 3' end with the 
quencher TAMRA and synthesised by PE Biosystem (PE Biosystem, 
Nieuwerkerk aan de IJssel, The Netherlands). Primers just outside the 
Taqman primer/probe sets were designed for the evaluation of the 
variability within the Taqman primer/probe sets in the Rotterdam cohort of 
HIV-2 seropositive individuals. For set 1 and set B the primers HIV-
2TM1sfpr and HIV-2TM1srpr were used and for set 2 HIV-2TM2sfpr and 
HIV-2TM2srpr were chosen (Table1). 
Nucleic acid isolation. 
For the isolation of HIV-2 RNA, a modification of the High pure viral RNA 
isolation kit (Roche Diagnostics, Almere, The Netherlands) was used. 
Briefly, 800 ).\1 of binding buffer (6M guanidine hydrochloride, 50 mM Tris-
HCI, 30% Triton X-100 (w/v) and 10fl9/ml poly (A) carrier RNA, pH 6.6) was 
added to 400 ).\1 sample. The mixture was incubated for 10 minutes at room 
temperature and subsequently loaded onto the filter columns. The columns 
were centrifuged at 8000x g, the flow-through was discarded and the 
column was washed once with an inhibition removal buffer (5 M guanidine 
hydrochloride, 20 mM Tris-HCI and 36% EtOH, pH 6.6) and twice with a 
wash buffer (20mM NaCI, 2mM Tris-HCI and 75% EtOH, pH7.5). The viral 
RNA was eluted from the columns with 50).\1 redistilled H20 and stored at -
80°C until further use. DNA from patient PBMC's was isolated using the 
High pure viral nucleic acid kit according to the manufacturers instructions 
(Roche Diagnostics, Almere, The Netherlands). 
Taqman HIV-2 RNA quantification. 
The number of HIV-2 RNA copies was determined using the Taqman real-
time PCR measurement system(Kimura et al. 1999; Martell et al. 1999; 
Niesters et al. 2000). For reverse transcription, 15 fd viral RNA was incuba-
ted with 2 fd 35pmolhd of either HIV-2TMrpr1 or HIV-2TMrpr2 for two 
minutes at 80°C. The complementary DNA (cDNA) reaction (final concen-
tration 2 units AMV-RT (Promega, Leiden, the Netherlands), 50 mM Tris-
HCI, 50 mM KCI, 3mM MgCI" 4 mM OTT and 10mM of each dNTP) was 
performed in a final volume of 25).\1 for 30 minutes at 55°C. For the set 1 
Taqman reaction 1ftl35pmolfitl HIV-2TMfpr1, 1pl35pmolhd HIV-2TMrpr1, 1 
fiI5pmol/illTMprobel,2ftl H,Oand 30 pi" 2xTaqmanUniversalPCR 
mastermix (PE Biosystems, Nieuwerkerk aan de IJssel, The Netherlands) 
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was added to the HIV-2TMrpr1 initiated cDNA. For the set 2 Taqman reac-
tion 1pl30pmolhd HIV-2TMfpr2, 1ft! 20pmol/ft! HIV-2TMrpr2, 2pl H20, 30 pi 
2x Taqman Universal PCR mastermix and either 1pl 5pmol Tmprobe2.1 or 
1pl 10pmol/fll TMprobe2.2 was added to the HIV-2TMrpr2 initiated cDNA. 
For the set B Taqman reaction 1 pi 25 pmol/pl HIV-2TMfprB, 1 pi 25 pmollpl 
HIV-2TMrprB, 1 pi 5pmol/pl TMprobeB, 2pl H20 and 30 fll 2x Taqman 
Universal PCR mastermix was added to the HIV-2TMrprB initiated eDNA. 
The real-time PCR amplification and detection were performed on an ABI 
Prism 7700 Sequence Detection System (PE Biosystem, Nieuwerkerk aan 
de IJssel, The Netherlands) using standard cycling conditions (2 min. 50 
'c, 10 min. 95'C and 50 two step cycles of 15 seconds at 95'C and 60 
seconds at 60'C). 
RESULTS AND DISCUSSION 
Detection limit, linearity and intra-/interassay variability. 
The efficacy of the assay was initially determined using serial dilutions of 
the HIV-2 NIHZ standard and Taqman set1. The PCR cycle at which the 
FAM fluorescent signal exceeded a limit of 0.04 was taken as threshold 
cycle (Ct) value. The Ct value was determined in six independent assays of 
serial dilutions of the HIV-2 NIHZ standard made in diethyl pyrocarbonate 
(DEPC) treated water. The sensitivity of the assay was 50% at 50 virus 
particles/ml input and 100% at all higher input samples (102_106 virus 
particles/ml, Figure 1A). The detection limit of the assay was therefore set 
at 102 virus particles/ml, although samples with 50 virus particles/ ml are 
regularly detected at ct values above 40. At these Ct values however, the 
chance of false positive samples increases to approx. 5% (data not shown). 
The Ct values of virtually all samples above this detection limit fell within 
the 10% confidence interval (Figure 1 A). The linear range of the assay was 
at least 4 logs with a Spearman regression coefficient of 0.99 and the inter-
assay variability based on the dilution series Ct values ranged from 2% at 
106 virus particles/ml to 7.5% at the detection limit (102 virus particles/ml). 
The intra-assay variability was determined by processing 32 samples of 104 
virus particles/ml and proved to be 2.5%. 
Viral RNA detection in EDTA plasma. 
Since the assay should predict the number of virus particles in plasma of 
individuals, we determined the efficiency of the assay to detect virus RNA 
isolated from plasma relative to virus RNA isolated from DEPC treated 
water. The HIV-2 NIHZ standard was diluted in EDTA plasma pooled from 
six HIV seronegative volunteers and in DE PC treated water and 
subsequently processed according to the standard procedure. Figure 1B 
represents the average from three independent assays. The HIV-2 NIHZ 
standard dilution series Ct values were taken to generate a standard curve 
and the Ct values obtainedwith theplasma dilutions of the HIV-2NIHZ 
particles, were osedto calculate the oufpulnurilber OTvlrus partides. The 
regression curve of the plasma dilution series proved to be almost parallel 
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to but 2.7 times lower (y=0.36x, Spearman regression coefficient of 0,97) 
than the water dilution series (by definition y=x). Since each HIV-2 particle 
contains two RNA copies, it can be calculated that the cut-off of the assay 
for the detection of HIV-2 RNA copies per ml of EDTA plasma is (2) x (2,7) 
x (102)= 5x102. 
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Figure 1 A) Regression curve based on the mean of six independently processed 
serial dilutions of the HIV-2 NIHZ EM counted standard. The error bars indicate the 
90% confidence interval of the mean. The regression curve is given for the samp-
les above· thec!etectionlimitof· the assay (1 00 virusparticles/ml). -: individuaLdata 
points, : mean of six independent samples. 8) Regression curve of three indepen-
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dent processed serial dilutions of the HIV-2 NIHZ EM counted standard diluted in 
DEPC treated water and EDTA plasma 6: HIV-2 NIHZ particles diluted in water. II: 
HIV-2 NIHZ particles diluted in EDTA plasma. 
Patient1 HIV-1/ HIV-22 Set 1 Set 2.1 Set 2.2 SetB Best fit4 
1 2 153 20 21 ;jij 1 +2.1 +2.2 
2 1+2 :Ii) :)lJ ' l(j '/.1 None 
3 2 14 :)'! 20 ;l(J 1+2.2 
4 2 14 );; 23 :lO 1+2.2 
5. 2 14 20 20 ; )() 1+2.1 +2.2 
6 2 // 21 20 ~ )(} 2.1+2.2 
7 2 15 hO 21 :,() 1+2.2 
8 1+2 '1 ~,) )(j )() r )() None 
9 2 16 20 20 ~ lU 1+2.1+2.2 
10 2 19 22 22 : )() 2.1+2.2 
11 1+2 , ,f) i 1(1 : )0 :;0 None 
12 1+2 ! )() i )() :)n 19 B 
13 1+2 14 20 20 ~ )0 1 +2.1 +2.2 
14 2 "Il 23 ;J' ,) ')(i 2.1 
15 2 : iO 20 20 :)0 2.1 +2.2 
16 2 14 20 20 "O 1+2.1+2.2 
Table 2. Efficacy of HIV-2 detection with the Taqman primer/probe sets. 1 Proviral 
DNA from 16 patients was tested for it's fit with the Ta~man primers/probe sets. 
2Serological reactivity as determined by Western blot. Ct value measured with a 
standard amount of target input. Ct values more than three Ct values higher than 
the lowest Ct value obtained with a set are shown in grey. 4 ct values shown in 
grey are considered a misfit. 
Nucleotide variation within HIV-2 from Rotterdam patients 
To overcome possible variation within the target HIV-2 RNA sequence of 
the Taqman set 1 primers and probe, two additional sets were developed. 
The second set was located within a relatively conserved region of the Gag 
p24 gene. Furthermore, for the detection of subtype B HIV-2 strains, the 
primers and probe from set 1 were slightly modified to fit subtype B 
sequences. In order to determine which Taqman set had the best fit with 
HIV-2 sequences from HIV-2 seropositive individuals visiting our outpatient 
clinic, a PCR was carried out on proviral DNA in PBMC's from these 
individuals with primers covering approximately 400 base pairs including 
. the Taqman·set··1····and "setBtarget"sequences'(forwardprimerHIVc 
2TM1seqfpr and reverse primer HIV-2TM1seqrpr) and the Taqman set 2 
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target sequence (forward primer HIV-2TM2seqfpr and reverse primer HIV-
2TM2seqrpr). The amount of the amplicon generated for each patient was 
estimated by agarose gel separation using ethidium bromide staining. For 
all patients an approximately similar amount of the amplicon covering the 
Taqman set 1 region was subsequently analysed in the Taqman procedure 
with Taqman set 1. In this way we ensured that from each patient 
approximately the same amount of target was present in the Taqman 
assay. Differences in Ct output are therefore directly related to nucleotide 
sequence differences between the target sequence and the primers or 
probe used in the Taqman assay. For Taqman set 2 and set B the same 
procedure was followed. Ct values obtained in this way are shown in table 
1. A Ct value that differed more than 3.0 from the lowest Ct value obtained 
with that same set was considered a misfit. Set 1, Band 2 proved to detect 
respectively seven, one and twelve proviral DNA sequences out of the 16 
patients tested (Table 2). The proviral DNA detected with the Taqman 
primer/probe set B, which was designed to fit with subtype B HIV-2 strains, 
was isolated from a patient originating from Ivory-Coast, where subtype B 
HIV-2 strains is most prevalent (Pieniazek et al. 1999). Three out of the 16 
HIV-2 seropositive individuals were not covered with the three Taqman sets 
used. Interestingly all three patients were both HIV-1 and HIV-2 
seropositive with a high CD4 count (>600/fd). Whether these patients are 
indeed HIV-2 infected or HIV-1 infected with serological HIV-2 cross-
reactivity therefore remains to be elucidated. 
In summary, our data show that the quantitative molecular assay may be 
used to quantify the plasma HIV-2 RNA load in the vast majority of the 
HIV-2 seropositive patients living in the Rotterdam area visiting our out-
patient clinic. 
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Increasing numbers of patients with HIV-2 infection are being seen in 
Western Europe. 630 HIV-1, 14 HIV-2 and 6 dual HIV-1 and HIV-2 
seropositive patients attend our hospital. The HIV-2 seropositive patients all 
belong to, or have direct links with a group of West African immigrants 
residing in the Rotterdam area. Six of the previously untreated HIV-2 
seropositive patients who all started on zidovudine 300 mg twice daily, 
lamivudine 150 mg twice daily and indinavir 800 mg thrice daily, have so far 
shown clinical improvement with plasma HIV-2 RNA levels <5x102 
copies/ml (data not shown). Here we describe the response to antiretroviral 
therapy of two previously untreated dually HIV-1 and HIV-2 infected 
patients whom both unexpectedly failed on antiretroviral therapy. 
One was a 55-year-old, asymptomatic Cape Verdian man. At baseline 
his CD4' cell count was 50/ftl and his plasma HIV-1 RNA level was 7,5x103 
copieslml (Cobas Amplicor 1.5, Roche Diagnostics, Capelle aId IJssel). He 
was treated with ritonavir 400 mg twice daily and saquinavir 400 mg twice 
daily. His plasma HIV-1 RNA was undetectable «5,Ox102 copies/ml) within 
4 weeks and has remained undetectable for 18 months. The second patient 
was a 28-year-old, asymptomatic man from the Ivory Coast. At baseline his 
CD4' cell count was 40/ftl and his plasma HIV-1 RNA level was 5,4x103 
copieslml. He was treated with zidovudine 300 mg twice daily, lamivudine 
150 mg twice daily and nelfinavir 1250 mg twice daily. His plasma HIV-1 
RNA level decreased to <5,Ox102 copieslml within 4 weeks and has 
remained undetectable for 9 months. The reduction in plasma HIV-1 RNA 
levels suggested adequate viral suppression in both patients. However, 
retrospective analysis of HIV-2 RNA levels revealed no decrease of HIV-2 
RNA in patient 1 (>2,5x104 copieslml during follow-up) and in patient 2 an 
initial decrease in HIV-2 RNA levels from 5,Ox103 too undetectable 
«5,Ox102 copies/ml) followed by a rebound above baseline (2,1 xi 04 
copies/ml)(figure). 
HIV-2 is thought to have a protective effect on HIV-1 super infection, so 
that either HIV-1 or HIV-2 but not both are thought to actively replicate in 
dually infected patients. In these two patients however both HIV-1 and HIV-
2 actively replicated at the same time. Given the different susceptibilities of 
HlV-2 strains to protease inhibitors and the more . limiledoptidris fOr 
treatment of HIV-2 infection (3,4), we recommend caution before the 
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initiation of antiretroviral therapy in dual HIV-1 and HIV-2 seropositive 
individuals. Especially since plasma HIV-2 RNA levels >1 ,Ox1 04 copies/ml 
during antiretroviral therapy as measured in the two patients described 
above are expected to result in progression to end stage disease. 
Serological testing for HIV-2 infection and monitoring HIV-1 and HIV-2 
plasma viral loads in dually HIV-1/HIV-2 seropositive individuals are 
therefore essential for adequate management of disease in HIV 
seropositive individuals. 
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General discussion and summary 
Infection with human immunodeficiency virus type 2 (HIV-2) predominantly 
occurs in West African countries around the Gulf of Guinee, but has spread 
to many countries outside Africa through immigrants and sexual partners of 
West Africans (1). Although the structure and the replication strategy of 
HIV-2 are similar to those of HIV-1, the pathogenesis (2-5) and 
transmission rate - both sexual (6) and perinatal (7-12) - differ from those of 
HIV-1 infection. The mechanism involved in the apparently lower 
pathogenicity of HIV-2 infection is currently unresolved. During this study, 
which lasted from 1995 t01999, the population visiting the HIV-clinic in 
Rotterdam (n=766) was multinational and consisted of patients from 60 
different nationalities. Among these, 67 individuals from seven nationalities 
originated from West Africa. Fourty percent (n = 23) of this patient 
population proved to be HIV-2 seropositive and 60 percent (n = 42) HIV-1 
seropositive. From the HIV-2 seropositive individuals, about one fifth (n=5) 
proved to be dually HIV-1/HIV-2 seropositive by Western blot analysis, 
according to WHO guidelines. This study was started to increase our 
understanding of the different clinical courses observed for HIV-1 and HIV-
2 induced disease. This understanding may lead to a better disease 
management and choice of antiretroviral treatment of individuals infected 
with HIV-2. 
First we were interested in the rates of disease progression amongst the 
HIV-2 and HIV-1 infected individuals from West African origin, and in the 
characteristics of the HIV-2 strains involved. The ratios of asymptomatic 
versus symptomatic individuals were 2:7 for HIV-2 and 8:9 for HIV-1 
infected individuals in our cohort. Like in HIV-1 infection, the success of 
HIV-2 isolation from PHA-stimulated PBMC correlated with disease 
progression, low CD4+ T cell counts, and the ability of the virus to induce 
syncytia in T cell lines (13,chapter 2). We also observed that HIV-2 
infection may have a rapid progressive course, judged by a CD4+ T cell 
decline from 600htl to less than 200htl within 36 months after acute HIV-2 
infection in a French homosexual individual, who did not belong to the 
Rotterdam cohort. The more favourable asymptomatic /symptomatic ratio 
for HIV-1 infected patients may have been influenced by our patient 
selection. However, the observed rapid progressive course of HIV-2 
infection in a patient with a known seroconversion date, led us to believe 
that the course of HIV-2 infection may be as rapid as in HIV-1 infection. 
In HIV-1 infection plasma HIV-1 RNA is an important prognostic 
parameter for disease progression (14). Several studies have reported on 
tissue HIV-1 RNA load before and after initiation of antiretroviral treatment, 
the tissue HIV-1 RNA load proved to correlate with plasma HIV-1 RNA load 
(15,16). It is generally accepted that plasma HIV-1 RNA load is an 
important. tooL in the. decision-making on startingantiretroviraltherapy, Fer . 
HIV-2 infection a reliable quantitative assay to measure plasma HIV-2 RNA 
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load was missing, so we set out to study lymphoid tissue biopsies from 
HIV-2 infected individuals by in situ hybridisation and immunohisto-
chemistry in order to determine tissue HIV-RNA load (chapter 3). The histo-
logical characteristics, like irregular follicular hyperplasia upon disease 
progression, were in general similar to the observations made in HIV-1 
infection (for review see reference 17). The number of productively infected 
cells per mm2 of tissue was found to be five times lower as compared to 
quantitative data obtained from HIV-1 infected individuals during 
comparable stages of disease. Immunohistochemistry studies furthermore 
revealed a significantly higher percentage of CD8' T cells in the germinal 
centres (GC) of the lymphoid tissues (L T) taken from HIV-2 infected 
individuals as compared to those of HIV-1 infected individuals. In HIV-1 
infection, CD8' T cells are considered a major antiviral component of the 
HIV-1 specific immune response (18,19). Therefore, we conclude that the 
relatively low numbers of productively HIV-2 infected cells may be related 
to the presence of the relative high numbers of CD8' T cells. From the 
tissue viral load data it was estimated that the mean plasma viral load in 
asymptomatic HIV-2 infected individuals is five-fold lower than in HIV-1 
infected individuals at the same stage of the disease. This would result in a 
slower disease course in HIV-2 infected individuals. Recently we developed 
an assay to assess quantitative plasma HIV-2 RNA loads (chapter 7), and 
found the plasma HIV-2 RNA levels to be even 100 times lower at this 
stage. This discrepancy between tissue and plasma viral load differences in 
HIV-1 and HIV-2 infected individuals could either be due to a slower 
replication of HIV-2 or to a higher clearance of HIV-2 virions (20). There are 
several arguments in favour of a more efficient control of virus replication in 
HIV-2 infected individuals. The observed amount of produced virions per 
infected cell by in situ hybridisation analysis proved to be considerably 
higher in HIV-1 infection than in HIV-2 infection (P. Racz personal 
observation). Moreover, we recently observed in an individual during acute 
HIV-2 seroconversion, HIV-2 RNA levels before seroconversion as low as 
10.000 copies/ml, arguing against a more efficient clearance. 
Production of HIV-1 in macrophages is lower than in CD4' T cells, as 
judged by a lower overlay of virion particles (Racz, not published). As CD4' 
T cells were predominantly the major source of HIV-2 production in the 
study described in chapter 3, the low plasma HIV-2 RNA load could not be 
attributed to a switch from CD4' T cells to macrophages as the major 
source of virus production. For HIV-1 infection this switch has been 
reported during opportunistic infections (21). In order to confirm this 
difference in the nature of virus producing cells, we looked into lymphoid 
tissue samples from HIV-1 infected patients during opportunistic infections 
and end-stage disease (chapter 4). We could not confirm this finding in our 
lymphoid tissue samples. Therefore we concluded that CD4' T cells remain 
the major source of virus production during late stage disease in both HIV-1 
and HIV-2 infection, 
Chapters 2, 3 and 4 were based upon ex vivo and in vivo studies on 
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HIV-2 infection. Virus characteristics of HIV-1 and HIV-2 were comparable, 
however, tissue and plasma HIV-2 RNA were five and at least 100 times 
lower respectively than tissue and plasma viral in loads in HIV-1 infection. 
This may be due to the high numbers of CD8+ T cells - possibly controlling 
virus replication - found in the GC of L T from HIV-2 infected individuals. We 
were interested to determine whether specific virus properties of HIV-2 
contributed to the observed differences found in chapters 3 and 4. 
Entry of HIV-1 into target cells is mediated by binding of the surface 
envelope glycoprotein to the CD4 molecule (22). This binding triggers 
conformational changes in gp120 allowing the subsequent interaction of 
gp120 with an C(- or iJ-chemokine receptor. (23) The latter depends on the 
biological phenotype of the virus. Subsequently the fusion process is 
initiated. CCR-5 and CXCR-4 are the main coreceptors for macrophage 
and T-cell-Iine tropic variants of HIV-1 respectively (24,25). In HIV-1 
infection longitudinal studies have shown a shift towards the usage of 
CXCR-4 as co-receptor for HIV-1 during disease progression (26,27). This 
suggested that broadening of coreceptor usage contributes to the 
cytopathic potential of HIV-1 strains in vivo. In chapter 5 we have evaluated 
the capacity of primary isolates and biological e/ones of HIV-2 infected 
individuals at different stages of the infection to use coreceptors. To this 
end we used a panel of human cells stable transfected with chemokine 
receptor genes. Like primary HIV-1 strains, all biological e/ones and primary 
HIV-2 isolates, of SI or NSI phenotype, were able to use CCR-5. Thus we 
cone/uded that CCR-5 is the main coreceptor for HIV-2. There was no 
difference between HIV-2 SI and NSI e/ones with respect to their usage of 
CXCR-4, or any other co receptor. So, in contrast to HIV-1, there seems to 
be no correlation between specific coreceptor usage and HIV-2 syncytium-
inducing capacity. Furthermore, almost all primary isolates and biological 
e/ones used in this study exhibited the usage of a broad range of 
coreceptors, ine/uding CCR-1, CCR-3 and/or CXCR-4 in addition to CCR-5. 
This suggested that the broad coreceptor usage in vitro does not add to the 
in vivo cytopathogenicity of HIV-2. 
To further address this issue we studied the in vivo pathogenic potential 
of HIV-2 isolates and biological e/ones in a chimeric human to mouse 
model for in vivo HIV infection (the xeno-GvHD mouse model) (chapter 6). 
Although it may be argued that this model functions as a refined test-tube, 
a e/ear advantage of the model is that large numbers of antigen-presenting 
macrophages and activated T-cells are present (28). In this model high 
numbers of numbers of human peripheral blood mononue/ear cells (PBMC) 
are grafted in the peritoneal cavity of immune deficient mice. Within seven 
to 14 days an acute graft versus host reaction develops. The human PBMC 
repopulate mouse tissue, eventually resulting in human cell populations 
with a high CD4/CD8 ratio (29). Depletion of human CD4+ T cells from the 
graft results in a complete abrogation of the acute xeno-GvHD reaction. 
Depletion of antigen presenting cells results in IdWefCD41CD8' ratios and a 
concomitant delay of the xeno-GvHD symptoms. In this model direct killing 
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of CD4+ T cells as well as indirect pathogenic effects of different HIV-2 
strains and primary isolates could be studied. It was found that a SI 
macrophage-tropic clone, using only CCR-5 as its coreceptor, proved to be 
more pathogenic than a NSI macrophage-tropic biological clone with a 
broad coreceptor usage (CCR-1, CCR-3, CCR-5 and CXCR-4). This 
suggested a broadening of cellular host-range does not increase the 
pathogenic potential of HIV-2. From two HIV-2 strains using CXCR-4, both 
cytopathic for CD4 + T cells in vitro, the macrophage-tropic isolate proved to 
be far more pathogenic than the non-macrophage tropic one, indicating that 
the ability to infect human macrophages influences in vivo pathogenicity. 
Also, the replication rate and the relatively low CD4/CD8 ratio of an early 
HIV-2 NSI in the xeno-GvHD mouse model did not differ significantly from 
several other HIV-1 and HIV-2 isolates from end-stage AIDS patients. It 
therefore seems that in both in vitro and in our chimeric animal model, HIV-
1 and HIV-2 may have comparable replicative and pathogenic potential. 
From the data presented in chapters 2 to 6 we conclude that the lower 
viral load and pathogenicity observed in HIV-2 infected individuals as 
compared to HIV-1 infected individuals, are rather related to a different 
interaction of the virus with the specific immune response, than solely to 
virus characteristics. 
In chapter 7, 8 and 9 we studied issues related to antiretroviral therapy 
(ART) in HIV-2 infected patients. First, we examined the development of 
phenotypic and genotypic resistance of HIV-2 during nucleoside reverse 
transcriptase inhibitors (NRTI) treatment. NRTI treatment strategy from 
1987 to 1994 was initially limited to AZT monotherapy, which temporarily 
delays disease progression in asymptomatic and advanced HIV-1 disease 
and decreases plasma HIV-1 RNA loads by approximately 0.3 log10 
copies/ml (30,31). Subsequent results from studies on combination NRTI 
therapy showed slower disease progression and an improved survival for 
antiviral naive HIV-1 infected patients on combination therapy versus 
monotherapy (32-34). In HIV-1 infection this degree of virus suppression is 
usually insufficient, resulting in the rapid selection of NRTI-resistant virus 
mutants, with specific genotypic mutations on the RT gene, which 
correlates with diminished phenotypic sensitivity to NRTI (35). We found 
that phenotypic resistance of HIV-2 to nucleoside analogues, which 
developed in HIV-2 infected patients treated with NRTI, was also 
associated with genotypic changes. Although some of the mutations at 
amino acid positions in the HIV-2 reverse transcriptase gene corresponded 
with those involved in HIV-1 resistance, no conventional mutations 
associated with resistance to AZT were observed. A noteworthy 
observation was the appearance of a Q151 M mutation after 6 months of 
monotherapy with AZT. In HIV-1 infection this mutation emerges only in 2% 
of patients treated with mUltiple NRTI (36,37). 
t = 0 t=4wk t = 12 wk t = last follow-u p 
patient regimen C04 HIV-2 RNA C04 HIV-2 RNA C04 HIV-2 RNA C04 HIV-2 RNA t** 
RH2-7 AZT 60 NO 50 NO 60 NO 50 3E5 28 
PH2:'1 AZT/ddl 160 2E4 NO NO 185 3E3 170 2E4 6 
RH2-5 AZT 110 NO NO NO 160 NO 170 6E4 16 
AZT/3TC 170 6E4 NO NO 180 NO 210 1E5 22 
Rtv/sqv 210 1E5 630 2,OE3 390 3,8E5 180 1E5 14 
RHZ-19 Rtv/sqv 50 1,8E4 NO 2,8E4 190 4,3E4 40 1.9E4 22 
RH2~20 AZT/3TC/nfv 40 1.5E3 NO <500 60 8.0E3 40 4.8E4 12 
RH2~17 AZT/3TCI ind 210 <500 430 <500 250 <500 300 <500 24 
RH2c16 AZT/3TCI ind 270 <500 310 <500 330 <500 340 <500 30 
RH2c18 AZT/3TClind 110 2.4E3 160 <500 170 NO 150 <500 18 
RH2L21 AZT/3TCI ind 30 7.3E4 90 <500 70 <500 90 <500 15 
RH2-23 AZT/3TCI ind 70 3.0E3 290 <500 230 <500 290 <500 6 
RH2+24 AZT/3TCI ind 40 5.0E4 60 <500 NO NO NO <500 12 
RH2-25 AZT/3TCI ind 100 +* 140 +* NO NO 90 +* 6 
AH2+1 AZT/3TCI ind 1.5E4 NO NO NO <500 NO 2.7E4 12 
AH2-2 AZT/3TCI ind 50 3.2E5 NO 2.1 E3 NO 3.9E4 NO 9.8E5 6 
Table' 1. Response to antiretroviral therapy. NO - not done 
*HIV-2 RNA could not be quantified, ** moment of last follow-up in months, rtv is ritonavir, sqv is saquinavir, nfv is nelfinavir, ~ w 
ind is;indinavir 
'" 
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In vivo monitoring of the effectiveness of ART in HIV-2 infected patients 
has been hampered by the absence of validated assays to measure 
plasma HIV-2 RNA, We have recently developed and validated an assay 
which allows us to quantify plasma HIV-2 RNA levels with a detection level 
of 500 copies/ml (chapter 8), From 1994 on 14 HIV-2 infected individuals 
received ART, The response to therapy is shown in table 1, Monotherapy 
or dual NRTI therapy resulted in failure in all three patients, as judged from 
the kinetics of their plasma HIV-2 RNA loads, Two out of two patients failed 
double protease-inhibitor (PI) therapy: one of them (RH2-19) was treatment 
naive and had an HIV-1/HIV-2 dual infection (chapter 9) and the other 
patient (RH2-5) was AlT/3TC experienced, A combination of AlT/3TC and 
nelfinavir failed in a naive HIV-1/HIV-2 infected patient (RH2-20), AZT/3TC 
and jndinavir induced sustained plasma HIV-2 RNA suppression in 6 out of 
9 patients, Two of the three failing patients (AH2-1, RH2-25) did so after 
stopping the indinavir because of side effects, One failing patient (AH2-2) 
proved to have low indinavir plasma levels, probably because of insufficient 
compliance, 
After failing double PI therapy (saquinavir/ritonavir) and triple therapy 
consisting of two NRTI and one PI, we did a sequence analysis of the RT 
and protease gene in some of the patients, The wild type HIV-2 protease 
gene and the reverse transcriptase gene differed from HIV-1 on some 
positions in amino acids, For the RT gene it concerns position 101, 106, 
181, 188, 190, 210, 215 and 219, On the positions 181, 188 and 190 the 
amino acids of HIV-2 RT are the same as those found in HIV-1 strains that 
are resistant to non-NRTI (NNRTI), The most important difference of wild 
type HIV-1 and HIV-2 in the protease protein is the amino acid valine on 
position 71, In HIV-1 a mutation at position 71 (A-->V) is associated with 
resistance to nelfinavir. In addition, there are several different amino acids 
on positions that are considered secundary mutations for HIV-1 PI 
resistance, associated with some resistance to various pi's, It concerns the 
positions 10, 20, 32, 36, 46, 47, 77 and 82, The relevance of several of the 
mutations at positions 210, 215 and 219 in the RT protein and positions 20, 
63, 77, 82 in protease remains unclear, since mutations in HIV-1 
associated with resistance involve mutations to other amino acids than 
those observed in the wild type HIV-2 protease, No resistance associated 
mutations were found in the protease proteins of patients RH2-20 and AH2-
1 failing on AlT, 3TC and nelfinavir and AlT, 3TC and indinavir 
respectively, For patient AH2-2 a mutation was found at position 90 (L -->M) 
and for patient RH2-5 the 184V and L90M mutations were observed, These 
data show that only few mutations relative to HIV-1 suffice for resistance to 
PI's, 
We furthermore described a different response to ART of two ART naive 
patients, who were dually HIV-1/HIV-2 infected (chapter 9), One patient 
received double PI combination therapy, ritonavir and saquinavir 400 mg 
bid, the seCbr1d patient received AlT300mg bid ;3TC150mg bid and 
nelfinavir 1250 mg bid, The observed reduction of HIV-1 RNA loads below 
the detection limit of 500 copies/ml suggested adequate sustained viral 
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suppression in both patients. However, retrospective analysis of HIV-2 RNA 
loads showed inadequate viral suppression in both patients. 
Both observations, the rapid unusual development of a Q151 M mutation 
and the failure on double PI therapy (ritonavirlsaquinavir) and triple therapy 
(two NRTI plus nelfinavir) suggests that ART in HIV-2 seropositive 
individuals should be carried out with great caution. Non-nucleoside 
reverse transcriptase inhibitors, such as nevirapine, have shown minimal in 
vitro inhibitory effect on HIV-2 replication (38,39). Obviously these findings 
seriously limit the choice of ART combinations in HIV-2 infected individuals. 
Probably, in contrast to the situation for HIV-1 infected individuals, for HIV-2 
infected individuals only one possible ART combination is available. Given 
the reluctance of many individuals to adhere for many years faithfully to an 
ART regimen, and knowing the setpoint of plasma HIV-2 RNA after acute 
infection in general is comparable to that of non-progressors in HIV-1 
infection (14), ART in HIV-2 infected patients should not be started too 
early. Most of our HIV-2 infected patients with CD4+ T cells >200/rll, did not 
have detectable plasma HIV-2 RNA levels. This is comparable to HIV-1 
infected individuals with a long-term non-progressive infection. Recently an 
HIV-1 infected individual has been described, infected with only nef-
deleted forms of HIV-1, which proved to be associated with a long-term 
non-progressive infection (40,41). He had been asymptomatic for 15 years. 
However, his CD4+ T cells were observed to decline, with non-detectable 
plasma HIV-1 RNA levels. It may be speculated that viral replication at 
levels that cannot be detected by current plasma HIV-RNA assays, is 
sufficient to cause the loss of CD4+ T cells. It therefore seems wise to start 
ART in HIV-2 infected individuals around 300 CD4 cells per Ill, before the 
rise in plamsa HIV-2 RNA level and before the occurrence of AIDS defining 
opportunistic infections. Furthermore, in contrast to what is generally 
believed, our data show that both HIV-1 and HIV-2 may actively replicate at 
the same time in dually infected patients. Therefore we are convinced that 
both HIV-1 RNA and HIV-2 RNA should be monitored before and during 
ART in dually infected individuals. 
Taken together, we conclude that the relatively low in vivo cytopatho-
genicity of HIV-2 as compared to that of HIV-1, is not primarily dependent 
on currently determined differences in virus characteristics between H IV-1 
and HIV-2, but is rather the result of a difference in the mutual interaction 
between the virus and the host immune system. This apparently results in a 
long, non-progressive course of the infection, with prolonged periods of low 
viral loads and consequently low sexual and low perinatal transmission 
rates and different epidemiological characteristics of HIV-2 infection 
compared to HIV-1 infection. Undoubtedly, the 'relatively low in vivo 
replication rate of HIV -2 and the difference in amino acid composition of the 
RT and protease genes, contribute to the observed differences in 
susceptibility .ntH IV.2 strainstoART,and· inthe development· of resistance 
towards antiretroviral compounds. 
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Samenvatting 
Besmetting met het humaan immunodeficientie virus type 2 (HIV-2) treft 
men vooral aan in Westafrikaanse landen rond de Golf van Guinee. Het 
heeft zich echter ook verspreid naar vele landen buiten Afrika via 
immigranten en seksuele partners van Westafrikanen (1). Hoewel de struc-
tuur en de wijze van vermenigvuldigen van HIV-1 en HIV-2 overeenkomen, 
is het verloop van de ziekte (2-5) en de kans op overdracht - zowel 
seksueel (6) als verticaal van moeder op kind (7-12) - verschillend. Het 
mechanisme dat verantwoordelijk is voor het duidelijk tragere ziektebeloop 
van HIV-2 is onopgehelderd. Gedurende de periode van deze studie, 1995-
1999, was de samenstelling van de HIV-ge'lnfecteerde patientenpopulatie 
(n=766) zeer divers, en bestond uit 60 verschillende nationaliteiten. Zeven-
enzestig personen waren afkomstig van 7 verschillende Westafrikaanse 
landen. Zestig procent hiervan (n=42) was HIV-1 seropositief, terwijl veertig 
procent (n=23) HIV-2 seropositief bleek. Van de 23 HIV-2 seropositieve 
individuen waren er in de Western Blot 5 seroreactief tegen zowel HIV-1 als 
HIV-2. 
Deze studie had als doer inzicht te verkrijgen in factoren die 
samenhangen met het verschil in ziektebeloop van HIV-1 en HIV-2 ge'infec-
teerde individuen. Een grotere kennis hiervan biedt hulp bij het maken van 
keuzes met betrekking tot antiretrovirale therapie en draagt bij aan een 
betere behandeling van HIV-2 ge'lnfecteerde patienten 
Allereerst waren we ge'lnteresseerd in de mate van ziekteprogressie in 
HIV-1 en HIV-2 ge'lnfecteerde patienten van Westafrikaanse origine, en in 
de karakteristieken van de daarbij behorende HIV-2 stammen. In ons 
cohort waren de ratio's van asymptomatisch versus symptomatisch 2:7 
voor HIV-2 en 8:9 voor HIV-1 ge'lnfecteerde individuen. Het succes van het 
isoleren van het HIV-2 uit perifere Iymfocyten bleek, gelijk aan de 
bevindingen in HIV-1 infectie, te correleren met ziekteprogressie, lage CD4+ 
cel aantallen, en de capaciteit van het virus syncytia te induceren in T cel 
lijnen (13). We zagen ook dat HIV-2 infectie een snel progressief beloop 
kan hebben. Het CD4+ aantal in het perifere bloed van een Franse 
homoseksuele man daalde van 600/j.ll naar 200/j.ll binnen 36 maanden na 
een acute HIV-2 infectie. De gunstige asymptomatisch/symptomatische 
ratio in de HIV-1 ge'lnfecteerde patientengroep kan be'lnvloed zijn door 
patienten selectie. Echter, het snelle progressieve beloop van een HIV-2 
infectie, wat we mochten waarnemen na acute seroconversie in het Franse 
individu, doet ons geloven dat een HIV-2 infectie in potentie net zo snel kan 
verlopen als een HIV-1 infectie. 
In HIV-1 infectie is plasma HIV-1 RNA een belangrijke prognostische 
parameter voor ziekteprogressie (14). Meerdere studies hebben daarbij ook 
laten zien dat de hoeveelheid HIV-1 RNA in het weefsel correleert met het 
plasma HIV-1 RNA (15,16). Voor de beslissing om antiretrovirale therapie 
testarten 'is dehoogtevan' hetplasmaH IV-1··· RNA· belangrijk.ln.hetgeval 
van HIV-2 infectie was zo'n kwantitatieve test niet beschikbaar, zodat we 
besloten biopten van Iymfoid weefsel, verkregen van HIV-2 ge'lnfecteerde 
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patienten, te bestuderen met behulp van in situ hybridisatie en immuno-
histochemie, om zodoende de hoeveelheid virus van een individu te 
kunnen inschatten, en daarmee de indicatie voor wei of geen therapie te 
kunnen vaststel/en. Histologische karakteristieken, zoals onregelmatige 
fol/iculaire hyperplasie tijdens ziekteprogressie, bleken in het algemeen 
overeen te komen met observaties die gedaan zijn bij HIV-1 infectie (voor 
een review zie ref.17). Het aantal productief ge'infecteerde cel/en per mm2 
bleek in HIV-2 ge'infecteerd Iymfoid weefsel van asymptomatische 
individuen 5 keer lager te zijn dan in HIV-1 ge'infecteerd Iymfoid weefsel 
verkregen van individuen in hetzelfde stadium van de infectie. Bovendien 
bleek het percentage CDB+ cel/en in de kiemcentra van het Iymfoid weefsel 
van HIV-2 ge'infecteerde individuen significant hoger ten opzichte van HIV-
1 ge'infecteerde individuen. In HIV-1 infectie worden CDB+ cel/en als een 
belangrijk onderdeel gezien van de HIV-1 specifieke afweer reactie. 
Mogelijk dat er een relatie is tussen het hoge percentage CDB+ cel/en en 
het lage aantal productief ge'infecteerde cel/en in HIV-2 infectie. Vanuit de 
aanwezige hoeveelheid HIV-2 RNA in het weefsel schatten we dat het 
plasma HIV-2 RNA vijfvoudig verlaagd zou zijn (20). Oil zou passen bij een 
trager ziektebeloop. Recent is door ons een kwantitatieve test ontwikkeld 
om het plasma HIV-2 RNA te meten (hoofdstuk 7), en het bleek dat het 
plasma HIV-2 RNA zelfs 100 keer lager was dan het plasma HIV-1 RNA 
van patienten in dezelfde fase van de infectie. Dit verschil in geschatte 
plasma HIV-2 RNA en gemeten plasma HIV-2 RNA zou veroorzaakt 
kunnen worden door of wei een tragere replicatie of een verhoogde klaring 
van HIV-2 virionen (20). Er is een aantal argumenten die pleiten voor een 
tragere replicatie. Ten eerste is het aantal virionen wat per HIV-2 
ge'infecteerde cel gezien wordt m.b.v. in situ hybridisatie, kleiner dan dat bij 
een productief ge'infecteerde HIV-1 cel (Racz, niet gepub/iceerd). 
Bovendien bleek tijdens een geobserveerde acute HIV-2 infectie het 
plasma HIV-2 RNA, nog v66r seroconversie, slechts 10.000 copies/ml te 
zijn, hetgeen tegen een effectievere klaring pleit. Vervolgens bleek de viral 
load in HIV-2 ge'infecteerde patienten met AIDS ook significant lager te zijn 
dan in patienten met AIDS en een HIV-1 infectie. Dit ondersteunt eerdere 
berichten, dat de overleving met HIV-2 en AIDS langer is dan die van HIV-1 
en AIDS. 
De productie van HIV-1 virionen is hoger in CD4+ T cel/en dan in macro-
fagen (Racz, niet gepubliceerd). In onze studie waren CD4+ T cel/en de 
voornaamste bron van HIV-2 virionen, zodat een tragere productie niet 
geweten kan worden aan een productie switch van CD4+ T cel/en naar 
macrofagen. Voor HIV-1 is deze switch beschreven tijdens het optreden 
van opportunistische infecties (21). Wij hebben geprobeerd dit te 
bevestigen, maar in tot onze beschikking bestaand HIV-1 ge'infecteerd 
Iymfoid weefsel bleven CD4+ T cel/en, ook tijdens opportunistische 
infecties, de belangrijkste bron van virusproductie (hoofdstuk 4). 
Hoofdstuk2,· 3en4zijngebaseerdop/n vivo stUdiesVahHIV-2irifedie.·· 
Viruskarakteristieken van HIV-1 en HIV-2 waren gelijk, echter weefsel en 
plasma viral load waren vijf en respectievelijk 100 keer lager tijdens HIV-2 
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infeclie. Mogelijk is er een verband met de hoge aantallen CD8+ T cellen -
deze kunnen virusreplicatie beperken-, die in de kiemcentra van de Iymfe-
klieren worden aangetroffen. We waren vervolgens gei'nteresseerd in 
virusspecifieke eigenschappen van HIV-2, die konden bijdragen aan de 
verschillen die we gevonden hadden in hoofdstuk 3 en 4. 
Het binnenkomen van HIV-1 in target cellen wordt mogelijk gemaakt 
door het binden van het glycoprotei'ne (gp120) dat aanwezig is op het 
oppervlak van het virus en het CD4 molecuul van de target cel (22). Deze 
binding zet een reeks veranderingen op gang, waardoor het gp120 een 
interactie aangaat met een a of een J3 chemokine receptor (23). Welke 
gekozen wordt hangt af van het biologische fenotype van het virus. 
Vervolgens kan het fusieproces beginnen. CCR-5 en CXCR-4 zijn de 
voornaamste coreceptoren voor respectievelijk macrofagen en T -cellijn-
trope virussen (24,25). In HIV-1 infeclie hebben studies laten zien dat er 
tijdens ziekteprogressie in toenemende mate gebruik wordt gemaakt van 
CXCR-4 als coreceptor (26,27). Dit 'bredere' gebruik van coreceptoren 
suggereert daarmee bij te dragen aan het cytopatische vermogen van HIV-
1 in vivo. In hoofdstuk 5 hebben we primaire isolaten en biologische kloons 
van HIV-2 gei'nfecleerde individuen in verschillende stadia van de infeclie 
getest op hun vermogen om gebruik te maken van coreceptoren. Hiertoe 
kozen we voor een aantal menselijke cellijnen die de verschillende receptor 
genen bezaten. In tegenstelling tot HIV-1 waren aile primaire HIV-2 isolaten 
en biologische kloons, zowel van het 81 als het non-81 fenotype, in staat 
CCR-5 als coreceptor te gebruiken. Wij concludeerden hieruit dat CCR-5 
de belangrijkste coreceptor is voor HIV-2. Er was geen verschil tussen HIV-
2 81 en HIV-2 non-81 in het gebruik van CXCR-4 (of welke andere receptor 
dan ook) als coreceptor. Er bleek dus geen correlatie tussen een specifiek 
coreceptor gebruik en syncytium-inducerend vermogen, zoals dat bij HIV-1 
wei is gevonden. Voorts lie ten bijna aile primaire isolaten en biologische 
kloons in deze studie een breed gebruik van coreceptoren zien, inclusief 
CCR-1, CCR-3 en/of CXCR-4, in aanvulling op CCR-5. Dit suggereert dat 
een breed gebruik in vitro niet bepalend is voor het cytopathisch vermogen 
van HIV-2 in vivo. 
Om dit verder te onderzoeken bestudeerden we dezelfde primaire 
isolaten en biologische kloons in een (xeno-GvHD) muizenmodel voor HIV-
infectie (hoofdstuk 6). Hoewel het model slechts functioneert als een 
veredelde reageerbuis, heeft het als voordeel dat er grote hoeveelheden 
antigeen-presenterende macrofagen en geactiveerde T -cellen aanwezig 
zijn (28). Grote aantallen humane perifere Iymfocyten worden in de 
buikholte van de immuundeficiente muis gebracht. Binnen 7 tot 14 dagen 
ontstaat er een acute graft versus host reaclie. De humane cellen nemen 
bezit van de organen van de muis, hetgeen resulteert in humane cel 
populaties met hoge CD4/CD8 ratios (29). Depletie van CD4+ T cellen van 
de graft resulteertin hetuitblijven vaneenGvHD reaclie. Depletie van 
antigeen-preseriterende' Gelleri' VerobrzaaktlagEJ CD4/CI:l8 ratioseneen 
daarmee samenhangend uitstel van GvHD symptomen. In dit model zijn de 
directe killing van CD4+ T cellen en het indirect pathogeen effect van 
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verschillende HIV-2 stammen te bestuderen. Er werd gevonden dat een SI 
macrofaag-trope clone, die aileen CCR-5 als co-receptor gebruikt, 
pathogener was dan een NSI macrophaag-trope kloon met een breed 
gebruik van coreceptoren. Oit suggereert dat voor HIV-2 een breed gebruik 
van coreceptoren niet bijdraagt aan het pathogeen vermogen. Oit wordt 
gesteund door de observatie dat van twee HIV-2 stammen, die beide 
CXCR-4 gebruikten en cytopathisch in vitro zijn, het macrofaag-trope 
isolaat veel schadelijker bleek dan de non-macrofaag-trope stam. Het lijkt 
erop dat de capaciteit om macrofagen te infecteren het in vivo pathogeen 
vermogen be'invloedt. Verder bleek de replicatiesnelheid en de relatief lage 
C04/C08 ratios van een vroeg HIV-2 NSI isolaat niet wezenlijk te 
verschillen van diverse HIV-1 isolaten of van late HIV-2 isolaten. Gelet op 
de resultaten van in vitro en in vivo onderzoek, kan geconcludeerd worden 
dat HIV-1 en HIV-2 in potentie hetzelfde pathogeen vermogen hebben. 
In hoofdstuk 7, 8 en 9 hebben we een aantal therapie-gerelateerde 
onderwerpen bestudeerd. Ten eerste hebben we de ontwikkeling van 
fenotypische en genotypische resistentie voor en na het gebruik van 
nucleoside reverse transcriptase remmers (NRTI) onderzocht. De reguliere 
behandeling van HIV-1 geInfecteerde patienten in de periode van 1987 tot 
1994 bestond uit NRTI's, en was aanvankelijk beperkt tot zidovudine (AZT) 
monotherapie, wat tijdelijk de ziekteprogressie remt in asymptomatische en 
gevorderde stadia van HIV-1 infectie. Het verlaagt de plasma HIV-1 RNA 
met circa 0.3 10glO copies/ml (30,31). Resultaten van daaropvolgende 
studies in therapie-naieve HIV-1 geInfecteerde patienten lieten zien dat 
combinaties van 2 NRTI's tot betere resultaten leiden dan monotherapie 
(32-34). Echter suppressie van de virusreplicatie van HIV-1 is meestal nog 
onvoldoende met 2 NRTI's, zodat er een selectie optreedt van NRTI-
resistente mutanten, met specifieke mutaties op het RT gen, wat correleert 
met verminderde fenotypische gevoeligheid voor NRTI's (35). Wij vonden 
dat fenotypische resistentie van HIV-2 voor nucleoside-analogen zich ook 
in HIV-2 ge'infecteerde patienten ontwikkelde die met NRTI's behandeld 
werden. Er werden genotypische veranderingen op aminozuur posities in 
het HIV-2 RT gezien die in HIV-1 infectie geassocieerd zijn met resistentie 
voor NRTl's. Er werden echter geen conventionele mutaties gevonden 
passend bij resistentie voor AZT. In een patient werd na slechts 6 maanden 
monotherapie AZT een Q151 M mutatie gevonden. In HIV-1 infectie 
verschijnt die mutatie slechts in 2% van patienten die gedurende langere 
tijd met meerdere NRTI's behandeld werden (36,37). 
Het in vivo monitoren van HIV-2 infecties beperkte zich tot con troles van 
C04 aantallen, wegens het ontbreken van een test om plasma HIV-2 RNA 
te meten. Recent werd deze in ons laboratorium ontwikkeld. De 
detectiegrens van de test ligt bij 500 copies/ml (hoofdstuk 7). Vanaf 1994 
kregen 14 HIV-2 geInfecteerde patienten antiretrovirale therapie voor-
geschreven. Zie voor de resultaten tabel 1 pagina 137. Mono- en duo 
therapie·met·NRTl's'faalde'(3/3};therapiemettwee' protease remmers'(PI) 
faalde (2/2): een patient (RH2-5) was tevoren met AZTllamivudine (3TC) 
behandeld, en een patient (RH2-19) was met HIV-1 en HIV-2 tegelijk 
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ge'infecteerd, AZT/3TC/nelfinavir faalde (1/1) in een andere patient (RH2-
20) met een HIV-1/HIV-2 dubbel infectie, en AZT/3TC/indinavir faalde in 3 
van 9 patienten met een HIV-2 mono-infectie, Bij de twee patienten met 
een dubbel HIV-1/HIV-2 infectie, liet het plasma HIV-1 RNA wei een goede 
respons zien (Hoofdstuk 9). Twee van de 3 patienten die op' het indinavir 
bevatlende regiem faalden (AH2-1, RH2-25), waren gestopt met de 
medicatie i.v,m, intolerantie, Een patient (AH2-2) had een slechte 
compliance met lage indinavir spiegels, De andere 6 patienten behielden 
ook bij verdere follow-up (tot 30 maanden) ondetecteerbare plasma HIV-2 
RNA spiegels, 
Na het falen op dubbel PI therapie (ritonavir/saquinavir) en triple therapie 
bestaande uit 2 NRTI's en €len PI hebben we bij een aantal patienten het 
protease gen gesequenced, Hierbij bleek dat in wild type HIV-2 een aantal 
aminozuren van het RT gen en het protease gen verschillend zijn tOY het 
HIV-1 protease gen, waaronder ook op plaatsen die bij HIV-1 geassocieerd 
zijn met verminderde gevoeligheid voor non-nucleoside analoog RT 
remmers en proteaseremmers. Het belangrijkste verschil is de Valine groep 
op positie 71, In HIV-1 betekent een mutatie van 71A naar 71V een 
intermediate resistentie voor nelfinavir. Verder is er een aantal verschillen 
op posities die bij HIV-1 als secundaire mutaties geduid worden en 
geassocieerd zijn met licht verminderde gevoeligheid voor meerdere 
proteaseremmers, Deze laatste twee observaties zijn mogelijk de reden 
voar het falen van RH2-5, RH2-19 en RH2-20 op therapie, Verder werden 
er geen resistentie geassocieerde mutaties gevonden in het protease eiwit 
van RH2-20 en AH2-1 die respectievelijk faalden op AZT, 3TC en Nelfinavir 
en AZT, 3TC en Indinavir. Bij patient AH2-2 werd een mutatie op positie 90 
(L90M) en bij patient RH2"5 werden mutaties op posities 84 (184V) en 90 
(L90M) gevonden, Deze observaties tonen aan dat relatief weinig mutaties 
in HIV"2 protease ten opzichte van HIV-1, resistentie kunnen geven tegen 
protease inhibitors, 
Non-NRTI's, zoals nevirapine, hebben in vitro geen remmend effect op 
HIV-2 replicatie (38,39), Het kleinere aantal middelen dat beschikbaar is en 
de snellere ontwikkeling van resistentie, beperken het aantal mogelijkheden 
van antiretrovirale therapie voor HIV"2 ge'infecteerde patienten, Op dit 
moment is er waarschijnlijk slechts €len kans op een werkzame combinatie 
beschikbaar. Er van uitgaand dat bij vele patienten in de loop der tijd de 
therapie trouw afneemt, door ingewikkelde regiems, dietaire beperkingen 
en/of bijwerkingen, en wetende dat bij de meeste HIV-2 ge'infecteerde 
patienten de plasma viral load pas gaat stijgen wanneer het CD4 aantal 
beneden de 200/~1 daalt, is het aan te bevelen behandeling niet te vroeg te 
starten, Het ziektebeloop van HIV"2 ge'infecteerde patienten is 
vergelijkbaar met dat van long term non"progressors onder de HIV-1 
ge'infecteerde populatie (14), Recent is een dergelijke patient, ge'infecteerd 
met HIV-1 waarbij het nef ontbreekt, beschreven, HIV-1 zonder nef gen 
wbrdfg eassoCieerd "met eerrnoTT'progressiefziektebeloop(40 ;41}:De ' 
betreffende patient had een asymptomatisch ziektebeloop gedurende 15 
jaar, AI die tijd was er geen detecteerbaar plasma HIV-1 RNA, terwijl het 
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C04 aantal toch bleek te dalen. Hieruit zou geconcludeerd kunnen worden 
dat replicatie van HIV-1 op een niet detecteerbaar plasma-niveau 
uiteindelijk ook voldoende is om het aantal C04 cellen te doen 
verminderen. Het starten van antiretrovirale therapie lijkt gerechtvaardigd 
bij 300 C04+ T cellen, voordat er een forse stijging van het plasma HIV-2 
RNA voigt, en voordat er kans is op opportunistische infecties. 
Tenslotte hebben we, in tegenstelling tot wat algemeen wordt 
aangenomen, aangetoond dat HIV-1 en HIV-2 naast elkaar actief kunnen 
repliceren in patienten die met beide virussen besmet zijn. In patienten, die 
seroreactief zijn voor HIV-1 en HIV-2 , dient voor en tijdens therapie zowel 
het HIV-1 RNA en het HIV-2 RNA gemeten worden. 
Samenvattend kunnen we stellen dat het relatief lage in vivo pathogeen 
vermogen van HIV-2 in vergelijking met dat van HIV-1, niet primair 
afhankelijk is van verschillen in eigenschappen van de twee virussen. Het 
is meer een gevolg van verschillende interacties tussen de virussen en het 
immuunsysteem van de gastheer. Oit resulteert voor HIV-2 in een lang 
ziektevrij beloop van de infectie met daarbij behorende langdurige periodes 
met lage plasma HIV-2 RNA's. De relatief lage snelheid van 
vermenigvuldigen van het virus in vivo, de verschillen van een aantal 
aminozuren op het RT gen en het protease gen, dragen mogelijk bij aan de 
waargenomen verschillen in gevoeligheid voor antivirale middelen en het 
tempo waarin resistente mutanten geselecteerd worden. 
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